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 i 
Abstract 
Antibiotic resistance is a major problem estimated to cost $100 trillion and cause 10 
million deaths per year by 2050. Despite novel molecules targeting Gram-positive 
bacteria, there are no new antibiotics active against Gram-negatives. To prolong use of 
current drugs, we need to understand mechanisms of resistance to inform prescribing 
practices and drug discovery. Quinolone resistance is primarily conferred by mutations in 
the target loci: DNA gyrase (gyrA) and topoisomerase IV. Quinolone resistance arising 
from gyrA mutations has also been shown to confer a low level of protection against a 
range of non-quinolone drugs. This thesis investigated the hypotheses that altered 
supercoiling levels, resulting from gyrA mutations, alter expression of stress response 
genes and confer a generic protective effect against other antibiotics and chemicals. The 
effects of equivalent gyrA mutations in Salmonella and E. coli upon supercoiling were 
analysed. Both GyrA Ser83Phe and GyrA Asp87Gly substitutions resulted in altered 
topoisomer profiles, although these were different between the species. When exposed 
to stresses, Salmonella gyrA mutants maintain supercoiling in a relatively fixed manner, 
providing a degree of antimicrobial protection but possibly limiting flexibility in response 
to environmental change. Fluorescent reporter assays showed a modest elevation of 
stress responses in Salmonella GyrA Asp87Gly cells, but highly upregulated stress 
responses in E. coli GyrA Asp87Gly cells. This correlated with a competitive fitness 
benefit of E. coli GyrA Asp87Gly cells vs the parent in the presence of low levels of 
triclosan. The elevated stress responses likely result from supercoiling-induced changes 
in promoter accessibility, and are probably responsible for the generic protective effect 
gyrA mutation confers against other chemicals and antibiotics. Non-quinolone 
antimicrobials can provide a selective pressure that favours gyrA mutants, although this 
is highly dependent on condition and species. 
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“We’re throwing science at the wall here to see what sticks. No idea what it’ll do - 
probably nothing.” 
Cave Johnson, Portal Two 
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1. Introduction  
1.1 Antibiotics 
The name “antibiotic” comes from the Greek term “αντι-βιος”, meaning “against life”, 
and in practice describes compounds that are used to treat bacterial infections. While 
the term “antimicrobial” can be applied to antibiotics, it is an umbrella term that also 
includes agents that have activity against viruses (antivirals and/or antiretrovirals) 
and/or fungi (antifungals). In common parlance, antibiotics are chemical compounds 
that specifically target bacteria and either kill them (termed “bacteriocidal” antibiotics), 
or prevent their growth (termed “bacteriostatic” antibiotics) (Pankey and Sabath, 
2004). Antibiotics act by targeting and interfering with essential cellular processes, or 
the mechanisms controlling said processes (Zaffiri et al., 2012). Antibiotics are used 
in medicine and animal husbandry for the treatment and prevention of bacterial 
disease. The majority of antibiotics have been derived from molecules that occur 
naturally, and have been isolated from microbes - primarily the Actinomycetes (Barka 
et al., 2016). In their natural environment, antibiotics are produced by bacteria to 
prevent the growth of competing organisms (Baltz, 2008).  
 
1.1.1 Early Discovery – Fleming, Penicillin & Other Early Antibiotics 
Penicillin, while not the first modern antibiotic, is arguably the most famous antibiotic. 
A product of Penicillium notatum accidentally discovered by Alexander Fleming in the 
1920s (Fleming, 1929), penicillin is a broad-spectrum beta lactam that acts by 
binding to Penicillin Binding Protein to disrupt bacterial cell wall synthesis (Spratt, 
1977). Fleming was awarded the Nobel Prize in Physiology or Medicine in 1945 for 
the discovery of penicillin, an award that he shared with Florey and Chain, who 
3 
realised its therapeutic benefits (Raju, 1999). However, penicillin was not easily 
purified, and the earliest mention in the literature of it being produced in large 
quantities was not until 1943 (Clifton, 1943), with a patent for its industrial purification 
being granted in 1947 (Jacques L Watchell, 1947). The first widely used antibiotics 
were the sulphonamides (Bickel, 1988), which were derivatives of a dye and first 
described by Domagk (1935). Marketed as Prontosil, the first sulphonamide in use 
was effective against Gram-positive cocci (Gibberd, 1937) and was used by Domagk 
to cure his daughter of an infection (Bentley, 2009). He was awarded the Nobel Prize 
in Physiology or Medicine in 1939 for his work (Nobel Foundation, 1965), but was 
unable to accept it because of the political situation in his native Germany at the time 
(Nobel Media AB, 2014). Since these initial discoveries were made, a wide range of 
antibiotics belonging to different classes were discovered allowing new treatments for 
many infections to be introduced. 
 
1.1.2 Uses of Antibiotics 
Antibiotics are used to treat bacterial infections, both in humans and animals. They 
are also used prophylactically, to prevent patients undergoing surgery from acquiring 
infections (Kavanagh et al., 2014), and this usage has been shown to reduce 
mortality in immunocompromised individuals, e.g. cancer patients (Schlesinger et al., 
2009). Antibiotics are also used to promote growth in livestock (Phillips et al., 2004) 
in some parts of the world, including the United States of America. The use of 
antibiotics for this purpose was banned in Sweden in 1986, followed by Denmark a 
decade later, and then banned throughout the European Union by 1999 (Casewell et 
al., 2003). After Denmark stopped using antibiotics for growth promotion in livestock, 
4 
the amount of antibiotics used to treat infections in livestock increased each year until 
2009. However, the amount of antibiotics used for the treatment of infections each 
year after the ban was enacted was still less than the total amount of antibiotics used 
each year before the ban was put in place (Statens Serum Institut et al., 2015).   
 
Antibiotic use is controlled in Northern Europe and North America, requiring a 
prescription from a medical professional. However, in developing countries, many 
antibiotics can be obtained over-the-counter without a prescription (Morgan et al., 
2011). Antibiotics can also be obtained without a prescription online (Boyd et al., 
2017). Unregulated antibiotic use contributes to the development and spread of 
antibiotic resitance, as patients may take wrong or unnecessary antibiotics, or a dose 
which is too low to clear the infection (Review on Antimicrobial Resistance, 2015a). 
 
1.1.3 Overview of Antibiotic Targets 
Antibiotics act by interfering with a process and/or component essential to bacterial 
viability, either killing cells or stopping them from growing any further. Ideally, 
antibiotics should target components which are specific to bacteria, so as to minimise 
the possibility of negative effects, e.g. toxicity, affecting the patient (Duffield et al., 
2010), The main ways antibiotics function are as follows (Lange et al., 2007): 
• Disruption of the cell envelope’s integrity – e.g. penicillin and other beta lactam 
antibiotics, which bind to penicillin binding proteins and prevent peptidoglycan 
from being incorporated into the cell wall. The cell continues to attempt to 
grow, but as it cannot remodel the cell wall, this leads to a build-up of internal 
pressure inside the cell and, ultimately, lysis (Spratt, 1980). Daptomycin and 
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colistin are two antibiotics that disrupt the integrity of the cell membrane by 
triggering a loss of membrane potential, leading to the leakage of the cell’s 
internal contents (Falagas and Kasiakou, 2005; Silverman et al., 2003). It has 
been shown that exposure of bacteria to polymixins ultimately leads to cell 
lysis (David and Rastogi, 1985; Mohamed et al., 2016). 
• Protein synthesis inhibition is a viable antibacterial strategy as protein 
production is an essential process that is targeted by various antibiotics – for 
example, mupirocin inhibits the tRNA synthetase that loads isoleucine onto its 
respective tRNA molecules, thus preventing isoleucine from being 
incorporated into polypeptide chains (Nakama et al., 2001). Chloramphenicol 
and tetracycline stop tRNAs from entering the A site of the ribosome, which 
stops the amino acids loaded on them from being added to nascent 
polypeptide chains (Connell et al., 2003; Schlünzen et al., 2001). 
• Inhibition of nucleic acid synthesis – rifampicin and other rifamycins target the 
β subunit of the bacterial RNA polymerase and physically block it from being 
able to lengthen the nascent chain of nucleotides (Floss and Yu, 2005). 
Quinolones target the complexes formed between Type II topoisomerases and 
DNA, which are involved in the decatenation of daughter chromosomes and 
relaxing supercoils introduced into the chromosome by replication and 
transcription forks, and lead to an accumulation of double stranded breaks in 
the DNA (Redgrave et al., 2014). As they are one of the focal points of this 
work, quinolones will be discussed in more detail later. 
• It is also possible to inhibit essential enzymes. Two examples are the inhibition 
of fatty acid biosynthesis and folate biosynthesis. Triclosan is a widely-used 
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biocide that targets FabI, and inhibits fatty acid biosynthesis (McMurry et al., 
1998). Although a biocide and not an antibiotic, it is of relevance as it has 
been shown that mutations in gyrA confer reduced susceptibility to triclosan 
(Webber et al., 2008). Trimethoprim is an example of an antibiotic that 
prevents folate biosynthesis in bacteria by inhibiting the dihydrofolate 
reductase enzyme (Quinlivan et al., 2000). The sulphonamides target a 
different enzyme in the folate biosynthesis pathway (Mondal et al., 2015). 
Folate is a cofactor for the enzymes used in the synthesis of a variety of 
essential cellular components, such as nucleic acids and amino acids. 
Although folate is required by all forms of life, mammals cannot synthesise 
their own folate and instead acquire it through their diet, making the bacterial 
enzymes involved in its synthesis good drug targets (Bermingham and 
Derrick, 2002; Hawser et al., 2006). 
 
1.1.4 Discovery Void 
Most of the classes of antibiotics in use today were discovered in the 1950s through 
to the mid-1970s (Silver, 2011). Traditionally, antibiotics have been isolated from 
screening the products made by soil microorganisms (Butler et al., 2016). There has, 
however, been a subsequent “discovery void” with only four new classes of antibiotic 
having been discovered since. This is demonstrated graphically in Figure 1.1.4.1. It 
has been proposed that one of the reasons for the lack of new classes of compounds 
is that all the major potential targets have been discovered and utilised, so there are 
no new targets, and thus no new classes of compounds, that could be developed 
effectively (Bumann, 2008; Silver, 2011). It has also been observed that the 
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continued use of a natural product screening approach has led to a high rate of 
rediscovery of existing antibiotics (Baltz, 2006). Other factors contributing to the 
stalling of the antibiotic development pipeline are the time, financial cost and low 
success rate. The development of a new antibacterial agent by a company that has 
the workforce and financial ability to invest in doing so, such as GlaxoSmithKline, can 
take at least a decade going from high-throughput screening of compounds all the 
way through to optimisation, clinical trials and the agent’s launch (Payne et al., 2007).  
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Figure 1.1.4.1: Timeline of antibiotic development, introduction and resistance 
Timeline showing when major antibiotics were introduced into clinical use (top), as 
well as when clinical resistance (bottom) to those antibiotics was first reported. 
Resistance to linezolid and daptomyicn was observed witin five years of their 
introduction. The section marked in red, between 1970 and 2000, marks a time often 
referred to as the “discovery void”, when no new classes of antibiotics were 
discovered or deployed (adapted from Clatworthy et al., 2007). There have since 
been new classes of antimicrobial agents discovered, such as teixobactin, but these 
require further development before they may be used in a clinical setting. 
Discovery void 
9 
1.2 Antibiotic Resistance 
Antibiotic resistance occurs naturally and has evolved to protect bacteria against 
antimicrobial threats in the environment. Metagenomic analysis of 30,000-year-old 
permafrost from Canada has identified a vancomycin resistance locus similar to that 
found in modern Staphylococcus aureus (D’Costa et al., 2011), and phylogenetic 
analyses have shown serine beta lactamase enzymes to be over two billion years old 
(Hall and Barlow, 2004). A recent genomic analysis of a Shigella flexneri strain, the 
first strain to be stored in the National Collection of Type Cultures and which was 
isolated from a soldier who died of bacillary dysentery in World War 1, showed it to 
be naturally resistant to penicillin and erythromycin, despite these antibiotics not 
having been discovered or used in a clinical setting until several decades later (Baker 
et al., 2014). The reliance on naturally derived antibiotics in human medicine results 
in a high likelihood that resistant strains will already exist in nature. 
 
According to the European Committee on Antimicrobial Susceptibility Testing, 
bacteria are defined as being resistant to antibiotics when they possess a resistance 
mechanism against the agent that is being tested, and if the minimum inhibitory 
concentration of that antibiotic agent exceeds a defined value, or “breakpoint”, and is 
“associated with a high likelihood of therapeutic failure” (European Committee on 
Antimicrobial Susceptibility Testing, 2013). Antibiotic resistance is a term based on 
clinical definitions and should only really be used in such contexts, but organisms 
defined as “wild type” may also intrinsically resist treatment from particular antibiotics 
if they lack the components which are targeted by the antibiotics in question 
(European Committee on Antimicrobial Susceptibility Testing, 2013).  
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Whilst resistant strains that pre-exist in nature can be selected for through the use of 
antibiotics, it is also possible for resistance to emerge de novo. Upon being awarded 
the Nobel Prize for Physiology or Medicine in 1945, Fleming said in his acceptance 
speech that, “it is not difficult to make microbes resistant to penicillin in the laboratory 
by exposing them to concentrations not sufficient to kill them, and the same thing has 
occasionally happened in the body”, and also feared of a time penicillin would be 
available over the counter, as it would increase the potential for its misuse (Fleming, 
1999). 
 
A more recent antibiotic family, the oxazolidinones, were approved for use in the 
early 2000s, although they were originally patented in the 1970s (Silver, 2011) and 
the development of resistance was observed not long after their introduction into use, 
even allowing for modern pharmacokinetic guidelines (Marchese and Schito, 2001).  
 
Rises in numbers of resistant isolates have altered therapeutic options. Colistin, a 
polymyxin that kills bacteria by disrupting the structure and stability of their 
membranes, was retired from clinical use in the 1970s because of concerns over the 
toxicity of antibiotics of this class (Yu et al., 2015). However, it was brought back into 
use in the 1990s because of increasing levels of resistance to other antibiotics 
amongst Gram-negative bacteria, and the dearth of novel antibiotics (Zavascki et al., 
2007). As a result, it is widely regarded as the last line of defence against some 
antibiotic-resistant Gram-negatives. Colistin resistance has long been known to be 
possible, and is classically associated with chromosomal mutations in genes 
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controlling lipopolysaccharide structure. However, towards the end of 2015, plasmid-
mediated polymyxin resistance alleles were identified in south-eastern China, and the 
plasmid on which they are contained, pHNSHP45, is capable of transforming E. coli, 
K. pneumoniae and P. aeruginosa with relative ease in a laboratory setting. 
Subsequently, the mcr1 gene has been seen in isolates from patients in the USA, 
showing the possibility for this plasmid to spread easily in the “wild” (Liu et al., 2016). 
These examples illustrate the dynamic nature of the evolution of resistance 
mechanisms.  
 
1.2.1 Problem, Scale and Outlook 
It has been suggested that, unless something is done about antibiotic resistance, the 
inability to treat bacterial infections with antibiotics would render surgery and 
chemotherapy, amongst other procedures, highly risky as the chance of infection 
would be greatly elevated (Davies, 2013). Dame Sally Davies, the Chief Medical 
Officer for Her Majesty’s Government, has gone on record to say that the threat of 
global antimicrobial resistance is as severe as the threats from terrorism and global 
warming (McCarthy, 2013). In their 2016 report on global risks and their impacts, the 
World Economic Forum considered the impact of the spread of infectious disease to 
be as severe as those of another global financial meltdown, cyber-terrorism attacks 
and global food shortages, but about as likely as a “critical information infrastructure 
breakdown”. One of the main concerns raised by the World Economic Forum was 
that the mechanisms by which infections spread do not respect political borders 
(World Economic Forum, 2016). 
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Although antibiotics have been a major driver in the advancement of healthcare and 
are arguably the cornerstone of modern medicine, there have been other factors 
contributing to improved clinical outcomes, such as improved hygiene and 
vaccination programmes (Edwards, 2016). Politicians, pharmaceutical companies 
and investors have started taking action to address the problem – action which is 
considered too late in some circles (Smith and Coast, 2013).  
 
The European Commission was encouraged to foster co-operation between the 
different agencies and members of the European Union by coming up with suitable 
incentives for the development of new antimicrobials. The European Parliament later 
declared an official stance of antimicrobial resistance being an issue of major 
concern, and recommended that the European Commission come up with a plan to 
deal with the problem. The Commission presented a twelve-point five-year plan of 
action, which, in broad strokes, encompasses improving the regulation of antibiotic 
use, preventing the unnecessary use of antibiotics in animals, improving hygiene 
levels to prevent infection, and making a concerted effort to monitor the levels of 
antibiotic resistance throughout the European Union (European Commission, 2011).  
 
A recent review by Lord O’Neill of Gatley analysed the problem of antibiotic 
resistance from an economic standpoint and present recommendations on how to 
solve the crisis. Lord O’Neill’s committee has published a series of reports, stating 
that around 700,000 people currently die per year worldwide as a result of 
antimicrobial-resistant infections, and that, left unchecked, this will likely increase to 
10,000,000 deaths per annum in the year 2050 (Review on Antimicrobial Resistance, 
13 
2014). This would also lead to a global loss of productivity to the tune of US$100 
trillion. The main recommendations of the committee are to increase investment in 
antibiotic research (Review on Antimicrobial Resistance, 2015b), to incentivise 
pharmaceutical companies to develop more antibiotics (Review on Antimicrobial 
Resistance, 2015c), and to be more protective of the antibiotics we currently have 
(Review on Antimicrobial Resistance, 2015b). 
 
Whilst novel drugs are not likely to be introduced into clinical use in the immediate 
short term, increased efforts in researching lead compounds are promising. For 
example, teixobactin, a novel antimicrobial compound, has been discovered using 
the “iChip” method to culture microorganisms in their native environments as 
opposed to the lab, This allows around 50% of soil-borne bacteria to grow, a fifty-fold 
increase on conventional methods (Ling et al., 2015). However, it will be many years 
before any novel drugs pass through all the stages of drug development that come 
in-between the initial discovery phase of a compound and its deployment as a 
medicine – even in well-funded pharmaceutical companies, this can take around 
fourteen years (Payne et al., 2007). Teixobactin itself shows good activity against 
Gram-positive bacteria with a low rate of selection for mutants with reduced 
susceptibility (Ling et al., 2015). Unfortunately, teixobactin is inactive against E. coli 
and other Gram-negative bacteria (Piddock, 2015). Its inactivity against them is a 
concern as the majority of pathogens that concern the National Health Service are 
Gram-negative organisms (Davies, 2013; Davies and Gibbens, 2014) and there is 
consequently less demand for agents that are active against Gram-positive 
organisms. 
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Although new drugs are needed, improved diagnostics could greatly reduce antibiotic 
misuse and ensure the appropriate use of antibiotics is improved. The Longitude 
prize, originally set up in the 18th Century to incentivise people to solve the problem 
of how to tell the time at sea, is, in its current incarnation, a competition to develop a 
cheap, fast, simple and effective test to distinguish between bacterial and viral 
infections, and ideally also identify the pathogen’s antibiotic susceptibility profile 
(Nesta, 2014).  
 
Other proposed ways of combatting the problem of antibiotic resistance include:  
• Combination therapies, e.g. treating an infection with both a beta lactam and a 
beta lactamase inhibitor at the same time (Nesta, 2014). Combination therapy 
has been shown to not select for the development of resistance (Yeh et al., 
2009), and is considered to be one of the only options left for treating 
extensively-drug resistant Enterobacter cloacae infections (Cai et al., 2016).  
However, combination therapy is likely little more than a “stop-gap” solution – 
there have been reports of failure to successfully treat Neisseria gonorrhoeae 
through the simultaneous use of ceftriaxone and azithromyocin in a clinical 
setting (Fifer et al., 2016). 
• “Antibiotic cycling” – sequentially treating an infection with a number of 
different antibiotics, starting and ending with the same drug. The idea behind 
this is that it is energetically unfavourable for bacteria to maintain mechanisms 
to reduce their susceptibility towards agents to which they are not currently 
being exposed, meaning that if they tolerate antibiotic X and are exposed to 
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antibiotic Y and then antibiotic Z, they will no longer tolerate antibiotic X when 
they are treated with it again (Fuentes-Hernandez et al., 2015; Imamovic and 
Sommer, 2013). Computer simulations of this approach have appeared 
promising, but it has not been shown to be any more effective in real life than 
current treatments (Cobos-Trigueros et al., 2016). The revival of old antibiotics 
(Bergen et al., 2012) could be interpreted as using this principle on a longer-
term scale.  
• Vaccination (Review on Antimicrobial Resistance, 2016) – by challenging the 
immune system with fragments of bacterial antigens, antibodies against said 
antigen are produced. This leads to the development of memory cells that will 
produce the same antibody should the antigen be encountered again (Hajj 
Hussein et al., 2015). Some examples of vaccination against bacterial 
infections include: the diphtheria vaccine was introduced in the UK in 1940 
and led to a reduction in reported cases, from over 61,000 cases and 3,283 
deaths in 1940, to 38 cases and six deaths in 1957 (Sailsbury and Ramsay, 
2013); vaccines are used to inoculate poultry against Salmonella infections 
(Preisler et al., 2006); trials of an Acinetobacter baumannii vaccine in mice 
have shown promise (Shu et al., 2016); vaccines against the common 
microbial cell surface antigen poly-N-acetyl glucosamine have undergone 
phase I clinical trials in humans (Skurnik et al., 2016), and the UK has 
vaccinated against some forms of Neisseria meningitidis since 1999 (Ladhani 
et al., 2016). 
• Phage therapy - lytic bacteriophages were discovered in the early 20th century 
and were used to treat dysentery and cholera (Domingo-Calap et al., 2016). 
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They were largely forgotten by the West in the wake of the Second World War 
and the discovery of antibiotics, but remained a popular field of study in the 
Soviet Union and its allied nations. However, the clinical trials conducted in the 
Eastern Bloc are considered to have been mismanaged in hindsight 
(Sulakvelidze et al., 2001). Bacteriophages invade a host cell, utilise the host’s 
replication machinery to make copies of their genome, surround the resulting 
copies of the genome within capsids, and then cause the host cell to lyse. 
Phages can also propagate their genome lysogenically, incorporating their 
genome into that of their host (Sulakvelidze et al., 2001). Modern studies have 
shown the potential applications of phage therapy include, but are not limited 
to, the treatment of urinary tract infections (Sybesma et al., 2016) and the 
prevention and treatment of bacterial infections in food animals (Atterbury et 
al., 2007). It has been suggested that, as bacteria can evolve to be less 
susceptible to antibiotics, they can also evolve to be less susceptible to 
treatment with phage, but there is a counter-argument that phages themselves 
can in turn evolve to overcome this (Koskella and Brockhurst, 2014). Although 
the T4 bacteriophage has been shown to be safe for human consumption 
(Bruttin and Brüssow, 2005), there remains no officially approved phage 
treatment for human use in the West (Lu and Koeris, 2011). 
• In a similar vein to bacteriophages, Bacteriovorax is a genus of bacteria that 
are obligate predators of other bacteria. Bdellovirbio bacteriovorus, a member 
of this genus (Chen et al., 2015), has been shown to prey on Escherichia, 
Acinetobacter, Salmonella, Campylobacter, Pseudomonas, Klebsiella and 
Shigella species, amongst others (Dashiff et al., 2011). It has also been shown 
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to have activity against Staphylococcus aureus biofilms (Monnappa et al., 
2014). The lipopolysaccharides of B. bacteriovorus have been shown to be 
less effective at inducing the human immune response compared with 
Escherichia coli (Schwudke et al., 2003), leading some groups to suggest that 
Bdellovibrio could be exploited therapeutically (Dwidar et al., 2012). 
 
1.2.2 Overview of Resistance Mechanisms 
There are many factors that can influence the selection and expansion of antibiotic 
resistant bacteria (Stokes and Gillings, 2011). Resistance often develops in response 
to selective pressure in a classically Darwinian manner; mutants within large 
populations resistant to an antibiotic will proliferate when exposed to the antibiotic, at 
the expense of susceptible strains (Rodríguez-Rojas et al., 2013; Sykes, 2010). More 
recently, the powerful selective pressure exerted by low-levels of antimicrobials such 
as those found in the environment has been shown to select for resistance alleles 
and resistant strains (Andersson and Hughes, 2012; Andersson and Hughes, 2014). 
The carriage of antibiotic resistance can have an associated fitness cost, particularly 
if mediated by alterations to target sites which encode essential enzymes (Deris et 
al., 2013; Spratt, 1996). Subsequent additional mutations are often able to 
compensate for the fitness cost (Björkman et al., 2000), restoring growth levels to 
normality and antibiotic resistant isolates from patients are often able to grow as well 
as susceptible strains. 
Resistance to a drug may occur as a result of a number of different methods: 
• Enzymes may develop which degrade or alter drugs and prevent their 
function. For example, penicillin and other beta lactams can be degraded by 
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beta lactamases, preventing their binding to the target penicillin binding 
proteins (Jovetic et al., 2010). 
• The target site of the antibiotic can be altered or protected. Mutations can 
arise in the target site for an antibiotic (Spratt, 1994), preventing the drug from 
interacting with the target and thus having any effect. These are often single 
nucleotide changes that alter amino acids at critical positions. Mutations 
conferring quinolone resistance, such as aspartate to glycine substitutions at 
codon 87 (GAC to GGC) of GyrA in S. Typhimurium are an example of this 
(Brown et al., 1996). Targets may be protected by the addition of different 
groups. Examples include the methylation of ribosomes to protect against 
aminoglycosides, and the decoration of topoisomerases with pentapeptide 
repeats to block quinolone activity. This stops the antibiotic from having an 
effect, but does not prevent the target from carrying out its normal function 
(Blair et al., 2015b). 
• Cells may prevent access of drugs to targets, either by changes to membrane 
structure, in particular loss of porin expression in Gram-negative bacteria or by 
increasing expression of multi-drug or drug-specific efflux pumps, such as the 
AcrAB-TolC system, both resulting in a reduced amount of antibiotic 
accumulation at target sites (Nikaido et al., 2008).  
• Finally, bacteria can acquire new alleles that replace the function of an 
antibiotic target, but are themselves resistant to the action of the antibiotic. For 
example, the mecA gene, encoding an alternative penicillin binding protein 
and conferring methicillin resistance to Staphylococcus aureus, is a classic 
example of this ‘metabolic bypass’ (Hao et al., 2012). 
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For some antibiotics, multiple mechanisms of resistance are relevant. 
 
1.2.3 Quinolones 
Quinolones are synthetic compounds derived from 1,8-naphthyridine that possess 
antimicrobial activity. The earliest description of a quinolone was in 1949, as a 
modification of melicopine (Price, 1949). Quinolones with antibiotic activity were not 
discovered until a few years later, as impure by-products arising from the production 
process of quinines (Mitscher, 2005). The activity of these molecules against Gram-
negative bacteria looked promising, and the first paper describing their intentional 
synthesis and their effectiveness was published in 1962, with particular interest being 
given to 1-ethyl-7-methyl-1,8-naphthyridin-4-one-3-carboxylic acid, now more 
commonly known as nalidixic acid (Lesher et al., 1962). Since the synthesis of 
nalidixic acid, a large number of derivatives have also been synthesised. Table 
1.2.3.1 shows a number of quinolones from each of the four existing generations, 
their chemical formulae and their uses, and Figure 1.2.3.1 shows the structures of 
seven quinolones. 
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Gen. Drug  Formula Usage 
I Nalidixic acid C12H12N2O3 Urinary tract infections and gastroenteritis 
(Hopkins et al., 2005) 
 Cinoxacin C12H12N2O5 Discontinued (Hopkins et al., 2005). 
II Norfloxacin C16H18FN3O3 Withdrawn in Europe (Committee for 
Medicinal Products for Human Use, 2009). 
 Ciprofloxacin C17H18FN3O3 Urinary tract infections, respiratory infections, 
gastroenteritis and joint infections (BMJ Group 
and Royal Pharmaceutical Society of Great 
Britain, 2016a). 
 Levofloxacin C18H20FN3O4 Respiratory infections (BMJ Group and Royal 
Pharmaceutical Society of Great Britain, 
2016a).  
III Sparfloxacin C19H22F2N4O3 Withdrawn; linked to heart failure (Ball, 2003; 
Qureshi et al., 2011). 
 Gatifloxacin C19H22FN3O4 Withdrawn; linked to dysglycemia (Mehlhorn 
and Brown, 2007; Qureshi et al., 2011). 
 Grepafloxacin C19H22FN3O3 Withdrawn; linked to cardiac arrests (Ball, 
2003; Qureshi et al., 2011). 
 Tosufloxacin C19H15F3N4O3 Mainly used in Japan to treat a variety of 
conditions – some side effects (Niki, 2002). 
IV Trovafloxacin C20H15F3N4O3 Withdrawn; linked to liver failure (Ball, 2003; 
Qureshi et al., 2011). 
 Moxifloxacin C21H23FN3O4 Respiratory, skin and intra-abdominal 
infections, and pelvic inflammation (Tulkens et 
al., 2012). 
 Gemifloxacin C18H20FN5O4 Not approved in Europe (European Medicines 
Agency, 2009). 
 
Table 1.2.3.1: Examples of quinolones. Table showing examples of quinolones 
and their uses, ordered by generation. Nalidixic acid acid has a much narrower range 
of targets than later quinolones, as it only displayed effectiveness against Gram 
negative organisms causing urinary tract infections and gastroenteritis. The main 
structural differences between first generation quinolones and later quinolones is the 
addition of a fluorine atom at the C-6 position, and additional inclusions at the C-7 
position. Quinolones which have a fluorine atom at the C-6 position are referred to as 
fluoroquinolones. 
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Figure 1.2.3.1: Chemical structures of a selection of quinolone antibiotics. The structures of the first-generation 
quinolone, nalidixic acid, and a selection of fluoroquinolones are shown. The core structure common to all quinolones is a 
naphthalene-like structure of two fused six-carbon rings, with a nitrogen atom replacing the carbon at position 1, a carboxyl 
group at position C-3, and a ketone group at position C-4. The key differences between nalidixic acid and later quinolones are 
the addition of the C-7 ring, and the fluorine atom at position C-6, as circled on norfloxacin. Figure adapted from Aldred et al., 
2014.
C-7 ring 
C-6 fluorine 
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1.2.3.1 Uses and Importance 
Quinolones are widely used in both human and veterinary medicine for the treatment 
of bacterial infections (Aldred et al., 2014; Redgrave et al., 2014). They are broad-
spectrum antibiotics that disrupt the ability of bacterial Type IIa topoisomerases to 
disentangle DNA (Drlica, 1999; Redgrave et al., 2014) . The use of quinolones to 
treat children and pregnant women is not recommended as a link to joint problems 
has been observed in young animals, nor is their use recommended in cases where 
the patient has pre-existing heart complaints (BMJ Group and Royal Pharmaceutical 
Society of Great Britain, 2016a). A number of quinolones have been withdrawn from 
use, and others have failed to pass the clinical trial stage, either because of toxicity 
concerns or because they have since been supplanted by better medicines (Ball, 
2003; Hopkins et al., 2005; Mehlhorn and Brown, 2007; Qureshi et al., 2011) - see 
Table 1.2.3.1 for more details. Nalidixic acid, the first quinolone to be used, only 
displayed effectiveness against Gram-negative bacteria causing urinary tract 
infections. Subsequent modifications, including the addition of a fluorine molecule to 
the carbon at the sixth position of the core aromatic ring structure (Bolon, 2011), 
have broadened the range of pathogens against which the antibiotics are effective.  
Fluorinated quinolones are referred to as fluoroquinolones. The division of 
quinolones into generations is largely based on shared components of their 
structures, and the bacteria against which they were effective upon their introduction 
(Andriole, 2005; Ball, 2000; Bolon, 2011). 
 
Ciprofloxacin, a second-generation fluoroquinolone, is considered by the World 
Health Organization to be an essential medicine for the treatment of a wide range of 
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bacterial infections. The British National Formulary advises that ciprofloxacin may be 
used for the treatment of respiratory tract infections, urinary tract infections, 
prostatitis, gonorrhoea, anthrax, the prevention of meningococcal meningitis and the 
prevention of the development of infections during surgery, and the treatment of most 
other infections (BMJ Group and Royal Pharmaceutical Society of Great Britain, 
2016b). It may also be used to treat some cases of perianal fistulae that can occur as 
a result of Crohn’s disease (BMJ Group and Royal Pharmaceutical Society of Great 
Britain, 2016c), and corneal infections (BMJ Group and Royal Pharmaceutical 
Society of Great Britain, 2016d). Levofloxacin is also considered an essential 
medicine; it may be used in the treatment of tuberculosis (World Health Organization, 
2015). The World Health Organization defines essential medicines as those that 
address the healthcare needs of a population to a satisfactory standard (World 
Health Organization, 2016). Levofloxacin is considered a second-line medicine for 
the treatment of a range of respiratory infections in Britain (BMJ Group and Royal 
Pharmaceutical Society of Great Britain, 2016a). 
 
As discussed in my review (Redgrave et al., 2014), although prescribing guidelines 
advise that fluoroquinolones should be reserved, resistance rates continue to rise. In 
the United Kingdom, 7% of E. coli isolates were classified as resistant in 2001, and 
this figure had risen to 23% by 2006. This eventually fell to 19% by 2011. In 
Klebsiella spp., approximately 10% of isolates were classified as resistant to 
fluoroquinolones in 2001, rising to 18% in 2007, and falling again to 10% by 2009 
(Livermore et al., 2013). 
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1.2.3.2 Mechanism of Action 
Quinolones target the GyrA subunit of the Type IIa topoisomerase, DNA gyrase, in 
most Gram-negative bacteria, and the equivalent protein subunit in Topoisomerase 
IV of most Gram-positive bacteria, ParC, though this can vary depending on the 
quinolone and/or bacterial species. They inhibit the ability of the enzymes to reseal 
double stranded DNA breaks created during the relaxation of DNA by intercalating 
with the enzyme-DNA complex to form an enzyme-drug-DNA complex, or “ternary 
complex”. This ultimately leads up to an accumulation of double stranded DNA 
breaks, and cell death (Drlica et al., 2008). Quinolones specifically target GyrA, 
forming ionic bonds with Ser83 and Asp87, or the amino acids at the equivalent 
positions in ParC. This interaction is mediated by a water-metal ion bridge (Aldred et 
al., 2014). The amino acids in GyrA targeted by the quinolones are very close to 
important residues in the enzyme, with the residues His78 and His80 having been 
shown to be key determinants of the ability of GyrA to cleave DNA in E. coli 
(Hockings and Maxwell, 2002).  The crystal structure of the enzyme-drug-DNA 
complex has been solved at a resolution of 2.4 Å for DNA gyrase from 
Mycobacterium tuberculosis, in a complex with DNA and the quinolone moxifloxacin 
(Blower et al., 2016).  This is shown in Figure 1.2.3.2.1.  
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 GyrA  GyrB  DNA 
 GyrA  GyrB  Moxifloxacin 
Figure 1.2.3.2.1: Structure of DNA Gyrase in complex with DNA and 
moxifloxacin. A) Space-filling model of two Mycobacterium tuberculosis GyrBA 
protein fusions (blue and pink; the pale colours represent GyrA, and the dark colours 
are GyrB) in complex with DNA (orange) and the quinolone moxifloxacin (green). B) 
Ribbon model of part A). Parts C) and D) provide additional views of part B), rotated 
90º about the axes shown. The C gate, which is labelled in part D), is the region of 
the enzyme through which DNA is passed after being cleaved and religated. Figure 
from Blower et al. (2016).  
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1.2.4 Quinolone Resistance Mechanisms 
The main mechanism of conferring reduced susceptibility to quinolones is the 
acquisition of mutations in gyrA and parC, resulting single amino-acid substitutions in 
the active site of the enzyme. The most common clinically-relevant substitutions are 
found at GyrA Ser83 and GyrA Asp87 in Escherichia coli and Salmonella spp. 
(Everett et al., 1996; Webber et al., 2013), though these are not the only substitutions 
that can arise (S. Baker et al., 2013) and the precise positions of the amino acids can 
vary depending on the species in question. Table 1.2.4.1 shows the impacts different 
quinolone resistance mechanisms have upon the minimum inhibitory concentration of 
ciprofloxacin for E. coli and S. aureus.  
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Resistance mechanism Fold change in 
ciprofloxacin MIC 
Source(s) 
Gram-negative species (Escherichia coli) 
Topoisomerase substitutions 
gyrA 10-16 Everett et al., 1996; 
Lindgren et al., 2005; 
Morgan-Linnell and 
Zechiedrich, 2007; 
Piddock, 1999 
parC 0 
gyrA (x2) + parC 60 
Permeability changes   
Efflux upregulation 2-8 Lindgren et al., 2005 
Porin loss 4 Strahilevitz et al., 2009 
Plasmid mediated quinolone resistance 
Carriage of qnr alleles >30 Briales et al., 2012; 
Martínez-Martínez et al., 
1998 
Carriage of qepA 32 Yamane et al., 2007 
Carriage of oxqAB 16 Hansen et al., 2007 
Carriage of aac(6’)Ib-cr 4 Robicsek et al., 2006 
Gram-positive species (Staphylococcus aureus) 
Topoisomerase substitutions 
grlA 4-8 Hooper, 2000; Hooper, 
1999 grlB 4-8 
gyrA 0 
grlA + gyrB 64-128 
Permeability changes   
Efflux upregulation 4 Hooper, 2000; Hooper, 
1999; Kaatz et al., 1999 
Table 1.2.4.1: Quinolone resistance mechanisms and their impact on 
ciprofloxacin MIC. Table, adapted from Redgrave et al., 2014, showing the impact 
of various quinolone resistance mechanisms on the minimum inhibitory concentration 
of ciprofloxacin for a Gram-negative species (Escherichia coli) and a Gram-positive 
species (Staphylococcus aureus). Mutations in the genes encoding the target 
proteins result in a greater change in MIC than alterations to the genes regulating 
efflux pumps, but antibiotics can overcome target site mutations if efflux is inhibited 
completely.  
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The two most commonly occurring amino acid substitutions that confer reduced 
quinolone susceptibility are GyrA Ser83 and GyrA Asp87, using the numbering of the 
amino acids in the E. coli version of the protein (Hooper and Jacoby, 2015). The 
development of a gyrA mutation precedes that of the development of a parC mutation 
in Gram-negative organisms, and vice versa in Gram-positive organisms (Zhao and 
Drlica, 2001). The additional mutations allow extremely high levels of resistance to be 
achieved although single topoisomerase mutations can confer clinically relevant 
resistance. This order has been shown in Neisseria gonorrhoeae, where selection 
experiments resulted in mutations conferring substitutions equivalent to GyrA 
Ser83Phe and GyrA Asp87Asn in E. coli, followed by ParC Ser88Pro and ParC 
Glu91Lys, in that order (Belland et al., 1994). 
 
The Quinolone Resistance Determining Region (QRDR) is a region in the GyrA 
protein that, when the amino acids therein are altered, confers a reduction in 
quinolone susceptibility. This was initially defined as spanning the region between the 
67th and 106th amino acids in GyrA in E. coli (Yoshida et al., 1990), or the equivalent 
amino acids in different species, though other substitutions that confer reduced 
quinolone susceptibility have since been found outside this range and its borders 
have moved to account for this (Friedman et al., 2001; Griggs et al., 1996). The 
amino acid substitutions in E. coli GyrA that confer reduced quinolone susceptibility 
identified so far can occur at the following positions (their wild type residues are 
shown): Ala51, Ala61, Gly81, Asp82, Ser83, Ala84, Asp87, Gln106 and Ala196 
(Hopkins et al., 2005). The QRDR concept is not confined to GyrA and a QRDR also 
exists within ParC (Choi et al., 1998). The active site of GyrA in E. coli is Tyr122 
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(Horowitz and Wang, 1987), though the residues Arg32, Arg47, His78 and His80 
have been shown to play roles in the DNA gyrase-mediated DNA breakage-reunion 
reaction (Hockings and Maxwell, 2002). The proximity of these key residues to amino 
acids in positions that, when substituted, confer reduced quinolone susceptibility 
therefore interferes with the ability of DNA gyrase to function efficiently. The 
detrimental effects of amino acid substitution on DNA gyrase efficiency have been 
shown experimentally although the fitness cost is not prohibitive as mutations within 
gyrA are commonly recovered in isolates from patients (Webber et al., 2013). 
It was initially proposed that, because quinolones are synthetic compounds and were 
not known to be naturally produced by microorganisms, resistance to them would be 
uncommon and there would be no horizontally transferrable resistance loci. It was 
instead thought that resistance would be confined to vertically transferred gene 
mutations. Rather naively, it was also thought that there would be no enzymes 
dedicated to quinolone degradation (Burman, 1977).  
 
A number of plasmid-mediated quinolone resistance (PMQR) genes have been 
identified. The first confirmed transferable PMQR determinant was reported in 
Shigella dysenteriae ten years later (Munshi et al., 1987). Although other potential 
PMQR determinants were described previously (Panhotra et al., 1985), the authors 
were unable to confirm that they were plasmid-mediated at that time. The Qnr 
proteins, of which there are five families (Vetting et al., 2011), are transferable PMQR 
determinants first described in 1998, with the archetypal locus, qnrA, having been 
found on the plasmid pMG252 in a clinical isolate of Klebsiella pneumoniae 
(Martínez-Martínez et al., 1998). However, they are not exclusively plasmid-
30 
mediated, with chromosomal copies having been found more recently in some Gram-
positive bacteria (Rodríguez-Martínez et al., 2008). They take the form of 
pentapeptide repeat proteins and QnrA is similar to the protein McbG (Tran and 
Jacoby, 2002), which confers immunity to microcin B17, a DNA replication inhibitor 
(Garrido et al., 1988). Structural analysis of QnrB1 has suggested that the Qnr 
proteins bind to and destabilise the topoisomerase/DNA/quinolone complex, 
removing the quinolone and restoring topoisomerase function (Vetting et al., 2011). 
Additionally, the QepA efflux system is another plasmid-mediated resistance 
mechanism. It takes the form of a 14-transmembrane MFS-type efflux pump that 
increases the minimum inhibitory concentration of ciprofloxacin 32-fold in comparison 
to strains of E. coli lacking the qepA gene (Yamane et al., 2007). OqxAB is another 
plasmid-mediated efflux pump and a member of the RND multidrug efflux pump 
family, and its expression has been shown to confer reduced susceptibility to both 
fluorinated and non-fluorinated quinolones (Hansen et al., 2007). 
 
In addition to the PMQR genes, chromosomally encoded multidrug efflux pumps, 
such as the tripartite RND-type AcrAB-TolC complex, are able to remove quinolones 
and other drugs from Gram-negative bacteria in exchange for importing hydrogen 
ions (Piddock, 2006). Fluoroquinolones exert selective pressure that favours the 
emergence of mutants that constitutively express the loci which encode for these 
proteins, usually through the de-repression of the mar, sox or ram global regulatory 
systems (Sun et al., 2011; Zheng et al., 2011, 2009), as well as single nucleotide 
mutations that result in an AcrB Gly288Asp substitution, as shown in Salmonella 
(Blair et al., 2015a). Combinations of mutations in the efflux pump loci and the genes 
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which encode the pump’s regulators can have a synergistic effect, further reducing 
quinolone susceptibility (Blair et al., 2015a). Figure 1.2.4.1, adapted from Aldred et 
al., 2014, represents these and other quinolone resistance mechanisms 
diagrammatically. 
 
It should be noted that exposure to other antimicrobial agents is able to confer 
reduced quinolone susceptibility. It has been shown that the use of biocides, such as 
the widely-used triclosan (Schweizer, 2001), selects for increased expression of 
genes encoding efflux pump components and regulators, leading to increased 
antibiotic tolerance (Randall et al., 2007; Webber et al., 2015, 2008). Biocide 
exposure has also been shown to select for point mutations in gyrA, reducing the 
effectiveness of quinolones (Randall et al., 2004). The precise reason why this 
occurs is unknown, since triclosan targets FabI rather than GyrA (McMurry et al., 
1998), but it is thought that gyrA mutations confer a reduction in triclosan 
susceptibility by changing supercoiling levels. This then alters gene expression, a 
consequence of which would be differences in the expression of outer membrane 
proteins (Randall et al., 2007). This could manifest as either increased efflux pump 
activity and the removal of biocides, or reduced levels of porins, preventing biocides 
from entering the cell. 
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Figure 1.2.4.1: Overview of quinolone resistance mechanisms. 
Figure showing chromosomal and plasmid-mediated mechanisms of quinolone 
resistance. Adapted from Aldred et al. (2014). Chromsomal resistance mechanisms 
include mutations occurring within the topoisomerase that reduce the effectiveness of 
the quinolone, decreasing porin expression so that the drug cannot enter the cell, 
and increasing efflux pump expression so that the drug is unable to remain in the 
cells should it enter. Plasmid-mediated quinolone resistance mechanisms include the 
enzyme-mediated modification of the quinolone to stop it from functioning, the 
introduction of efflux pumps that can transport the drug out of the cell, or 
destabilisation of the topoisomerase/DNA/quinolone complex by Qnr proteins.  
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1.2.5 Resistance and Fitness 
It has been shown by experimentation that having an antibiotic resistance 
mechanism can incur a fitness cost to the cell (Marcusson et al., 2009), though this 
has usually been shown through competition assays with isogenic strains in a 
laboratory setting, and does not necessarily translate to what is seen in clinical 
practice (Andersson, 2006). One experiment showed that, after eight isogenic single 
mutants that conferred reduced norfloxacin susceptibility were derived from 
Pseudomonas aeruginosa PA01, only three of the eight mutants had reduced fitness 
compared with the parent strain; these were GyrA Thr83Ile, GyrA Asp87Tyr and 
GyrB Glu469Asp. The other mutants carried substitutions which conferred a neutral 
fitness cost (Kugelberg et al., 2005). Additionally, isogenic mutants in the gyrA and 
gyrB loci of Clostridium difficile that resulted in reduced fluoroquinolone susceptibility 
did not incur a fitness cost in vivo and persisted in the absence of selective pressure 
(Wasels et al., 2015). It was also shown that GyrA Ser91Phe and GyrA Asp95Asn 
substitutions in Neisseria gonorrhoeae reduce fluroquinolone susceptibility without a 
noticeable impact on cell fitness, but that the subsequent acquisition of a ParC 
Asp86Asn substitution is detrimental. The fitness cost of the ParC substitution is, 
however, ameliorated through the acquisition of further compensatory mutations 
(Kunz et al., 2012). 
 
The majority of gyrA point mutations that confer reduced quinolone susceptibility 
have been shown to have an associated fitness advantage in Salmonella Typhi when 
grown in minimal media, and strains carrying multiple mutations can show a further 
increase in fitness (S. Baker et al., 2013). Work from our research group has shown 
34 
that, in the absence of any selective pressure, S. Typhimurium SL1344 grows faster 
in LB media than isogenic strains with gyrA mutations (Webber et al., 2013) and 
additionally out-competes gyrA mutant strains when grown in co-culture (Webber et 
al., manuscript under review). The GyrA Ser83Phe and GyrA Asp87Gly proteins 
have both been shown to be less efficient than wild type GyrA in vitro, each with a 3-
fold and 6-fold drop in gyrase activity compared with the wild type, respectively 
(Webber et al., 2017). However, in the presence of various antibiotics or biocides, the 
gyrA mutants outperform the wild type strains, demonstrating a fitness advantage in 
the presence of antimicrobials (Webber et al., 2013).  
 
1.3 DNA Topology 
Bacteria do not have a membrane-bound nucleus containing multiple paired, linear 
chromosomes like most eukaryotes, but instead usually possess a single circular 
chromosome, which is found in a membrane-free region known as the nucleoid 
(Kellenberger et al., 1958; Thanbichler et al., 2005). Additional genetic information 
may be conveyed on plasmids, which are transmissible (Meynell et al., 1968). When 
extruded, the bacterial chromosome is approximately ten times longer than the length 
of the cell in which it resides, famously demonstrated in Ruth Kavenoff’s electron 
micrograph of the E. coli chromosome, and shown in Figure 1.3.1 (Wang et al., 
2013). In the case of E. coli, the chromosome has to be compacted down to 
approximately a thousandth of its relaxed size to be able to fit within the cell (Holmes 
and Cozzarelli, 2000). 
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Figure 1.3.1: The extruded bacterial nucleoid. Figure from Kavenoff, via Wang et al., 
2013, showing the extruded nucleoid of E. coli, bound to cytochrome C and visualised using 
transmission electron microscopy. The nucleoid is approximately an order of magnitude 
greater (about 20 !m) than the average E. coli cell (around 2 !m).  
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Fluorescent in situ hybridisation experiments, as well as recombination experiments, 
have identified four major regions of the E. coli chromosome, termed macrodomains 
(Niki et al., 2000; Valens et al., 2004). These are the ori, ter, left and right 
macrodomains, and they localise to different parts of the cell as the cell cycle 
progresses. Macrodomains are highly ordered structures, approximately 1 megabase 
in size in E. coli (Dame et al., 2011), and are defined by the regions in which long-
range DNA interactions do and do not occur (Thiel et al., 2012; Valens et al., 2004). 
 
The macrodomains are sub-divided into supercoiled regions, known as plectonemic 
loops, microdomains, or supercoiled domains (Worcel and Burgi, 1972). Plectonemic 
loops are transient regions of overwound DNA, changing their size and location as 
the cell grows, but average a size of about 10 kilobases (Postow et al., 2004; Stein et 
al., 2005). Changes in supercoiling in one loop are confined to that loop (Higgins et 
al., 1996; Postow et al., 2004). This is different to what is observed in plasmids, 
where changes in supercoiling affect the whole plasmid (Wang et al., 2013). The 
ability of the change in supercoiling to spread throughout the rest of the chromosome 
is limited by microdomains, and additional supercoils can be introduced by the effects 
of transcription (Deng et al., 2004; Scheirer and Higgins, 2001). 
 
Nucleoid-associated proteins are another important aspect of bacterial chromosomal 
architecture (Dillon and Dorman, 2010), and they are the closest equivalent bacteria 
have to histones – when they were first discovered, many were initially described as 
“histone-like proteins” (Drlica and Rouvière-Yaniv, 1987). They are able to form 
physical links between parts of the chromosome that would otherwise be distant if the 
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chromosome were purely linear (Dorman, 2013), and are involved in defining the 
limits of supercoiling domains (Hardy and Cozzarelli, 2005). It has been suggested 
that nucleoid-associated proteins may play more of a role in regulating gene 
expression levels than they do in terms of controlling nucleoid structure (Zimmerman, 
2006). The expression levels and binding profiles of nucleoid-associated proteins can 
change in response to environmental stimuli and depending on the growth phase of a 
cell, and consequently alter global chromosome structure (Cameron et al., 2011). 
The changes in expression levels are represented in Figure 1.3.2. 
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Figure 1.3.2: Nucleoid associated protein levels change with growth. 
Graph showing the relative protein concentrations of the major nucleoid associated 
proteins, Fis (yellow), H-NS (red), IHF (blue) and Dps (orange) and how they change 
as a population of phase progresses through its growth cycle (black). H-NS is 
relatively constant, Fis levels peak at the transition between lag phase and 
logarithmic phase, IHF falls, then rises again, and Dps gradually increases. Figure 
from Dillon and Dorman, 2010. 
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Some of the more important nucleoid-associated proteins found in Gram-negative 
bacteria (Dillon and Dorman, 2010) are discussed below. Each can bind DNA and 
therefore alter chromosome structure, although this can happen in response to 
different stresses at different times. 
 
• HU, a histone-like protein named after E. coli strain U93 (Oberto et al., 2009), 
has two subunits, HUα and HUβ – these form dimers, but whether they form 
heterodimers or homodimers is dependent upon which growth phase the cell 
is currently going through (Claret and Rouvière-Yaniv, 1997). HUα and HUβ 
have both been implicated in the ability of S. Typhimurium to invade epithelial 
cells (Mangan et al., 2011); double mutants of hupA and hupB were shown to 
be less able to tolerate extremes of temperature (Wada et al., 1988) and to 
have altered mini chromosome stability, but were still able to initiate 
replication, possibly by being compensated for by other histone-like proteins 
(Ogawa et al., 1989). 
• H-NS (Histone-like Nucleoid Structuring protein) favours binding to AT-rich 
sequences, which are usually acquired from other organisms, and has been 
shown to compete with the sigma subunit of the RNA polymerase complex for 
transcription start sites, silencing genes (Dame et al., 2002; Fang and Rimsky, 
2008; Lang et al., 2007). H-NS is capable of forming filaments and bridge 
structures with DNA; these are both different ways in which H-NS can 
polymerise, and which structure is formed depends upon the cellular 
magnesium concentration (Lim et al., 2014). There are some loci that H-NS is 
unable to repress when acting alone, but it can do so by forming complexes 
with Hha and YdgT, two small proteins only found in enteric bacteria, e.g. 
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Salmonella (Ali et al., 2013). The expression of H-NS is relatively constant and 
does not change substantially as the cell grows (Hinton et al., 1992). 
• FIS (Factor for Inversion Stimulation) forms dimers that bind to non-specific 
regions of DNA and ultimately interact with one another to form filamentous 
structures (Skoko et al., 2006), but more recent evidence has shown it binds 
to AT rich regions of DNA (Cho et al., 2008), and that it has a 15 bp core 
binding sequence of GTTTGAATTTTGAGC (Hancock et al., 2016). Its 
expression is highest during exponential phase (Ó Cróinín and Dorman, 
2007). It was originally described as being involved in site-specific 
recombination (Osuna et al., 1995), but has since been shown to control 
expression of the Type III secretion systems involved in virulence in S. 
Typhimurium (Kelly et al., 2004). 
• IHF (Integration Host Factor) forms complexes with Dps (DNA-binding Protein 
from Starved cells), another nucleoid associated protein (Lee et al., 2015; 
Mangan et al., 2006). Both are most commonly found in stationary phase, with 
Dps being the most commonly occurring of the two.  IHF also has an AT-rich 
consensus sequence (Goodrich et al., 1990). Interestingly, HU and IHF have 
been shown to able to substitute for one another, owing to an amino acid 
sequence similarity of around 60% (Segall et al., 1994). 
• MatP, which is not shown in Figure 1.3.2, binds to a repeated motif found in 
the Ter domain (Mercier et al., 2008). It interacts with ZapA and ZapB to link 
the Ter domain to the divisome (Männik et al., 2016), and is able to interact 
with MukBEF to ensure that topoisomerase IV segregates daughter 
chromosomes at the correct time (Nolivos et al., 2016). 
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DNA topology can be expressed in terms of “linking number” – this is a mathematical 
way of saying how many times one DNA strand crosses over another, and is the sum 
of the “twist” and the “writhe” (Mirkin, 2001). Twist is a measure of the number of 
turns in a piece of DNA; the most common form of DNA, B-DNA (Du et al., 2013), 
has 10.5 base pairs to every turn (Watson and Crick, 1953).  Writhe is a measure of 
how many times a strand of DNA crosses over itself. Linking number can only 
change through the action of topoisomerases - without them, it is static and a change 
in twist has to be compensated for by a change in writhe (Mirkin, 2001). 
 
1.3.1 Topoisomerases and Supercoiling 
Topoisomerases are highly conserved enzymes found in all kingdoms of life that 
create and repair breaks in DNA to alter DNA tension. They have roles in DNA 
replication and cell division, and are critical to cell survival (Champoux, 2001), 
making them an excellent target for antibiotics (Collin et al., 2011). Supercoiling can 
be used as a measure for how over or under-wound the DNA of a cell is. Over-wound 
DNA is described as being positively supercoiled, and under-wound DNA as 
negatively supercoiled. Supercoiling is not in a fixed state, and differs between micro-
domains within a bacterial chromosome and between species, which maintain their 
chromosomes at different basal levels of supercoiling. The degree of supercoiling 
within a cell can be altered in response to a number of different stimuli, including 
environmental factors (Cameron et al., 2011) and locally in response to DNA 
replication or the transcriptional state of a gene (Booker et al., 2010; Dorman and 
Corcoran, 2009). DNA is inherently negatively supercoiled in S. enterica and 
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Escherichia coli (Cameron et al., 2011) and this provides a store of potential energy 
which helps drive cellular processes (Mirkin, 2001).  
 
1.3.2 Type IIa Topoisomerases 
Topoisomerases are categorised as Type I or Type II depending on how many 
strands of DNA they cut. Type I topoisomerases cut one strand of DNA and are 
subdivided into further categories based on the precise mechanisms involved. Type II 
topoisomerases cut two strands of DNA (Champoux, 2001). Type II topoisomerases 
can be divided into Type IIa and Type IIb topoisomerases, based on their sequence 
similarities (Forterre et al., 2007).  
 
The Type IIa topoisomerases that are the focus of this work are DNA gyrase and 
Topoisomerase IV. Topoisomerase IV separates catenated daughter chromosomes 
and relaxes supercoils of both directions, whilst DNA gyrase is unique in its ability to 
introduce negative supercoils into DNA (Corbett et al., 2005); this is represented 
diagrammatically in Figure 1.3.2.1. These enzymes are highly conserved and 
essential, thus making good drug targets – the complexes which they form with DNA 
are targeted by quinolones (Giraud et al., 2006). Both topoisomerases are 
heterotetrameric protein complexes, comprising two copies of each of the A subunit, 
encoded by gyrA in DNA gyrase and parC in Topoisomerase IV, and the B subunit, 
encoded by gyrB in DNA gyrase and parE in Topoisomerase IV (Higgins et al., 1978; 
Peng and Marians, 1993). Figure 1.3.2.2 shows the structure of the E. coli DNA 
gyrase complex. Topoisomerase IV separates daughter chromosomes during the 
DNA replication process and relaxes supercoils of both directions, whereas DNA 
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gyrase increases the level of negative supercoiling. Gyrase does not favour any 
particular binding motifs (Messerschmidt and Waldminghaus, 2015), but 
preferentially localises to the Ori domain (Sobetzko et al., 2013). 
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Figure 1.3.2.1: The roles of Type IIa topoisomerases in altering chromosome 
dynamics. This figure, from Corbett et al., 2005, shows the processes in which Type 
IIa topoisomerases are involved in altering genomic supercoiling. Topoisomerase IV 
relaxes supercoils of both directions and separates catenated daughter 
chromosomes, which arise as a result of the DNA replication process. DNA gyrase, 
however, introduces negative supercoils into DNA. 
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Figure 1.3.2.2: Structure of Escherichia coli DNA gyrase. A) Ribbon model of the DNA gyrase holoenzyme. The enzyme is 
comprised of two copies of each of the GyrA and GyrB subunits. B) Space-filling model of the DNA gyrase holoenzyme. C) 
Subunits of Escherichia coli DNA gyrase. 1: GyrB subunit and ADPNP. 2: GyrB TOPRIM domain. 3: GyrA subunit. 4: Two 
views of the C-terminal domain of the GyrA subunit. (Figure from Bush et al., 2015).
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A comprehensive review of topoisomerase structure and mechanism was written by 
Schoeffler and Berger (2008); Type IIa topoisomerases are symmetrical, possess 
three gates and function in an ATP-dependent manner.  A double-stranded segment 
of DNA, termed the G segment, is captured by the DNA gate of the enzyme, then the 
N gate is closed and another double-stranded segment of DNA, termed the T 
segment, is captured upon the binding of two ATP molecules to the enzyme. One 
ATP is then hydrolysed and both strands of the G segment of DNA are cut, allowing 
the T segment to be passed through. The fragmented G segment is re-ligated and 
the C gate opens. The T segment can then be released from the enzyme, and the 
second ATP is hydrolysed (Schoeffler and Berger, 2008). This process is shown in 
Figure 1.3.2.3. 
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Figure 1.3.2.3: Cleavage of 
double-stranded DNA by DNA 
Gyrase. 
1) Free-floating GyrA homodimer, 
GyrB monomers and DNA.  
2) Assembly of the holoenzyme and 
capture of DNA. 
 
3) Initial ATP-mediated cleavage of 
the G segment of DNA. 
 
4) ATP hydrolysis and passing of 
the T segment of DNA through the 
cleaved G segment. 
5) Religation of the G segment. The 
enzyme can then either capture and 
cut more DNA, or be disassembled. 
 
(Figure from Costenaro et al., 2007) 
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1.3.3 The Impact of Location and Structure of DNA on Function 
The fact that the chromosomal location of a gene can affect its expression has been 
known about in eukaryotes for some time; its occurrence in bacteria is a 
comparatively recent discovery (Feuerborn and Cook, 2015). Through the use of 
fluorescent reporters controlled by the lac promoter in E. coli, it has been shown that 
the position of a gene in the chromosome can have an effect on how strongly it is 
expressed in bacteria, and that the transcription of one gene can cause the 
repression of its neighbours (Bryant et al., 2014). Location-dependent changes in 
promoter activity have also been observed in S. pneumoniae (Ferrándiz et al., 2014).  
It has also been shown that transcriptionally silent extensive protein occupancy 
domains, regions of the genome which are transcriptionally silent because of bound 
proteins blocking access by transcriptional machinery (Kröger et al., 2012; Zarei et 
al., 2013), correlate with regions bound and supressed by H-NS, with the activity of 
promoters in these regions and near the borders of macrodomains being more 
heavily repressed than promoters found elsewhere (Brambilla and Sclavi, 2015). 
 
The base pair content of a gene can also affect its expression. It has been shown 
that, although there are multiple mRNA triplets encoding for the same amino acid, 
transcripts containing specific triplets encoding for a given amino acid tend to be 
enriched, and this appears to be influenced by the hydrophobicity of the mRNA (Boël 
et al., 2016). Additionally, the nucleoid-associated protein H-NS preferentially binds 
AT-rich regions of DNA (Lang et al., 2007; Navarre et al., 2006), preventing them 
from being able to be accessed by RNA polymerase – though the precise 
mechanism by which RNA polymerase is occluded by H-NS is unclear (Landick et 
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al., 2015). The strength of the binding of H-NS to AT-rich regions is because of these 
regions’ inherent curvature (Dame et al., 2001).  In Salmonella, horizontally acquired 
DNA sequences often have a higher AT content than “native” DNA, so are bound and 
supressed by H-NS to prevent any potential detrimental impacts upon fitness the 
genes contained within may have upon the cell (Ali et al., 2014; Navarre et al., 2006), 
and a similar role has been observed in E. coli, where H-NS prevents the expression 
of intragenic DNA sequences from spurious promoters (Singh et al., 2014). 
 
1.4 Salmonella Typhimurium as a Model Organism 
1.4.1 Salmonella Genus and Phylogeny 
Salmonella is a genus of Gram-negative bacteria (Heinrichs et al., 1998) within the 
order Enterobacteriales, within the class Gammaproteobacteria. Other well-known 
members of Enterobacteriales include Escherichia coli and Yersinia pestis (Williams 
et al., 2010), and the last common ancestor of Salmonella and Escherichia is thought 
to have existed around 100 million years ago, based on molecular clock analyses 
(Doolittle et al., 1996). The genus Salmonella was given its name by Lignières in 
1901 (St John-Brooks, 1934) in honour of the discovery of Bacillus choleraesuis (now 
Salmonella enterica serovar Choleraesuis) by Smith and Salmon in the 1880s 
(Schultz, 2008). 
 
There were formerly approximately 2,500 species defined in the Salmonella genus, 
the organisation of which was based on serotyping (Kauffmann and Edwards, 1952). 
The genus has more recently been reorganised into two species, Salmonella bongori 
and Salmonella enterica, with almost all former species now being recognised as 
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serovars of S. enterica (Brenner et al., 2000). Public Health England has moved to 
using a combination of whole genome sequencing and multi-locus sequence typing 
to categorise serovars (Ashton et al., 2016). Various serovars of S. enterica can be 
pathogenic to humans and animals. The serovar Salmonella Typhimurium was first 
isolated by Löffler from a diseased population of field mice in Thessaly, but was 
named Bacillus typhi-murium at the time (H. J. Baker et al., 2013). 
 
1.4.2 Relevance as a Pathogen 
S. Typhimurium is a non-typhoidal serovar of Salmonella that causes gastroenteritis 
in humans, but causes typhoid fever in mice (“Typhimurium” is Latin for “mouse 
typhoid”). Mouse models of S. Typhimurium have historically been used to research 
S. Typhi, which causes typhoid fever in humans (Carter and Collins, 1974), but the 
role of S. Typhimurum as a major human gastrointestinal pathogen is still relevant.  
 
Despite the vaccination of chickens against Salmonella in the United Kingdom, there 
were approximately 90,000 reported cases of Salmonellosis in the European Union in 
2012, making it the second most common gastrointestinal infection (European Centre 
for Disease Prevention and Control, 2014). However, this figure will be less than the 
real value, as salmonellosis is widely underreported, both in Europe and throughout 
the rest of the world (Gibbons et al., 2014; Hall et al., 2008; Marzel et al., 2014; 
Mellou et al., 2013). Additionally, multiple outbreaks of Salmonella in the United 
Kingdom in the past decade have been caused by cheap eggs and poultry imported 
from countries which have lower food hygiene standards and do not vaccinate as 
thoroughly, if at all, such as Spain (Janmohamed et al., 2011; O’Brien et al., 2004; 
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Public Health England, 2015). Seven hundred and twenty one isolates of Salmonella 
from chickens were reported in Great Britain in 2014, none of which were found as a 
result of investigations under the Zoonoses Order (Animal and Plant Health Agency, 
2015).  
 
1.4.3 Infection Cycle and Treatment 
Salmonella usually enters the body through the digestive tract and can tolerate the 
acidic conditions of the stomach (Garcia-del Portillo et al., 1993). When Salmonella 
enters the small intestine, it invades macrophages (Gahring et al., 1990) or crosses 
the epithelial barrier through M cells within the Peyer’s patches (Hohmann et al., 
1978). Salmonella are able to secrete effectors via the Type 3 Secretion System 
(Galán, 2001; Zhou and Galán, 2001), and these effectors alter host cell behaviour 
and disrupt the water, ion and salt content of the intestine. This results in diarrhoea 
and the bacteria are ultimately shed into the intestine, either to re-invade the intestine 
or to be passed out of the digestive system (Haraga et al., 2008). 
 
Typhoidal serovars of Salmonella, such as Typhi, Sendai and Paratyphi, cause 
typhoidal and paratyphoidal fever. They are restricted to human hosts and incubate 
over a two-week period. Symptoms, mainly a high fever, last for three weeks, but can 
also include dehydration, rashes, nausea, headaches, a swollen liver and spleen, 
and either diarrhoea or constipation, depending on the patient. Untreated, this can be 
fatal (Gal-Mor et al., 2014). It is possible to be infected with a typhoidal strain and not 
exhibit symptoms (Del Bel Belluz et al., 2016) - Mary Mallon infamously was an 
asymptomatic carrier of typhoid in the late 1800s and, working as a cook, managed 
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to infect upwards of 122 people, five of whom died (Marineli et al., 2013). Typhoid 
should not be confused with typhus, which is caused by Rickettsia spp (Osterloh et 
al., 2016).  
 
Non-typhoidal Salmonella infections are caused by most other serovars of 
Salmonella to those aforementioned and present after six to twelve hours in the form 
of a fever and diarrhoea, and last about a week (Gal-Mor et al., 2014). The use of 
oral rehydration therapy is recommended to replenish liquids, salts and sugars lost 
as a consequence of diarrhoea (Sentongo, 2004). Non-typhoidal salmonellosis is 
usually self-limiting, but can become complicated. Fluoroquinolones or 
cephalosporins are the first choices of antibiotics in cases requiring antibiotic 
treatment (Gal-Mor et al., 2014). The British National Formulary recommends the use 
of ciprofloxacin or cefotaxime for the treatment of non-typhoidal Salmonella if, and 
only if, the infection is severe or there is a strong likelihood of the infection becoming 
invasive – for example, if the patient is immunocompromised, has a defective form of 
haemoglobin, or is under six months old (BMJ Group and Royal Pharmaceutical 
Society of Great Britain, 2016e). As of this writing, there are currently seven known 
programmes to develop a vaccine for non-typhoidal Salmonella, mainly targeting 
components of the outer membrane. Of the seven programmes, only one has passed 
the pre-clinical stage and is undergoing Phase I clinical trials (Tennant et al., 2016).  
  
1.4.4 Genome Organisation 
Salmonella Typhimurium strain LT2 was the first representative of the serovar 
Typhimurium to have its complete genome sequence published. It has a 4.86 
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megabase circular chromosome and a 94 kilobase virulence plasmid, with the two 
containing a total of approximately 4,500 coding sequences and both having a GC 
content of 53% (McClelland et al., 2001).  
 
The S. Typhimurium strain SL1344, which is the primary subject of this study, has a 
4.88 megabase circular chromosome and three plasmids, pSLT, pCol1b9 and 
pRSF1010, which are 94, 87 and 9 kilobases in size, respectively. The two smaller 
plasmids are not present in LT2. The SL1344 genome has a GC content of 52.3% 
and contains approximately 4,700 coding sequences (Kröger et al., 2012). Strain 
14028S has a 4.87 megabase genome and is 92% identical to strain LT2 (Jarvik et 
al., 2010). 
 
The Salmonella Pathogenicity Islands are AT-rich regions of DNA acquired from 
foreign sources, and are usually silenced by H-NS to counteract the negative fitness 
costs resulting from the acquisition of foreign DNA (Ali et al., 2014). SPI-I and SPI-II, 
the main islands, encode Type III secretion systems and other components that are 
involved in virulence (Figueira and Holden, 2012; Lostroh and Lee, 2001). There are 
at least nine known such pathogenicity islands (Velásquez et al., 2016). SPI-I is 40 
kilobases in length and absent from the E. coli chromosome (Mills et al., 1995), 
forming one of the main genetic differences between the two species (Ali et al., 
2014). The Salmonella genome is more negatively supercoiled than that of E. coli 
(Cameron et al., 2011; Higgins, 2016), and the levels of FIS, which has been shown 
to repress gyrA and gyrB expression in S. enterica (Keane and Dorman, 2003), vary 
between the two species (Cameron et al., 2011).  
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1.4.5 Quinolone Resistance in Salmonella 
Quinolone resistance in Salmonella is a major concern as quinolones and 
fluoroquinolones are the antibiotic of choice in human and animal medication to treat 
severe cases of gastroenteritis (Aarestrup et al., 2003), in addition to salmonellosis 
and bacteraemia. The Cochrane Collaboration, the medical meta-analysis and 
systematic review organisation, does not recommend the use of antibiotics to treat 
diarrhoea caused by non-typhoidal Salmonella as it can select for clinical resistance 
to antibiotics (Onwuezobe et al., 2012), and as the infection is usually self-limiting 
(Gal-Mor et al., 2014), there is no clinical benefit to their use (Onwuezobe et al., 
2012). The Cochrane Collaboration has also noted that “generally, fluoroquinolones 
performed well” when used to treat typhoid, but could not give a strong 
recommendation for or against their use because of fears of the development of 
resistance (Effa et al., 2011). 
 
In 2012, there were just over 91,000 confirmed cases of human salmonellosis in 
Europe (European Food Safety Authority and European Centre for Disease 
Prevention and Control, 2014a), and 5% of isolates were classified as resistant to 
ciprofloxacin (European Food Safety Authority and European Centre for Disease 
Prevention and Control, 2014b). This decreased to 83,000 reported human cases in 
2013 (European Food Safety Authority and European Centre for Disease Prevention 
and Control, 2015a), 4% of which were classified as resistant to ciprofloxacin 
(European Food Safety Authority and European Centre for Disease Prevention and 
Control, 2015b). In 2014, this figure increased to approximately 90,000 confirmed 
cases of human salmonellosis (European Food Safety Authority and European 
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Centre for Disease Prevention and Control, 2015c) and 9% of isolates were classified 
as resistant to ciprofloxacin (European Food Safety Authority and European Centre 
for Disease Prevention and Control, 2016). Eighty-four per cent of S. Kentucky 
isolates were found to be resistant to quinolones (European Food Safety Authority 
and European Centre for Disease Prevention and Control, 2016); this is owing to the 
massive expansion of the ST198 strain since having been isolated in the 1990s and 
its acquisition of substitutions in GyrA in the early 2000s (Le Hello et al., 2013). 
 
The first two cases of ciprofloxacin-resistant clinical isolates of Salmonella ever 
reported in the literature were published in 1990 (Piddock et al., 1990), three years 
after its introduction into clinical use in 1987 (Török et al., 2009). The first patient 
presented with a urinary tract infection that was caused by Salmonella Typhimurium 
and was initially susceptible to nalidixic acid and other antimicrobials. A combined 
treatment of amoxicillin and clavulanic acid did not clear the infection, so a two-week 
course of ciprofloxacin was prescribed instead. After a month, the MIC of nalidixic 
acid had increased 32-fold from 8 µg/mL at the start of treatment to 256 µg/mL, and 
the MIC of ciprofloxacin had increased approximately 64-fold from 0.03 µg/mL at the 
start of treatment to 2 µg/mL at the end of the month (Piddock et al., 1990). As a 
reference point, the MICs for nalidixic acid and ciprofloxacin against the type strain, 
Salmonella Typhimurium NCTC74 (Stanley et al., 1993; Public Health England, n.d.) 
were 2 µg/mL and 0.015 µg/mL, respectively (Piddock et al., 1990).  
 
The second patient had undergone aortic aneurysm surgery and S. Typhimurium 
was isolated from a haematoma. These isolates were initially sensitive to 
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ciprofloxacin, so the infection was treated with ciprofloxacin. After a week, two 
populations of S. Typhimurium were isolated from the wound; one was ciprofloxacin 
resistant and the other was ciprofloxacin susceptible. The MIC of ciprofloxacin 
required to kill the resistant isolate was within levels that were, at the time, 
considered acceptable. Treatment failed and the infection was ultimately cleared with 
a twelve-week course of aztreonam (Piddock et al., 1990). The timeline for this 
treatment is shown in Figure 1.4.5.1, and the MICs for a number of antibiotics against 
the clinical isolates are shown in Table 1.4.5.1.  
 
It is interesting to note that, since these cases were reported, the European 
Committee for Antimicrobial Susceptibility Testing has officially decided that the 
clinically acceptable breakpoint concentration of quinolone antibiotics for Salmonella 
is lower than that of other members of the Enterobacteriaceae by a factor of 
approximately 16-fold – 0.06 µg/mL compared with 2 µg/mL (European Committee 
on Antimicrobial Susceptibility Testing, 2016), after it had been observed that a 
common theme in the treatment of Salmonella infections was that doses of 
quinolones within this range of concentrations were ineffective (Aarestrup et al., 
2003).  
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Figure 1.4.5.1: Progression of treatment for a patient with one of the earliest reported cases of quinolone-resistant 
Salmonella Typhimurium. Figure, taken from Blair et al., (2015a) showing the course of treatment for Patient B, a 52-year old 
male with a  S. Typhimurium infection as described in Piddock et al., 1990. Bacterial isolates were obtained from the patient 
over a 21-week period. The patient was given a combination of gentamicin and flucloxacillin before the first isolate was taken. 
He then received intravenous ciprofloxacin for 10 days, followed by four weeks of oral ciprofloxacin. He was then administered 
intravenous ceftazidime for two weeks, followed by three months of treatment with intravenous aztreonam. Lx =  Antimicrobials 
Research Group internal culture collection numbers. The minimum inhibitory concentrations of the agents used to treat this 
infection are shown in Table 1.4.5.1, overleaf.
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Strain Timepoint isolated  
after therapy 
Minimum Inhibitory Concentration (µg/mL) 
Cip Nal Chl Tet Atm Caz 
L3 0 weeks 0.015 2 2 1 0.06 0.12 
L10 1 week 0.06 8 8 2 0.12 0.5 
L11 3 weeks 0.03 16 8 2 0.25 0.25 
L12 3 weeks 0.5 64 32 8 0.5 1 
L13 3 weeks 0.5 64 16 8 0.5 0.5 
L6 5 weeks 0.5 64 32 8 0.5 0.5 
L16 17 weeks 0.5 64 32 8 0.5 1 
L18 19 weeks 0.5 64 32 8 0.5 2 
 
Table 1.4.5.1: MICs of various antibiotics for bacterial isolates taken from a 
patient with one of the earliest reported cases of quinolone-resistant 
Salmonella Typhimurium. Table, taken from Blair et al., (2015a) showing the MICs 
for antibiotics tested against isolates of Salmonella Typhimurium taken from Patient 
B, a 52-year old male with a S. Typhimurium infection as described in Piddock et al., 
1990. The minimum inhibitory concentrations of all the antibiotics used, bar 
ceftazidime, reach a plateau around three weeks and do not increase further. Cip = 
ciprofloxacin; Nal = nalidixic acid; Chl = chlorpromazine; Tet = tetracyclone; Atm = 
aztreonam; Caz = ceftazidime. 
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1.5 Work Preceding This Study 
The work in this project is based on previous work from this laboratory (Webber et 
al., 2013). The previous work observed that a clinically-relevant amino acid 
substitution within GyrA conferring reduced fluoroquinolone susceptibility (Asp87Gly) 
in S. Typhimurium improved survival compared with the parent strain when 
challenged with a range of non-quinolone drugs. The presence of this substitution 
has been reported in quinolone-resistant isolates of Salmonella taken from both 
humans and animals (Griggs et al., 1996). The non-quinlone drugs to which the GyrA 
Asp87Gly susbsitution decreased susceptibility included beta-lactams, folate 
synthesis inhibitors, protein synthesis inhibitors and toxic anions (Webber et al., 
2013). The GyrA Asp87Gly substitution also resulted in a more negatively 
supercoiled topoisomer profile than both wild type S. Typhimurium and GyrA 
Ser83Phe cells. Based on the protective effects of the GyrA Asp87Gly substitution 
against other antibiotics (Webber et al., 2013), the fact that supercoiling changes in 
response to environmental stresses (Cameron et al., 2011), and the increasing build-
up of low levels of antibiotics in the environment (Andersson and Hughes, 2014), the 
next step would be to investigate what effect, if any, exposure to low-level stresses 
(antibiotic-mediated or otherwise) had upon supercoiling, how these impact upon 
gene expression and antibiotic resistance and the role of gyrA mutation in these 
processes. 
 
1.6 Aims, Objectives and Hypotheses 
The hypotheses to be investigated during this thesis are: 
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• Mutations within gyrase alter the supercoiling levels of Salmonella due to 
changes in chromosome structure, thereby influencing the expression of 
numerous genes around the chromosome; 
• The expression of genes involved in antimicrobial tolerance and environmental 
stresses are sensitive to supercoiling; 
• Analogous mutations within gyrA will have similar impacts in both Salmonella 
and E. coli; 
• Supercoiling-sensitive genes will be influenced by chromosomal location. 
The aims of this project are: 
• To precisely identify the repertoire of supercoiling-sensitive genes in 
Salmonella Typhimurium; 
• To determine the effect of supercoiling on chromosome structure, DNA 
binding protein distribution and promoter locations of supercoiling-sensitive 
genes, and to determine the dynamics of supercoiling changes; 
• To define the contribution of alterations in supercoiling to antibiotic resistance. 
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Chapter Two 
Materials and Methods 
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2. Materials and Methods 
2.1 Growth of Bacterial Strains 
The strains used in this study are listed in Table 2.1.1. This study used a number of 
strains of Salmonella Typhimurium SL1344 and Escherichia coli MG1655 with 
defined, clinically relevant mutations in gyrA. The S. Typhimurium strain SL1344 was 
obtained from the ARG Culture Collection, but was originally acquired from the 
AHVLA. The E. coli strain MG1655 was acquired from the Coli Genetic Stock Center 
at Yale University. Salmonella strains with separate GyrA Ser83Phe and GyrA 
Asp87Gly substitutions were previously made using site-directed mutagenesis and 
have already been characterised (Webber et al., 2013); they were obtained from the 
ARG Culture Collection. The E. coli GyrA Ser83Leu strain was made by an 
intercalating medical student using site-directed mutagenesis (Sutton, 2014), and the 
E. coli GyrA Asp87Gly strain was a kind gift from Tony Maxwell of the University of 
East Anglia. A range of plasmid constructs were also made and transformed into 
these strains as part of this study. 
 
In routine growth, cells were grown aerobically on Luria-Bertani (LB) agar (Sigma-
Aldrich, Poole, UK), supplemented with 50 µg/mL of ampicillin where necessary, at 
37 °C overnight without shaking unless otherwise stated. For liquid cultures, 
overnight cultures were grown aerobically at 37 °C for 16 hours in 5 mL of LB broth 
(Sigma-Aldrich, Poole, UK), supplemented with 50 µg/mL ampicillin where 
necessary. Cells were periodically grown on xylose lysine deoxycholate (XLD) 
medium (Oxoid, Basingstoke, UK) under the same conditions, to presumptively 
identify strains as Salmonella and to verify that contamination had not arisen.  The 
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genotypes of strains were also verified by PCR followed by DNA sequencing for 
specific loci. API(20E) strips were also used to confirm the species of each strain 
(Biomerieux, France).  
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Salmonella enterica serovar Typhimurium 
Lab code Parent Description Source 
L354 SL1344 Wild type strain Wray & Sojka (1978) 
L821 SL1344 GyrA Ser83Phe Webber et al. (2013) 
L825 SL1344 GyrA Asp87 Gly Webber et al. (2013) 
L1650 SL1344 Wild type carrying pBR322 This study 
L1651 SL1344 GyrA Ser83Phe/pBR322 This study 
L1652 SL1344 GyrA Asp87Gly/pBR322 This study 
L1781 SL1344 Wild type/pMW82 precA:gfpmut2 This study 
L1782 SL1344 Wild type/pMW82 pgabD:gfpmut2 This study 
L1783 SL1344 Wild type/pMW82 pglnA:gfpmut2 This study 
L1784 SL1344 Wild type/pMW82 pbamA:gfpmut2 This study 
L1785 SL1344 Wild type/pMW82 popdA:gfpmut2 This study 
L1786 SL1344 GyrA Ser83Phe/pMW82 precA:gfpmut2 This study 
L1787 SL1344 GyrA Ser83Phe/pMW82 pgabD:gfpmut2 This study 
L1788 SL1344 GyrA Ser83Phe/pMW82 pglnA:gfpmut2 This study 
L1789 SL1344 GyrA Ser83Phe/pMW82 pbamA:gfpmut2 This study 
L1790 SL1344 GyrA Ser83Phe/pMW82 popdA:gfpmut2 This study 
L1791 SL1344 GyrA Asp87Gly/pMW82 precA:gfpmut2 This study 
L1792 SL1344 GyrA Asp87Gly/pMW82 pgabD:gfpmut2 This study 
L1793 SL1344 GyrA Asp87Gly/pMW82 pglnA:gfpmut2 This study 
L1794 SL1344 GyrA Asp87Gly/pMW82 pbamA:gfpmut2 This study 
L1795 SL1344 GyrA Asp87Gly/pMW82 popdA:gfpmut2 This study 
L644 SL1344 ΔacrB Eaves et al. (2004) 
L1749 SL1344 ΔacrB/pBR322 This study 
L742 SL1344 ΔtolC Buckley et al. (2006) 
L1750 
L1232 
SL1344 
SL1344 
ΔtolC/pBR322 
Wild type/pMW82 pramA:gfpmut2 
This study 
Lawler et al. (2013) 
L1233 SL1344 ΔramA/pMW82 pramA:gfpmut2  Lawler et al. (2013) 
L1234 SL1344 ΔramRA/pMW82 pramA:gfpmut2  Lawler et al. (2013) 
L1407 SL1344 Wild type/pMW82 (no promoter) Lawler et al. (2013) 
Table continues on next page 
65 
Escherichia coli 
Lab code Parent Description Source 
I113 NCTC10418 Reference strain used for minimum inhibitory concentration 
assays 
National Collection of Type 
Cultures 
I364 MG1655 Wild type strain Coli Genetic Stock Center, Yale  
I980 MG1655 GyrA Ser83Leu Sutton (2014) 
I1042 MG1655 GyrA Asp87Gly Tony Maxwell, University of East 
Anglia 
I974 MG1655 Wild type strain/pBR322 Sutton (2014) 
I975 MG1655 GyrA Ser83Leu/pBR322 Sutton (2014) 
I1070 MG1655 GyrA Asp87Gly/pBR322 Iddles (2016) 
I1074 MG1655 Wild type/pMW82 precA:gfpmut2 This study 
I1075 MG1655 Wild type/pMW82 pgabD:gfpmut2 This study 
I1076 MG1655 Wild type/pMW82 pglnA:gfpmut2 This study 
I1077 MG1655 Wild type/pMW82 pbamA:gfpmut2 This study 
I1078 MG1655 Wild type/pMW82 popdA:gfpmut2 This study 
I1079 MG1655 GyrA Ser83Leu/pMW82 precA:gfpmut2 This study 
I1080 MG1655 GyrA Ser83Leu/pMW82 pgabD:gfpmut2 This study 
I1081 MG1655 GyrA Ser83Leu/pMW82 pglnA:gfpmut2 This study 
I1082 MG1655 GyrA Ser83Leu/pMW82 pbamA:gfpmut2 This study 
I1083 MG1655 GyrA Ser83Leu/pMW82 popdA:gfpmut2 This study 
I1084 MG1655 GyrA Asp87Gly/pMW82 precA:gfpmut2 This study 
I1085 MG1655 GyrA Asp87Gly/pMW82 pgabD:gfpmut2 This study 
I1086 MG1655 GyrA Asp87Gly/pMW82 pglnA:gfpmut2 This study 
I1087 MG1655 GyrA Asp87Gly/pMW82 pbamA:gfpmut2 This study 
I1088 MG1655 GyrA Asp87Gly/pMW82 popdA:gfpmut2 This study 
I825 DH5α Sub-cultured commercial electrocompetent cells Bioline, USA 
n/a DH5α Alpha-select gold efficiency chemically competent cells Bioline, USA 
n/a DH5α Alpha-select electrocompetent cells (discontinued by 
manufacturer) 
Bioline, USA 
Table 2.1.1: Strains used in this study. Wild type strains and gyrA mutants were obtained from the ARG Culture Collection, but their original 
sources are shown here. They were transformed with pMW82-based recA, gabD, glnA, bamA and opdA reporters as part of this project. 
66 
Bacteria were stored on Protect™ beads (Technical Service Consultants, Ltd., 
Heywood, UK) for long-term storage, Salmonella strains were stored at -20 °C and E. 
coli at -80 °C. When required for experiments, bacteria were resuscitated by being 
grown overnight on LB agar plates supplemented with the appropriate antibiotics, as 
described in Section 2.1.  To create fresh beads, a sterile loop was used to collect 
colonies from approximately half a freshly incubated plate and these were introduced 
to tubes of Protect™ beads. The tubes were shaken briefly and the glycerol was 
removed. Two sets of beads were made per strain; one was maintained for routine 
use and the other was stored in the main ARG culture collection, if required, after 
having been assigned a strain number.  
 
2.2 Antibiotics and Chemicals 
Antibiotics were used to select for antibiotic-resistant bacteria, determine 
susceptibility profiles, induce stress responses and ensure plasmid retention within 
populations. Working stocks of antibiotics were routinely made at a concentration of 
10,000 µg/mL by dissolving 0.1 g of antibiotic in 10 mL of the appropriate solvent, 
and then further diluted as necessary. Other chemicals were used as solvents for 
antibiotics or to induce stress responses. All antibiotics and chemicals were 
purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise, and are listed in 
Table 2.2.1. 
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Name Mode of action Solvent 
Ampicillin Cell wall synthesis inhibition Sodium bicarbonate 
Nalidixic acid DNA gyrase inhibition Sterile distilled water 
Chlorpromazine Efflux pump inhibition  Sterile distilled water 
Ciprofloxacin DNA gyrase inhibition Acetic acid 
Gentamicin 30S ribosome subunit inhibition Sterile distilled water 
Triclosan (Irgasan) Fatty acid synthesis inhibition 70% methanol 
Boric acid Toxic ion shock Sterile distilled water 
Sulphamethoxazole Folate biosynthesis inhibition Sterile distilled water 
Acriflavine DNA intercalation Sterile distilled water 
Serine hydroxamate Amino acid starvation Sterile distilled water 
Sucrose Osmotic shock Sterile distilled water 
Paraquat Superoxide stress generator Sterile distilled water 
Menadione Superoxide stress generator Dimethyl sulphoxide 
Kanamycin 30S ribosomal subunit inhibition Sterile distilled water 
Table 2.2.1: Antibiotics and chemicals. Table showing the antibiotics and other 
chemicals that were used in this study as selective agents or as a means of inducing 
cellular stresses. Solutions were usually made as 10,000 µg/mL stocks and diluted 
as required. The majority of agents listed above were purchased from Sigma-Aldrich 
(Poole, United Kingdom). The triclosan was from Ciba, now part of BASF (Germany). 
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2.3 The Polymerase Chain Reaction 
The polymerase chain reaction (PCR) was used to amplify regions of interest in the 
genome for further manipulation, to verify that the size of DNA inserts was as 
expected, to produce a sufficient quantity of DNA for sequencing, or to quantify the 
abundance of specific templates present in diluted cDNA samples.  
 
Primers, as listed in Table 2.3.1, were either obtained from the ARG primer 
collection, or designed using the genomic context of the sequence to be amplified 
and the Primer 3 Plus software (Untergasser et al., 2012). Newly synthesised primers 
were ordered from Life Technologies (ThermoFisher Scientific, USA). Reactions 
were performed in a Veriti 96-Well Thermal Cycler (ThermoFisher Scientific, USA) in 
25 µL, using 11.25 µL 2x MyTaq Red Mix (Bioline, USA), 11.25 µL Gibco nuclease-
free water (ThermoFisher Scientific, USA), 0.75 µL forward primer, 0.75 µL reverse 
primer and 1 µL template DNA unless stated otherwise. Samples were heated to 95 
°C for 1 minute, followed by 25-35 cycles of denaturing at 95 °C for 15 seconds, 
annealing at 54 °C for 15 seconds, and extending at 72 °C for 10 seconds, though 
the annealing temperature and extension times were changed if necessary. There 
was no final extension and samples were held at 4 °C after the last step of the cycle 
until they were ready for further processing.  
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No. Name Sequence Product size (bp) Tm (ºC) 
n/a recA F TCGAAATTTACGGGCCGGAA 599 60.0 
n/a recA R CTGGAACTCGGCCTGCTTAA 599 60.0 
n/a lexA F GTTAACGGCCAGGCAACAAG 594 60.0 
n/a lexA R CATTCCCCGTTGCGAATGAC 594 59.9 
238 K1 CAGTCATAGCCGAATAGCCT n/a 57.3 
239 K2 CGGTGCCCTGAATGAACTGC n/a 61.4 
324 16sRNAstm1 CCTCAGCACATTGACGTTAC 246 57.3 
325 16sRNAstm2 TTCCTCCAGATCTCTAGGCA 246 57.3 
981 gfp mut2 F TCCCATGGCCAACACTTGTC 373 72.0 
982 gfp mut2 R GCTAGTTGAACGCTTCAATC 373 68.0 
1341 pMW82 GFP Acc65I  TGCGGTACCGATAGTCATGCCCCGCGCCC 1304 51.0 
1477 gyrA_ST_int_F TGGATTATGCGATGTCGG 475 55.0 
1478 gyrA_ST_int_R GTCGCCATACCTACTGCG  475 55.0 
1511 pMW82 p-GFP ScaI TGCAGTACTGATAGTCATGCCCCGCGCCC n/a 54.0 
1914 RecA_gfp_F AAAGGATCCATGAAGCCAAAGCGCAGAT 383 60.9 
1916 GabD_gfp_F AAAGGATCCCTTATCGGCTGTGCAGGAC 370 60.4 
1918 GlnA_gfp_F AAAGGATCCTCGATCACAACTTTGCCTCA 354 60.4 
1920 YaeT_gfp_F AAAGGATCCCTCGAAGCCACGGATAAGAC 351 59.8 
1930 RecA_v2_R CGCTCTAGATGAACCGGATAGTGAATCGT 383 59.4 
1931 GabD_v2_R CGCTCTAGATGCACAGCGAGTTTTTCATC 370 60.0 
1932 GlnA_v2_R CGCTCTAGAGGTCGTCGTGGTAACGAGAT 354 60.0 
1933 YaeT_v2_R CGCTCTAGAGAAAAGTGCAAGCCCCATTA 351 60.1 
2090 opdA_prom_f_BamHI CGGAAGGATCCATGTTAAAGGGGCGGCTTAT 210 59.8 
2091 opdA_prom_r ACATGCTCCGTTTTAATTGC 210 60.0 
2094 aphFwd for pMW82 AGCTAGCTGCAGAGCTGTGTAGGCTGGAGCTGCTTC 1500 53.0 
2095 aphRev for pMW82 GACTTCAAGCTTAGCTGGGAATTAGCCATGGTCCATATGA 1500 53.0 
2216 2216_pyaeT_BamHI_NEW AAAGGATCCGAAATAACGCCCAACTCGAT 936 59.0 
Table 2.3.1: Primers used in this study. The recA, lexA and 16sRNAstm primer pairs were used for quantifying the 
expression of recA, lexA and the 16S RNA using RT-PCR. The gyrA_ST_int pair was used for plasmid-to-profile sequencing of 
the QRDR. All other primers listed were used in the construction of fluorescent reporter plasmids.
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PCR products were separated by electrophoresis on 1% agarose gels, made by 
combining 1 g agarose (Sigma-Aldrich, Poole, UK) and 100 mL 1x Tris/Borate/EDTA 
(TBE) buffer (Sigma-Aldrich, Poole, UK) and heating in a microwave at 50% power 
until dissolved. Upon cooling, 5 µL Midori Green (Nippon Genetics Europe, Germany) 
was added. The gel was loaded with 5 µL of each sample. In the event that a master 
mix that did not already contain loading dye was used, samples were combined with 
2 µL 5x DNA Loading Buffer Blue (Bioline, USA). Samples were separated alongside 
a HyperLadder 1 kilobase molecular weight marker (Bioline, USA). Electrophoresis 
used 100 V for 30 minutes. Gels were visualised using a G:BOX F3 gel imaging 
cabinet (Syngene UK, Cambridge, UK) and analysed with GeneSys and GeneTools 
software (Syngene UK, Cambridge, UK).  
 
2.4 Susceptibility Testing 
The minimum inhibitory concentration of a range of antibiotics was determined using 
two different methods. Agar-based assays were performed in accordance with the 
standardised British Society for Antimicrobial Chemotherapy (BSAC) agar doubling 
dilution protocol which has now been harmonised with recommendations of the 
European Committee of Antimicrobial Susceptibility Testing (EUCAST) (Andrews and 
BSAC Working Party on Susceptibility Testing, 2006), and microtitre tray-based MIC 
assays again used the EUCAST/BSAC microdilution method (Andrews, 2001). 
 
2.5 DNA Sequencing 
Genes and genomes were sequenced to confirm expected genotypes, and to check 
the results of PCRs and ligations. Sequencing of small fragments was carried out 
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using the plasmid-to-profile service provided by the University of Birmingham 
Functional Genomics Facility. Primers upstream and downstream of the region to be 
sequenced were diluted to 0.8 pmol. One diluted primer, at a volume of 4 µL, was 
combined with 4 µL of nuclease free water and 2 µL of the DNA of interest. This 
reaction was then taken to the Functional Genomics Facility. The Functional 
Genomics team added 10 µL of Big Dye Terminator Reaction Mix and sequenced the 
DNA using their ABI 3730 DNA Analyser (ThermoFisher Scientific, USA). Sequences 
were visualised using 4Peaks (Griekspoor and Groothius, 2006). They were 
analysed by aligning the obtained sequence data against the reference gene 
sequence, obtained from the NCBI Gene database (Brown et al., 2015). This 
alignment was performed using Clustal W2 (Larkin et al., 2007). 
 
2.6 Growth Kinetics Assays 
To determine the impacts of the addition of antibiotics and/or chemicals to bacterial 
cultures upon growth rate, growth kinetics assays were performed as described in 
Webber et al 2013. Overnight cultures were diluted 1:100, with 50 µL of culture being 
added to 5 mL LB broth. A clear plastic 96-well plate was inoculated with 200 µL 
aliquots of the cultures of interest and antibiotics or chemicals were added to a final 
concentration of half of the MIC. The plates were incubated overnight in a Fluostar 
Optima (BMG Labtech, Germany) at 37 ºC, and the optical density at 600 nm was 
recorded every three minutes. Data were exported to an .xls file and analysed in MS 
Excel for Mac 2011 (Microsoft Corportation, USA). 
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2.7 Perturbation of Cultures to Examine Impacts on Supercoiling and Gene 
Expression 
A central aim of this project was to determine if there was a relationship between 
alterations in stress response expression and supercoiling. To examine this the 
impact of a range of stress conditions on the supercoiling state of pBR322 or 
expression of stress responsive promoters was determined. Cultures were grown to 
mid-logarithmic phase before being perturbed. An example is determining the effects 
of induction of the SOS response; Salmonella Typhimurium or E. coli cells with and 
without gyrA mutations were grown in liquid culture (5 mL) to logarithmic phase at 37 
ºC under aerobic conditions. The cultures were divided into two groups, one of which 
had nalidixic acid added to a final concentration of 80 µg/mL, and the other had the 
equivalent volume of sterile distilled water added. These were then returned to the 
incubator for a further 45 minutes. Subsequently, either RNA or the plasmid pBR322 
was extracted (the use of fluorescent reporter fusions to determine gene expression 
is detailed later in Section 2.15), depending on the subsequent processes that were 
to be used. Plasmid extraction is described in Section 2.8, and RNA extraction is 
described in Section 2.13. This same scheme was used for perturbing supercoiling 
with other antibiotics and chemicals to assay supercoiling. The agents used for 
perturbation are described in Table 2.2.1, and the concentrations used to provoke 
perturbations were based on the results of susceptibility testing or the literature. 
 
2.8 Plasmid Extraction 
Plasmids were extracted from cells for a number of reasons, including acquiring a 
template for cloning, constructing fluorescent reporters, and for assaying 
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supercoiling. Overnight cultures carrying plasmids were harvested by centrifugation 
at 3,300 x g for 10 minutes in a Heraeus Megafuge 40R centrifuge (ThermoFisher 
Scientific, USA). Plasmids were subsequently extracted using a GeneJET Plasmid 
Miniprep kit (ThermoFisher Scientific, USA) according to the manufacturer’s 
instructions. This kit uses a combination of alkaline lysis and spin columns to isolate 
plasmid DNA of an appropriate size. The presence of products, and their sizes, were 
verified by separation on a 1% agarose gel for 30 minutes at 100 V alongside a 
HyperLadder 1 kb molecular weight marker (Bioline, USA), and visualised as 
described in Section 2.3. The concentrations of extracted plasmids were estimated 
using GeneTools (Syngene UK, Cambridge) and determined by measuring the ratio 
of absorbance at 260 nm and at 280 nm using a NanoDrop 1000 spectrophotometer 
(ThermoFisher Scientific, USA). 
 
2.9 Transformation of Strains with pBR322 
The plasmid pBR322, as shown in Figure 2.9.1, was transformed into cells so that it 
could be used as a proxy to assay genomic supercoiling. The plasmid was obtained 
from a pre-existing host using an alkaline lysis kit, as described in Section 2.8. Cells 
initially had to be made either electrocompetent or chemically competent before the 
plasmid could be transformed into them. 
 
To make cells electrocompetent, the strains of interest were grown to an optical 
density of 0.6 (600 nm), roughly equivalent to mid-logarithmic phase, in 5 mL LB 
broth supplemented with antibiotics as necessary. The mid-logarithmic phase cells 
were harvested in a centrifuge, cooled to 4 ºC, at 3,300 x g for ten minutes. The 
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supernatant was discarded and the pellet was re-suspended in 10 mL ice-cold 10% 
glycerol. The process of centrifugation and re-suspension was repeated twice more. 
The cells were harvested again under the same conditions and then re-suspended in 
500 µL ice-cold 10% glycerol. Cells were then stored at -20 ºC until required.
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Figure 2.9.1: The plasmid pBR322. Figure showing the plasmid pBR322, adapted 
from Bolivar et al., (1977) and Watson (1988), which was used as a proxy for 
genomic supercoiling. The plasmid is 4,361 bp in length, and contains a tetracycline 
resistance cassette (tet), an ampicillin resistance cassette (bla), an origin of 
replication (ori) and a restrictor of plasmid copy number (rop). The ampicillin 
resistance cassette was used to select for successful transformants by culturing cells 
on media containing ampicillin. 
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To make cells chemically competent, 0.5 mL of an overnight culture of cells was 
diluted in 50 mL of LB broth in a 500 mL bottle and growing aerobically at 37ºC to an 
optical density of between 0.4-0.6 at 600 nm. These cells were then harvested by 
centrifugation at 3,600 x g for 10 minutes at 4 ºC. The supernatant was removed and 
cells were re-suspended in 25 mL 0.1 M calcium chloride solution (Sigma-Aldrich, 
Poole, UK) and chilled on ice for half an hour before being harvested again. The 
supernatant was removed and the pellet was re-suspended in 2 mL 0.1 M calcium 
chloride. The cells were then heat shocked as described above. If the cells were to 
be used at a later date, 0.4 mL of 50% glycerol was added per millilitre of re-
suspended cells and they were then stored at -80 ºC. 
 
To transform plasmids into electrocompetent cells, 2 µL of the plasmid of interest, at 
a concentration of approximately 50 ng/µL, was combined with 50 µL of the cells of 
interest in a pre-cooled 2 mm gap electroporation cuvette and kept on ice for five 
minutes. Salmonella were subjected to a pulse of 2.5 kV for 5 ms and E. coli were 
subjected to a pulse of 1.5 kV. To transform plasmids into chemically competent 
cells, 50 µL aliquots of cells were combined with 2 µL of the plasmid of interest and 
kept on ice for half an hour. These were then placed in a water bath at 42 ºC for 45 
seconds and then placed on ice for two minutes.  
 
After transformation, cells were then transferred to universal tubes containing 1 mL 
pre-warmed LB broth and grown for an hour at 37 ºC and shaken at 200 rpm. The 
cultures were harvested and the supernatant was poured off, with the pellet being re-
suspended in the remaining supernatant. Spread plates were then made with 100 µL 
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aliquots of the recovery cultures on LB agar plates supplemented with an appropriate 
selective agent, and incubated overnight at 37 ºC without shaking. 
 
Recovery cultures were retained in the event that there was no growth on the plates 
and, in this case the remaining culture was harvested after recovery, most of the 
supernatant removed and the pellet re-suspended in the remainder before this was 
used to inoculatea plate. Plates were examined for growth and colonies were chosen 
and sub-cultured onto fresh LB agar plates containing an appropriate selective agent, 
as well as XLD agar plates, to verify they were the correct species and to give a 
quantity of bacteria that was suitable to work with. If the colonies on XLD agar were 
the correct colour (black for Salmonella and yellow for E. coli), bead stocks were 
made from the colonies grown on LB agar. 
 
2.10 One-Dimensional Topoisomer Separation 
To assay genomic supercoiling, the plasmid pBR322 was used as a proxy due to the 
difficulty in measuring chromosomal supercoiling directly and the need to complete a 
large number of supercoiling measurements in this project. Initially, a protocol 
adapted from Cameron et al. (2011) was utilised. After plasmids had been extracted 
from cells of interest as described in Section 2.8, a 1% agarose gel was made with 
2x TBE supplemented with 2.5 µg/mL >=98% chloroquine (Sigma-Aldrich, Poole, 
UK), and the running buffer was made of the same components bar the agarose. 
Aliquots of the plasmid containing 1 µg DNA were combined with 4 µL of 5x Loading 
Buffer Blue (Bioline, USA) and loaded into the gel alongside 5 µL of HyperLadder 1 
kilobase molecular weight marker (Bioline, USA). Topoisomers were then separated 
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by electrophoresis at a voltage of 3 V per centimetre of the length of the gel (e.g. a 
15 centimetre gel would be subjected to 45 V) for 16 hours. Subsequently, the gel 
was washed in a container of tap water on a shaking platform for 3 hours to remove 
the chloroquine, with the water being changed every 20 minutes. The gel was then 
stained with 1 µg/mL ethidium bromide or the same concentration Midori Green 
(Nippon Genetics Europe, Germany) by washing in water supplemented with the dye 
for 1 hour, followed by a brief wash in tap water before being imaged as described in 
Section 2.3. 
 
It was later found to be more efficient to run the gels at a higher voltage for a shorter 
time, producing comparable results whilst saving significant amounts of time. The 
revised method used 1x TBE gels containing 1.5% agarose, 5 µL Midori Green 
(Nippon Genetics Europe, Germany) per 100 mL of TBE and 2.5 µg/mL chloroquine. 
A volume of sample equivalent to 300 ng was combined with 5 µL 5x Loading Buffer 
Blue (Bioline, USA), and separated alongside 5 µL of HyperLadder 1 kilobase 
molecular weight marker (Bioline, USA). Electrophoresis was performed in a running 
buffer of 1x TBE supplemented with 2.5 µg/mL chloroquine at 80 V for 4 hours, and 
gels were imaged as described in Section 2.4. This protocol was adapted from prior 
work by Maxwell et al. (2006) after exploring various combinations of pre- and post-
run staining, with both Midori Green and ethidium bromide, no appreciable difference 
between pre-stained Midori Green gels and post-stained ethidium bromide gels was 
observed. Adapting the protocol involved topoisomers being separated on 1%, 1.5% 
and 2% agarose gels for 4h at 80 V and stained with different protocols. To compare 
methods, four 50 g 1% agarose gels were set up, two of which had 2.5 µL Midori 
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Green added before they solidified, and the remaining two were washed for an hour 
in tap water, had their water changed and washed again in tap water containing 20 
µL Midori Green. One gel from each pair also had 2.5 µg/mL of chloroquine added. 
Loading dye and 5 µL of the same preparation of plasmid pBR322 were combined 
and separated on each gel for 4 hours at 80 V. Subsequently, 1.5% and 2% 50 mL 
agarose gels were set up containing 2.5 µL Midori Green and no chloroquine; 
topoisomers of pBR322 from the same preparation were again separated on these 
gels for 4 hours at 80 V and the gels were imaged as described previously.  
 
2.11 Two-Dimensional Topoisomer Separation 
To separate topoisomers in two dimensions and thus differentiate between positively 
supercoiled and negatively supercoiled DNA, a number of methods were examined. 
Initially, 1% agarose gels were made with 1x TBE and 3 µL Midori Green (Nippon 
Genetics Europe, Germany) per 100 mL TBE. The gel and running buffer were 
supplemented with 2.5 µg/mL of chloroquine. (Sigma-Aldrich, Poole, UK) 
Approximately 10 µL of concentrated plasmid was mixed with 5 µL 5x Loading Buffer 
Blue (Bioline, USA), and topoisomers were separated by electrophoresis at 120 V for 
an hour and a half. Gels were then rotated 90º clockwise (so that the wells were on 
the right-hand side) and more chloroquine was added, to a final concentration of 2.5 
mL per litre of TBE (including the TBE in the gel). Separation then continued for 45 
minutes at the same voltage, and gels were then imaged as described in Section 2.3. 
This initial protocol was unsuccessful; gels were frequently blank when imaged. 
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Different combinations of staining the gel before running it, and staining and washing 
it afterwards were attempted as to address concerns that the gels were blank when 
imaged because they were being overstained resulting in a high amount of 
background stain on each gel. Changes to the duration of the steps during the 
washing section of the protocol were tried. The samples were also loaded with non-
commercial loading dye. However, these variations on the protocol did not make 
significant improvements and gels were still blank upon imaging. Ultimately, the most 
effective “quick” method was to make a 1% agarose gel with 1x Tris-Acetate-EDTA 
(TAE), supplemented with 3 µL Midori Green per 100 mL and poured to a thickness 
of 5 mm. TAE was made as a 50x stock by gradually adding 242 g of Tris (Sigma-
Aldrich, Poole, UK) and 18.6 g of EDTA (Sigma-Aldrich, Poole, UK) to 700 mL 
deionised water. This mixture was stirred on a magnetic stirring plate and then 
combined with 57.1 mL of glacial acetic acid (Sigma-Aldrich, Poole, UK), after which 
it was made up to a final volume of 1 L with deionised water. The 50x TAE stock was 
diluted in deionised water as required and 1x TAE was used for both the gel and the 
running buffer. Electrophoresis occurred at 120V for 2 hours in the first dimension, 
with imaging being carried out hourly in the G:BOX imaging cabinet as described in 
Section 2.3. The buffer was supplemented with 5 µL Midori Green upon the 
replacement of the gel in the tank. After the second hour, gels were rotated 90º 
clockwise in the tank and the buffer was supplemented with 1.5 mL 10,000 µg/mL 
chloroquine. Topoisomers were separated by electrophoresis for a further 15 minutes 
and gels were then imaged as described in the G:BOX imaging cabinet as described 
in Section 2.3. 
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2.12 RNA Extraction, cDNA Synthesis and RT-PCR 
RNA was extracted from cells grown in the presence and absence of nalidixic acid, to 
determine the level of induction of the SOS response. Centrifuge tubes with a 
capacity of 50 mL were pre-cooled on ice and then had 1 mL of ice cold 95% ethanol: 
5% phenol added. After reaching an appropriate optical density, 5 mL of bacterial 
culture was added to each 50 mL tube. The tubes were then left to incubate on ice 
for half an hour, before being harvested at 3,000 x g for 10 minutes in a centrifuge 
that had been pre-cooled to 4 ºC. The supernatant was then disposed of accordingly, 
and the tubes were stored at -80 ºC. The samples were later defrosted and re-
suspended in the residual liquid, then transferred to microfuge tubes. These were 
harvested at 10,000 x g for 60 seconds in a refrigerated centrifuge, and the 
supernatant was discarded. The pellets were then re-suspended in 100 µL Tris-
EDTA buffer containing 50 µg/mL lysozyme. This mixture was incubated at room 
temperature for five minutes, and then 75 µL SV40 Total RNA Isolation System lysis 
reagent (Promega, USA) was added and the tubes were mixed by inversion. Then, 
350 µL RNA dilution buffer (Promega, USA) was added and the samples were mixed 
by inversion. Samples were then heated at 70 ºC for 3 minutes, and spun in a 
microcentrifuge for 10 minutes at maximum speed. 
 
While the samples were being spun, a DNAse mixture was made by combining 50 µL 
90 mM manganese(II) chloride, 40 µL DNAse core buffer and 5 µL DNAse, each 
multiplied by the number of samples plus one. The reagents for making the DNAse 
mixture were, like the other buffers, obtained from the SV40 Total RNA Isolation 
System kit (Promega, USA).  
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Once the centrifugation had finished, the supernatant was transferred to a clean 
tube, combined with 200 µL 95% ethanol, and mixed by inversion. This was then 
transferred to a spin column and harvested in a refrigerated desktop centrifuge at full 
speed for 30 seconds. The elutate was discarded, and 600 µL wash buffer (also from 
the RNA isolation system kit) was added to each spin column before the columns 
were spun again under the same conditions. 
 
Subsequently, 50 µL of the DNAse mixture was added to each spin column and the 
columns were incubated at room temperature (approx. 22 ºC) for quarter of an hour. 
The reaction was then stopped through the addition of 200 µL DNAse stop mix 
(Promega, USA) and the spin columns were spun in a desktop centrifuge fro 30 
seconds. The columns had 600 µL wash buffer added to them and were spun again, 
with the eluate being discarded. The wash step was repeated with 250 µL buffer, 
then the spin filter was returned to the collection tube and spun for a minute at full 
speed. The columns were then transferred to sterile microfuge tubes with 1 µL 
RNase OUT (Promega, USA) and 100 µL nuclease-free distilled water. After being 
left to stand for 1 minute, the tubes were spun at 10,000 rpm for 2 minutes in a 
desktop centrifuge. The column was discarded and the tubes were immediately 
placed on ice. 
 
Subsequently, 5 µL of RNA was combined with 2 µL of 5x Loading Buffer Blue 
(Bioline, USA), and separated on a 1 % agarose gel at 100 V, alongside 5 µL of 
HyperLadder 1 kb molecular weight marker (Bioline, USA). The gel was visualised 
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using a G:BOX F3 gel imaging cabinet (Syngene UK, Cambridge, UK) and analysed 
with GeneSys and GeneTools (Syngene UK, Cambridge, UK) to determine an 
approximate RNA concentration. A more accurate measure of RNA concentration 
was determined by using a NanoDrop 1000 spectrophotometer (ThermoFisher 
Scientific, USA). 
 
To make cDNA, RNA was reverse transcribed by combining 5 µg RNA, 100 ng of 
Random Primers (ThermoFisher Scientific, USA), 1 µL 10 mM dNTP Mix 
(ThermoFisher Scientific, USA) and 5 µL of nuclease-free sterile distilled water to a 
final volume of 13 µL. This mixture was heated at 65 ºC for 5 minutes and then 
incubated on ice for 5 minutes. The mixture was briefly spun in a desktop centrifuge. 
After the spin had finished, 4 µL 5x First Strand Buffer, 1 µL 0.1 M dithiothreitol, 1 µL 
RNase Inhibitor and 1 µL Superscript III Reverse Transcriptase (all ThermoFisher 
Scientific, USA) were added to the mixture. This was then incubated at room 
temperature for 5 minutes, then at 50 ºC for an hour, and finally at 70 ºC for 10 
minutes. The resulting cDNA was then used for a reverse transcription PCR, with the 
remainder stored at -80 ºC. The aim of the reverse transcription PCR to determine 
the levels of transcripts identified as being part of the SOS response. Reactions were 
set up as per Section 2.3, using the cDNA and the recA F/R, lexA F/R and 
16SstmRNA1/2 primer pairs – the sequences of which are listed in that section. The 
resulting PCR products were analysed on an agarose gel, as described in Section 
2.3. 
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2.13 Identification of Sigma Factor Responsive Promoters and Construction of 
Fluorescent Reporters 
The regulons and binding motifs of a series of sigma factors implicated as being up-
regulated in gyrase mutants were identified via a literature survey and examination of 
available biochemical data in the Ecocyc database (Keseler et al., 2017). Promoters 
were chosen as representatives of each sigma regulon and those with promoters 
essentially identical in E. coli and Salmonella were selected as proxies for activation 
of the regulon as a whole. These are shown in Table 2.13.1, below. Once a promoter 
was chosen the coding sequence of the gene and 500 nucleotides upstream of the 
first members of each operon were obtained from the NCBI. Primers were designed 
using Primer 3 Plus so as to amplify the appropriate sigma factor binding sites, and 
then tagged with an XbaI site and a BamHI site so that the amplimers could be 
digested and inserted into the plasmid pMW82. This is represented diagrammatically 
in Figure 2.13.1. 
 
Plasmid pMW82 lacking a promoter upstream of the gfpmut2 locus was obtained 
from a strain of S. Typhimurium that was already carrying the plasmid, using a 
GeneJET Miniprep kit (ThermoFisher Scientific, USA) according to the 
manufacturer’s instructions, as described in Section 2.8. The previously identified 
promoter regions of interest were amplified from genomics DNA of SL1344 by PCR. 
Separate restriction digests were then set up for the plasmid and promoters, using 
XbaI and BamHI FastDigest restriction enzymes (ThermoFisher Scientific, USA) in 
accordance with the manufacturer’s instructions. The restriction enzymes were then 
deactivated by incubating the reaction mixtures at 80 ºC for five minutes.  The 
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reaction mixtures were then treated with 4 µL Calf Intestinal Alkaline Phosphatase 
(Promega, USA) and 4 µL Alkaline Phosphatase 10x Buffer (Promega, USA), and 
then incubating at 37 ºC for half an hour so as to prevent autoreligation. A further 4 
µL Calf Intestinal Alkaline Phosphatase was added and the reactions were incubated 
at 37 ºC for another half an hour.  
 
The digested promoter sequences were ligated with separate aliquots of the digested 
plasmid by combining them in the molar ratio of 3 parts insert to 1 part vector and 
adding this to 1 µL of Ligase 10x buffer (Promega, USA) and 1 µL of T4 DNA ligase 
(Promega, USA). This was then made up to a final volume of 10 µL with nuclease-
free water, and the reaction was incubated at 4 ºC overnight. The correct insertion of 
the promoters into the plasmid was verified by PCR, as described in Section 2.3, with 
the primers being the appropriate forward primer for amplifying the promoter 
sequence and the gfpmut2 reverse primer. The PCR products were then separated 
on a gel and imaged as described in Section 2.3. Cells were made competent and 
transformed with the pMW82 constructs using the same method for transforming 
cells with pBR322, as described in Section 2.10. 
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Stress 
condition 
Sigma 
factor 
Target 
locus 
Source Inducer used Amount 
Stationary 
phase 
RpoS gabD Bang et al. (2005) Time n/a 
Osmotic 
shock 
RpoE bamA Namdari et al. 
(2012); 
Skovierova et al. 
(2006) 
Sucrose 20% solution 
Heat shock RpoH opdA Conlin and Miller 
(2000) 
Growth at 42 ºC  n/a 
Nitrogen 
stress 
RpoN glnA Samuels et al. 
(2013) 
Serine 
hydroxamate 
100 µg/mL  
SOS 
response 
n/a recA Cox (2007) Nalidixic acid 80 µg/mL 
Table 2.13.1: Sigma factors and target loci that were used to design fluorescent 
reporter constructs. Sigma factors and the conditions in which they are 
incorporated into the RNA polymerase were identified on the basis of a literature 
survey. This literature survey also identified loci that were part of the regulons of 
these sigma factors, and the promoters of these loci were used to create a series of 
pMW82-derived fluorescent reporter constructs. 
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Figure 2.13.1: The plasmid pMW82, with detail of the BamHI and XbaI 
restriction sites. Part A) shows the fluorescent reporter plasmid pMW82. This is a 
5.1 kb plasmid with a promoterless GFP locus, and an ampicillin cassette that can be 
used to selection transformants. Part B) shows the sequence surrounding the BamHI 
and XbaI sites upstream of the gfpmut2 locus. Digesting the plasmid with these two 
enzymes allows for the insertion of a promoter sequence upstream of the gfpmut2, 
provided it is flanked with the appropriate sequences. The site of promoter insertion 
and the ribosome binding site are both highlighted in blue. Figure adapted from 
Bumann and Valdivia (2007). 
A) 
B) 
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2.14 Fluorescence Induction Assays 
To assay the effects of different stresses on the expression of gfpmut2 as controlled 
by the inserted promoters, a protocol adapted from that described in Lawler et al. 
(2013) was utilised. All strains (WT and gyrA mutants) were stratified into groups 
determined by which construct they were carrying (i.e. for the precA:gfpmut2 
reporter, a group consisted of SL1344 and the two gyrA mutants each carrying 
pMW82 with precA:gfpmut2). Each group were grown overnight as described in 
Section 2.1. Sub-cultures were grown aerobically at 37 ºC the following morning in 
the absence of any antibiotics until they reached an optical density of 0.3 at 600 nm. 
They were incubated in the absence of antibiotics as ampicillin has been shown to be 
auto-fluorescent under some conditions (Brittain, 2005) and can interfere with the 
behaviour of fluorescent probes (Renggli et al., 2013). Aliquots with a volume of 190 
µL were taken and inoculated on a black, clear-bottomed 96-well plate 
(ThermoFisher Scientific, USA), and then had varying concentrations of different 
chemicals added to make a final volume of 200 µL, using the layout shown in Figure 
2.14.1.  A Breathe-Easy sealing membrane (Sigma-Aldrich, Poole, UK) was then 
applied to the top of the plate. Plates were incubated overnight for 16-19 hours at 37 
ºC in a Fluostar Optima or Fluostar Omega (BMG Labtech, Germany), depending on 
whichever was available, with fluorescence (excitation 492 nm, emission 520 nm) 
and absorbance (600 nm) measured approximately every three minutes. The data for 
each time point was merged and combined into a spreadsheet, which was analysed 
in MS Excel for Mac 2011 (Microsoft Corporation, USA).  
 
The fluorescence reading for each well at each time point was then divided by the 
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corresponding absorbance reading to give the relative fluorescence with respect to 
absorbance. This reading was then pooled with wells containing the same 
combination of strain and inducer, and the average was taken. These data were then 
plotted on a graph. Additional graphs were plotted wherein the relative fluorescence 
readings for each strain under each condition were normalised to the reading for the 
wild type strain exposed to each of the inducers at time zero.  
 
The experiments were repeated with the pMW82 constructs of interest transformed 
into Escherichia coli MG1655-derived backgrounds. E. coli MG1655 itself was used 
as the wild type. E. coli MG1655 GyrA Ser83Leu and E. coli MG1655 GyrA Asp87Gly 
were used in place of S. Typhimurium SL1344 GyrA Ser83Phe and S. Typhimurium 
SL1344 GyrA Asp87Gly, respectively. The S. Typhimurium strains that were used as 
fluorescence controls (i.e., SL1344, SL1344/pMW82, SL1344/pMW82 
pramA:gfpmut2 and SL1344 ΔramRA/pMW82 pramA:gfpmut2) were still used in that 
capacity. Data were generated and analysed in the same way as when the 
experiments were done with the constructs in Salmonella backgrounds. The strategy 
used for generating data is represented diagrammatically in Figure 2.14.2. 
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SL1344 ramRA/pMW82 
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SL1344/ 
pMW82 
Escherichia coli MG1655 (only 
used when constructs in 
columns 3-11 were in an  
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W
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serine hydroxam
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W
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Typhimurium 
SL1344/pMW82 
pramA:gfpmut2 
  
H   
Figure 2.14.1: Fluorescence reporter assay plate layout. Layout used for fluorescence reporter assays in a black, clear-
bottomed 96-well plate as read in a Fluostar Optima or Omega (BMG Labtech, Germany). WT = the fluorescent reporter 
constructs in either a Salmonella Typhimurium SL1344 background or an Escherichia coli MG1655 background, depending on 
which species was being assayed. Columns 6 through 8 contained either cells with a GyrA Ser83Phe or GyrA Ser83Leu 
substitution, depending on which species was being assayed. GyrA Ser83Phe cells were used when the species assayed was 
S. Typhimurium, and GyrA Ser83Leu cells were used when the species assayed was E. coli.  
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Five pMW82 reporters were 
made (precA, pgabD, pglnA, 
pbamA and popdA). Each was 
transformed into three strains 
(WT GyrA, GyrA 
Ser83[Phe/Leu], GyrA 
Asp87Gly), in two species 
(Salmonella Typhimurium and E. 
coli). The reporters were 
assayed under six conditions. 
Experiments used two biological 
replicates, with two technical 
replicates each, per reporter in 
each each background under 
each condition. 6 conditions x 2 
technicals x 2 biologicals x 5 
constructs x 3 strains = 360 data 
points at each time point per 
species = 360 data points (720 
for both species). 
Data were generated over the 
course of 19 hours, with 
recordings made every 3 
minutes (i.e. 20 per hour). This 
equates to over a quarter of a 
million total data points 
(19x20x720 = 273,600). This 
number does not include data 
generated from control strains, 
which were also included in 
every run.
Figure 2.14.2: Overview of stress reporter expression assays 
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2.15 Cladistic Analysis of Topoisomerase Protein Sequences 
Toposiomerase genes are conserved across the Enterobacteriaceae although this is 
not complete. As some of the data generated in this project indicated that analogous 
mutations within gyrA had different impacts on DNA gyrase in E. coli and Salmonella 
the potential for lineage specific adaptations in gyrA was investigated. To determine if 
there was a correlation between the components of the bacterial topoisomerases and 
the pathogenic niche occupied by strains, a cladistic analysis of their protein 
sequences was performed. 
 
A number of extraintestinal pathogenic E. coli (ExPEC), enteropathogenic E. coli 
(EPEC), enterohaemorrhagic E. coli (EHEC), enterotoxigenic E. coli (ETEC) and 
uropathogenic E. coli (UPEC) strains were identified based on a literature survey and 
are listed in Table 2.15.1. The protein sequences of GyrA, GyrB, ParC, ParE and 
TopA from these strains, as well as the non-pathogenic E. coli strains MG1655 and 
BL21, and the S. Typhimurium strains SL1344, LT2 and 14028S, were obtained from 
the NCBI protein database. The protein sequences for the topoisomerases of 
Staphylococcus aureus strain 55-2053 were also obtained as they were expected to 
be an appropriate out-group. 
 
Multiple sequence alignments for each set of protein sequences were performed 
using Clustal Omega (Sievers et al., 2014) using the default parameters. Cladograms 
and percentage identity matrices were created by uploading the output file from 
Clustal Omega into Clustal W2 (Larkin et al., 2007) using the default settings, save 
for changing the Percentage Identity Matrix setting to “on”. 
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Strain Pathotype Source 
O157:H7 Enterohaemorrhagic Yoon and Hovde, 2008 
O104:H4 Enterohaemorrhagic Monecke et al., 2011 
ST95 Extraintestinal Ciesielczuk et al., 2016 
ST131 Extraintestinal Ciesielczuk et al., 2016 
O103:H2 Enteropathogenic Witsø et al., 2016 
O127:H6 Enteropathogenic Iguchi et al., 2009 
UTI89 Uropathogenic Hagan et al., 2009 
CFT073 Uropathogenic Hagan et al., 2009 
NA114 Uropathogenic Avasthi et al., 2011 
O139:H28 Enterotoxigenic Jordi et al., 1991 
H10407 Enterotoxigenic Yamamoto and Yokota, 
1983 
UMNF18 Enterotoxigenic Shepard et al., 2012 
MG1655 Non-pathogenic Bereswill et al., 2013 
BL21 Non-pathogenic Wu et al., 2003 
Table 2.15.1: List of Escherichia coli strains subjected to cladistic analysis of 
topoisomerase sequences. A list showing the Escherichia coli strains that were 
used to investigate the relationship between topoisomerase protein sequence and 
pathotype. A range of strains from a number of different pathotypes were chosen on 
the basis of a literature survey, and their topoisomerase protein sequences were then 
obtained from the NCBI Protein database. The analysis also included the Salmonella 
Typhimurium strains SL1344, 14028S and LT2, and the Staphylococcus aureus 
strain 55-2053; the Salmonella strains were expected to cluster together, and the 
Staphylococcus aureus strain was chosen to serve as an outgroup. 
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2.16 Flow Cytometry 
To assay the levels of fluorescence of the pMW82 reporter constructs on a per cell 
basis, rather than at a population level, cells with and without the reporter constructs 
were analysed using an Attune NxT Flow Cytometer (ThermoFisher Scientific, USA). 
 
Subcultures of cells were set up by adding 50 µL of an overnight culture to 5 mL of 
LB broth, with appropriate antibiotics added where necessary. Upon reaching a 
desired optical density, 200 µL aliquots were taken and harvested in a desktop 
centrifuge at full speed for 2 minutes. The supernatant was discarded, and then the 
pellet was re-suspended in 50 µL filtered, autoclaved phosphate-buffered saline 
solution (Sigma-Aldrich, Poole, UK). The re-suspended cells were then diluted further 
in 1 mL of filtered, autoclaved phosphate-buffered saline. 
 
Samples were loaded, one at a time, into the flow cytometer using the syringe pump. 
Phosphate-buffered saline, a non-fluorescent bacterial strain and a constitutively 
fluorescing bacterial strain, Salmonella Typhimurium ΔramAE carrying the pMW82 
pramA:gfp reporter construct, were used to define appropriate gates based on their 
forward scatter, side scatter and fluorescence. GFP was excited using the 488 nm 
blue laser, set to a voltage of 500 V. After the gates had been defined, the cells of 
interest were analysed. Ten thousand fluorescent cells were sampled at a rate of 50 
µL per minute. The data were exported as a .csv file and analysed in MS Excel 2016 
(Microsoft Corportation, USA). The level of expression within each population was 
compared as well as the numbers of individual cells producing high levels of gfp. 
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Chapter Three 
Mutations in gyrA Alter Supercoiling 
and Antibiotic Tolerance 
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3.1 Introduction 
Bacterial DNA is highly condensed so as to be able to fit inside the cell, as the 
bacterial chromosome is many times larger than the cell itself when unfurled. DNA 
supercoiling is one mechanism by which DNA can be compacted. In Escherichia coli 
and Salmonella Typhimurium, the supercoiling state of the chromosome has been 
shown to change after exposure to different conditions, e.g. temperature, acid stress, 
salt concentration, and also varies greatly depending on the growth phase of the cell 
(Cameron et al., 2011). 
 
Topoisomerases are enzymes that can modify the supercoiling state of DNA by 
relaxing or introducing supercoils. The Type II topoisomerases can introduce 
negative supercoils through strand-passage (Bush et al., 2015). They are highly 
conserved and make good targets for antibiotics (Redgrave et al., 2014). Quinolones 
and fluoroquinolones are antibiotics that disrupt the function of the Type IIa 
topoisomerases, DNA gyrase and topoisomerase IV, by intercalating with the 
complex the enzymes form with DNA (Aldred et al., 2014). Modern fluoroquinolones 
are broad-spectrum agents and are widely used in clinical settings (Aldred et al., 
2014), though clinical resistance to quinolones was first observed in the early 1990s 
(Piddock et al., 1990) and has since become widespread. The major mechanism of 
quinolone resistance is the mutation of the genes that encode the proteins that 
comprise DNA gyrase and topoisomerase IV (Redgrave et al., 2014). It has been 
shown that clinically relevant mutations in the quinolone-resistance determining 
region of gyrA in S. Typhimurium reduce susceptibility to quinolones, but also 
influence susceptibility to a number of other antimicrobials, and alter the supercoiling 
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profile of the cell (Webber et al., 2013). An explanation proposed for this phenotype 
is that mutations in gyrA can alter the supercoiling state of the genome and change 
the cells ability to respond to various stresses. This is investigated in this chapter. 
 
It was also felt that the effects of equivalent gyrA substitutions in Escherichia coli 
should be investigated. This was because Escherichia coli and Salmonella 
Typhimurium are both Gram-negative, rod-shaped Gammaproteobacteria (Williams 
et al., 2010) capable of causing intestinal illness. They are evolutionarily closely 
related and their core genomes are a similar size, with the E. coli genome having 4.6 
megabases (Blattner et al., 1997), and the S. Typhimurium genome having 4.8 
megabases (McClelland et al., 2001). Figure 3.1.1, created using PhyloPhlAn 
(Segata et al., 2013), shows a phylogenetic tree of bacterial relationships, with the 
positions of E. coli and S. Typhimurium highlighed. Some major differences between 
the core genomes of both species relate to horizontally acquired islands 
characterised by the presence of large AT-rich regions. Examples of such AT-rich 
regions in the Salmonella genome are the Salmonella Pathogenicity Islands, SPI-1 
and SPI-2, which encode for Type III Secretion System components involved in the 
infection pathway (Hansen-Wester and Hensel, 2001). The last common ancestor of 
the two species was estimated to be around 100 million years ago (Doolittle et al., 
1996), though the use of a constant molecular clock rate to determine this has been 
questioned by some, owing to differences between in vitro and in vivo mutation rates 
(Achtman, 2016; Ochman et al., 1999).  
 
98 
Whilst the core genomes are very similar between the two species, it has previously 
been shown that the basal supercoiling levels of Escherichia coli and Salmonella 
Typhimurium differ, and that the nucleoid associated protein FIS has greater 
influence over supercoiling in E. coli than in S. Typhimurium (Cameron et al., 2011). 
Topoisomerases are highly conserved between species, sharing common domains, 
owing to their essentiality for cell survival (Huang, 1996). For example, the gyrB 
sequences of the Salmonella Typhimurium strain 14028S and the E. coli strain ATCC 
25922 are 90.9% identical (Fukushima et al., 2002).   
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Figure 3.1.1: A representation of bacterial phylogeny created using 
“PhyloPhlAn”. Phylogenetic relationships inferred computationally from predicted 
sequences of 400 broadly conserved proteins in over 3,700 whole genome 
sequences. These proteins are highly similar in Salmonella and E. coli, and the 
position of these genera is highlighted in a red circle.  
Triangles correspond to sequence errors. Red arcs correspond to Firmicutes, blue 
arcs to Actinobacteria, yellow arcs to Bacteriodetes and green arcs correspond to 
Proteobacteria. Other coloured arcs correspond to smaller groups of species. Figure 
adapted from Segata et al. (2013). 
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It has previously shown that mutations in gyrA alter supercoiling in Salmonella 
(Webber et al., 2013), having the knock-on effects of altering gene expression and 
stress responses, thus conferring a generic protective effect against some antibiotics 
and stresses. Given the difference in basal supercoiling between the two species we 
aimed to determine whether alterations in DNA gyrase impacted both species in a 
similar way. 
 
The hypotheses tested in this chapter were: 
• Mutations in gyrA will cause changes in supercoiling in both Salmonella 
Typhimurium and Escherichia coli 
• Topoisomerase protein sequences will cluster based on pathotype; 
• Any changes in supercoiling conferred by gyrA mutations will alter the 
expression of stress response loci, in a manner similar to that seen in 
Salmonella. 
• Changes in supercoiling afford protection against various antibiotics; 
• Treatment with non-quinolone antibiotics will alter supercoiling; 
• Mutations in gyrA will “override” inducible changes in supercoiling. 
The aims for this chapter were: 
• To validate the impacts that GyrA Ser93Phe and GyrA Asp87Gly substitutions 
have on the supercoiling profile of Salmonella Typhimurium 
• To validate the impacts that GyrA Ser83Leu and GyrA Asp87Gly substitutions 
have on the supercoiling profile of Escherichia coli; 
• To compare and contrast any differences in supercoiling in the two species 
that are a consequence of equivalent substitutions; 
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• To determine if Escherichia coli topoisomerase protein sequences cluster 
based on pathotype; 
• To determine the effects of gyrA mutations on the relationship between 
stresses and supercoiling in multiple conditions in Salmonella; 
• To determine if mutations in gyrA alter levels of supercoiling in response to 
treatment with antibiotics compared with wild type cells in Salmomella; 
• To determine whether the nature of the response to antibiotic treatment varies 
depending upon the class of antibiotic in Salmonella. 
 
3.2 Results 
3.2.1 Verification of Strains by Phenotypic Analysis and Sequencing 
The Salmonella Typhimurium strains SL1344, SL1344 GyrA Ser83Phe and SL1344 
GyrA Asp87Gly were obtained from the ARG Culture Collection. The Salmonella 
parent strain SL1344 was previously obtained from the AHVLA and has been 
sequenced in house on multiple occasions, and specific gyrA mutants were created 
prior to the start of this project by site-directed mutagenesis and described previously 
(Webber et al., 2013). 
 
The Escherichia coli strain MG1655 was also obtained from the ARG Culture 
Collection, though it was originally obtained from the Coli Genetic Stock Center at 
Yale University. The GyrA Ser83Leu strain was created by site-directed mutagenesis 
by an intercalating medical student as part of his project (Sutton, 2014), and the GyrA 
Asp87Gly strain was a kind gift from Professor Tony Maxwell of the University of East 
Anglia.  
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The species were confirmed as being either Salmonella enterica or Escherichia coli 
by Gram staining, growth on chromogenic XLD agar, and verifying their metabolic 
profile with API(E) strips (Biomerieux, France). Growth kinetics assays, shown in 
Figure 3.2.1.1, were performed in control conditions and showed that gyrA mutation 
in Salmonella did not have an adverse effect on growth rate in drug free media, or in 
the presence of ampicillin for strains carrying pBR322 (used in supercoiling assays).  
 
At the start of this project the Quinolone Resistance Determining Region of the gyrA 
genes from all six strains were sequenced, and compared to the NCBI records of the 
sequences of the gyrA genes from each species’ respective parent strains. The 
expected sequences were present in all strains, with the gyrA mutant strains 
containing single-nucleotide changes that resulted in the expected amino acid 
substitutions. Cells were then transformed with the plasmid pBR322 so that it could 
be used as means of measuring supercoiling. 
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LB only       LB + 50 !g/mL ampicillin 
 
 SL1344/pBR322   GyrA Ser83Phe/pBR322   GyrA Asp87Gly/pBR322 
 
Figure 3.2.1.1: Growth kinetics data for SL1344 and gyrA mutant strains. Key: black = Salmonella Typhimurium 
SL1344/pBR322; blue = S. Typhimurium SL1344 GyrA Ser83Phe/pBR322; red = S. Typhimurium SL1344 GyrA 
Asp87Gly/pBR322. Part A) shows growth kinetics data for the strains carrying the plasmid pBR322 when grown in LB broth, 
the averages of readings from eight independent replicates. Part B) shows growth kinetics data for the strains carrying the 
plasmid pBR322 in LB broth supplemented with ampicillin. The lines shown are the averages of readings from 16 independent 
replicates. There is no appreciable difference in generation times between strains. 
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3.2.2 Susceptibility Testing 
The minimum inhibitory concentrations (MICs) of various antibiotics were determined 
for the strains in this study and are shown in Table 3.2.1. The MIC values for nalidixic 
acid, ciprofloxacin and triclosan were in agreement with those presented previously 
(Webber et al., 2013). The SL1344 cells were more susceptible to nalidixic acid and 
ciprofloxacin (a quinolone and fluoroquinolone, respectively), than the strains with 
GyrA substitutions, as expected. Both the GyrA Ser83Phe substitution and the GyrA 
Asp87Gly substitution had an MIC of nalidixic acid that was at least 64-fold higher 
than that for SL1344, increasing from 4 µg/mL to >256 µg/mL. Cells carrying these 
substitutions grew in the presence of 256 µg/mL nalidixic acid, but this was also the 
upper limit of the range of concentrations used. The presence of these substitutions 
also increased the MIC of ciprofloxacin eight-fold, from 0.03 µg/mL to 0.25 µg/mL, 
and increased the MIC of triclosan four-fold, from 0.06 µg/mL to 0.25 µg/mL. 
However, for all strains tested, the MICs for gentamicin and ampicillin were higher 
than previously reported. The acceptable difference in dilution from previously 
reported values is a two-fold difference (either higher or lower), but the difference in 
MIC values for gentamicin and ampicillin exceeded this acceptable range.  
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Strain  Minimum inhibitory concentration (µg/mL) 
Nal Cip Trc Gent Amp Chlor Nov  Tet Pqt Mnd Kan 
S. Typhimurium 
SL1344 
4 0.03 0.06 0.5 0.5 2 >256 1 512 128 2 
S. Typhimurium 
SL1344 GyrA 
Ser83Phe 
>256 0.25 0.25 0.5 1 4 >256 1 256 192 2 
S. Typhimurium 
SL1344 GyrA 
Asp87Gly 
>256 0.25 0.25 0.5 1 2 >256 1 512 128 2 
S. Typhimurium 
SL1344/pBR322 
8 0.03 0.06 0.5 0.5 2 >256 1 n/t n/t 2 
S. Typhimurium 
SL1344 GyrA 
Ser83Phe/pBR322 
>256 0.25 0.25 0.5 1 2 >256 1 n/t n/t 2 
S. Typhimurium 
SL1344 GyrA 
Asp87Gly/pBR322 
>256 0.25 0.25 0.5 1 2 >256 1 n/t n/t 2 
E. coli NCTC 10418  8 0.015 0.06 1 1 1 >256 0.5 256 192 1 
Table 3.2.2.1: Minimum inhibitory concentrations for a range of compounds as tested against Salmonella 
Typhimurium. Table showing the minimum inhibitory concentrations of antibiotics tested against the Salmonella Typhimurium 
strains used in this study. E. coli NCTC 10418 is included as a control.  Mutations in gyrA confer an over 64-fold increase for 
the MIC of nalidixic acid and an approximately 8-fold increase in the MIC of ciprofloxacin, and are also associated with an 
approximately 4-fold increase in the MIC of triclosan. 
 
Nal = nalidixic acid; Cip = ciprofloxacin; Trc = triclosan; Gent = gentamicin; Amp = ampicillin; Chlor = chloramphenicol; Nov = 
novobiocin; Tet = tetracycline; Ery = erythromycin; Pqt = paraquat; Mnd = menadione; Kan = kanamycin; n/t = not tested. 
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3.2.3 Effects of GyrA Substitutions on Tolerance to Triclosan in Salmonella 
It has previously been shown that gyrA mutation confers a protective benefit against 
the biocide triclosan, with both the GyrA Ser83Phe and GyrA Asp87Gly substitutions 
increasing the minimum inhibitory concentration three-fold, from 0.06 µg/mL to 0.25 
µg/mL. Additionally, growth kinetics assays in the presence of triclosan showed that 
strains carrying the GyrA Asp87Gly substitution grew better than those that carried 
either the GyrA Ser83Phe substitution, or Salmonella Typhimurium SL1344 without 
any substitution in GyrA (Webber et al., 2013). 
 
These previous observations suggested that, in competition with a wild type strain 
exposure of GyrA mutants to low levels of triclosan may promote their expansion. To 
test this hypothesis competition assays were performed over the course of a week 
between SL1344 and the GyrA Ser83Phe strain, as well as between SL1344 and the 
GyrA Asp87Gly strain. Whilst I helped design these experiments, they were 
completed by Dr M Buckner during my absence on account of a period of extended 
illness. The data are shown in Figure 3.2.3.1. In the absence of triclosan, SL1344 
was able to outcompete both of the gyrA mutant strains. In the presence of 0.03 
µg/mL triclosan (half the MIC for SL1344), both the gyrA mutant strains were still 
outcompeted by SL1344. 
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Figure 3.2.3.1: Competition assays between SL1344 and the gyrA mutant 
strains in the presence of absence of triclosan. Part A) shows Salmonella 
Typhimurium SL1344 (blue) vs. the GyrA Ser83Phe strain (yellow) in the absence of 
triclosan, and SL1344 is able to completely dominate the population after a week. 
Part B) shows SL1344 vs. GyrA Ser83Phe in the presence of 0.03 !g/mL triclosan. 
Part C) shows SL1344 vs. GyrA Asp87Gly (red) in the absence of triclosan, and part 
D) shows these two strains in the presence of 0.03 !g/mL triclosan. In all cases, the 
majority of cells throughout the course of a week isolated were SL1344; despite gyrA 
mutations being less susceptible to triclosan in MIC assays, they did not appear to 
confer a selective advantage in the presence of the biocide at the concentration 
used. The proportion of each colour in the bars is representative of the proportion of 
cells isolated that belong to each strain in the experiment. Each bar is the average of 
four independent replicates, and the error bars show the standard deviation from the 
mean. These experiments were performed in my absence by Dr. Michelle Buckner. 
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3.2.4 Effects of GyrA Substitutions on Tolerance to Triclosan in E. coli 
It has been shown that, as in Salmonella, gyrA mutation in E. coli decreases 
susceptibility to the biocide triclosan in addition to conferring resistance to quinolones 
(Webber et al., 2017). 
 
To test the hypothesis that the exposure of GyrA mutants to low levels of triclosan 
may promote their expansion in E. coli, competition experiments were performed 
over the course of a week between MG1655 and the GyrA Ser83Leu strain, as well 
as between MG1655 and the GyrA Asp87Gly strain. The data from these 
experiments were generated by Dr Michelle Buckner in my absence, and are shown 
in Figure 3.2.4.1. In the absence of triclosan, populations were evenly split between 
MG1655 and the mutant strains. In the presence of 0.03 µg/mL triclosan, the GyrA 
Ser83Leu strain was outcompeted by MG1655. However, MG1655 was markedly 
outcompeted by the GyrA Asp87Gly strain in the presence of this concentration of 
triclosan. This is in contrast to the results from Salmonella seen in Figure 3.2.3.1.  
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Figure 3.2.4.1: Competition assays between MG1655 and the gyrA mutant 
strains in the presence and absence of triclosan. Part A) shows Escherichia coli 
MG1655 (blue) vs. the GyrA Ser83Leu strain (yellow) in the absence of triclosan, and 
although the GyrA Ser83Leu strain is more abundant in the middle of the week, the 
distribution of strains is roughly even by the end of it. Part B) shows MG1655 vs. 
GyrA Ser83Leu in the presence of 0.03 !g/mL triclosan – MG1655 is the most 
abundant strain. Part C) shows MG1655 vs. GyrA Asp87Gly (red) in the absence of 
triclosan, and the population is roughly evenly split by between the two strains at the 
end of the week. Part D) shows these two strains in the presence of 0.03 !g/mL 
triclosan; the GyrA Asp87Gly strain was the only strain isolated at the end of the 
week, suggesting that the presence of the GyrA Asp87Gly substitution confers a 
selective advantage at the concentration of triclosan tested. The proportion of each 
colour in the bars is representative of the proportion of cells isolated that belong to 
each strain in the experiment. Each bar is the average of four independent replicates, 
and the error bars show the standard deviation from the mean. These experiments 
were performed in my absence by Dr. Michelle Buckner.  
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3.2.5 One-Dimensional Topoisomer Separation from Control Conditions 
To determine the baseline levels of supercoiling in cells, the plasmid pBR322 was 
extracted from stationary phase cultures and the topoisomers were separated 
overnight on chloroquine-containing gels. As shown in Figure 3.2.5.1 and using the 
wild type as a point of reference, the GyrA Asp87Gly strain had a much more 
supercoiled topoisomer profile, and the GyrA Ser83Phe strain had a topoisomer 
profile which was more supercoiled than the wild type, but less supercoiled than that 
of the GyrA Asp87Gly strain. This was in accordance with the data presented 
previously by Webber et al. (2013). 
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Figure 3.2.5.1: Images of separated topoisomers of pBR322 from stationary 
phase wild type, GyrA Ser83Phe and GyrA Asp87Gly cells, taken from the same 
gel. The more supercoiled a plasmid is, the further it travels down the gel. The 
plasmid from the GyrA Ser83Phe strain (middle) is more supercoiled than the wild 
type (right), and the profile of band distribution of the plasmid from the GyrA 
Asp87Gly strain (left) is supercoiled further still. The gel on which these topoisomers 
were separated is shown in the appendix, as Figure A.1.1. 
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3.2.6 Impact of Treatment with Nalidixic Acid on Supercoiling in Salmonella 
enterica 
Experiments were designed to examine the effects of nalidixic acid exposure on 
supercoiling in the strains. Nalidixic acid is known to induce the SOS response 
(Piddock and Wise, 1987), and the expression of the SOS response genes recA and 
lexA was increased in SL1344 GyrA Asp87Gly in previous microarray experiments 
(Webber et al., 2013). As these strains have differing supercoiling phenotypes and 
because supercoiling can be altered in response to stresses (Cameron et al., 2011), 
a potential link between SOS response induction and the genomic supercoiling 
profile was suspected.  
 
The Salmonella strains SL1344/pBR322, SL1344 GyrA Ser83Phe/pBR322 and 
SL1344 GyrA Asp87Gly/pBR322 were grown to late logarithmic/early stationary 
phase and then split. Half of the samples were incubated with nalidixic acid (80 
µg/mL) for 45 minutes; the remainder were not. This concentration of nalidixic acid 
was chosen as it would induce a strong SOS response phenotype (Piddock and 
Wise, 1987; Walters et al., 1989). Plasmids were extracted and the topoisomers were 
separated on a 2xTBE/chloroquine gel. Topoisomers obtained from SL1344/pBR322 
which had been treated with nalidixic acid had lost negative supercoiling compared 
with untreated controls and the supercoiling pattern now resembled that seen in the 
gyrA mutants (Figure 3.2.6.1). This is consistent with loss of full functionality of 
gyrase. This was repeated with stationary phase cultures and similar results obtained 
showing the impact of gyrA mutation on supercoiling was similar at different growth 
phases. 
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Figure 3.2.6.1: Densitometry plots of the levels of supercoiling in the pBR322 
plasmid before and after treatment of SL1344 with nalidixic acid. The black 
pattern of peaks and troughs show the position of bands of topoisomers within the 
lanes, with the height of the peaks representing the brightness (and thus amount of 
plasmid) of each band. The topoisomers in the nalidixic acid-treated sample from the 
wild type SL1344 cells are more widely distributed than the untreated sample from 
the same strain, and more topoisomers have migrated further down the gel. 
Therefore, it appears that nalidixic acid increases the level of supercoiling in SL1344.  
The GyrA Asp87Gly strain is included for comparative purposes.  
The red line shows the shortest distance between two troughs and is an artefact of 
the imaging software. It is not relevant to this discussion, but unfortunately it cannot 
be removed without disrupting the plot as a whole. 
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3.2.7 One-Dimensional Separation of Topoisomers from E. coli and 
Comparison with Topoisomers from Salmonella Typhimurium  
To investigate the impacts of separate GyrA Ser83Leu and GyrA Asp87Gly 
substitutions on MG1655, plasmid pBR322 was isolated from these strains and used 
as a proxy for genomic supercoiling. They were separated by electrophoresis on a 
gel containing chloroquine, alongside plasmids isolated from Salmonella strains 
containing the equivalent GyrA substitutions. These experiments were done by 
Robyn Iddles in my absence and the gel is shown in Figure 3.2.7.1.  
 
The “baseline” level of supercoiling appears to be similar for the two species – i.e. the 
topoisomers from the wild type strains, E. coli MG1655 (Lane B) and S. Typhimuirum 
SL1344 (Lane E), have migrated about the same distance and appear to be 
distributed in a similar manner to one another. The GyrA Ser83Leu (Lane C) and 
GyrA Ser83Phe (Lane F) substitutions appear to cause a similar shift in supercoiling 
and the topoisomer distribution skews slightly less negatively supercoiled in both 
species by roughly the same amount. However, the effects of the GyrA Asp87Gly 
substitution appear to be different in the two species. In Salmonella, the supercoiling 
state of the GyrA Asp87Gly (Lane G) strain was similar to that of SL1344. In E. coli, 
the GyrA Asp87Gly (Lane D) was more supercoiled than MG1655. 
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Figure 3.2.7.1: Supercoiling gel of pBR322 extracted from Escherichia coli and 
Salmonella Typhimurium wild type and gyrA mutant cells under control 
conditions. A) HyperLadder 1 kb B) E. coli MG1655 C) E. coli GyrA Ser83Leu D) E. 
coli GyrA Asp87Gly E) S. Typhimurium SL1344 F) S. Typhimurium GyrA Ser83Phe 
G) S. Typhimurium GyrA Asp87Gly. Topoisomers from E. coli GyrA Asp87Gly cells 
appear to migrate further than the MG1655 cells or the equivalent mutant in 
Salmonella. Topoisomers from MG1655 cells appear more densely packed than 
those from SL1344 cells. Those from cells with substitutions at the position GyrA 
Ser83 appear too faint to deterime effectively. These data were generated by Robyn 
Iddles as part of her BMedSci intercalation project. 
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3.2.8 Optimisation of “Quick” Supercoiling Gels 
Whilst the gold standard for measuring supercoiling requires extended 
electrophoretic separation, this is time consuming and not amenable to comparing 
large numbers of conditions for impacts on supercoiling. It is possible to carry out 
topoisomer separation assays within the space of one day (Lee et al., 2013; Mustaev 
et al., 2014). This is generally achieved by subjecting 1% agarose gels to 
electrophoresis at 80 V for four hours. Four 50 g gels were set up and the separation 
of pBR322 topoisomers were assayed under those conditions. To examine the 
impacts of pre- and post staining and the use of chloroquine to stabilise topoisomers 
two had 2.5 µL Midori Green added, one of which also contained 2.5 µg/mL 
chloroquine. The other two gels were identical, except for the fact that they did not 
contain Midori Green and were instead washed for an hour in water, and washed for 
another hour in water containing 20 µL Midori Green after the completion of 
electrophoresis. All the conditions tested resulted in similar results and banding 
patterns of toposiomers were visible in 1% agarose gels with Midori Green pre-added 
and without chloroquine. Further permutations of these conditions showed a 1.5% 
agarose gel containing Midori Green to be optimal, and this is shown in Figure 
3.2.8.1, below. A 1.5% agarose gel was therefore used for initial screens of large 
numbers of plasmids isolated from strains in different conditions.  
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Figure 3.2.8.1: Topoisomers separated using “quick” supercoiling gel 
procedures. Topoisomers of the plasmid pBR322 separated for 4 hours at 80 V on 
either a) a 2% agarose gel; or, b) a 1.5% agarose gel, both of which contain Midori 
Green, but no chloroquine. The purpose of this experiment was to deterime if there 
was a method of determining supercoiling using an agarose gel that was faster than 
the electrophoresis assay that lasted 16 hours, yet still produced comparable results. 
The plasmids were isolated from the same sample: a stationary phase culture of 
Salmonella Typhimurium SL1344, and 300 ng was loaded on each gel. The pattern 
of topoisomers is more distinct in the 1.5% agarose gel, so this is what was used for 
the rest of this study. 
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3.2.9 Analysis of Supercoiling Changes in Various Conditions 
To determine the effects of different stresses upon topoisomer profiles, wild type and 
gyrA mutant cells carrying the plasmid pBR322 were grown to mid-logarithmic phase 
and exposed to various stresses for 45 minutes. These were heat shock at 42 ºC; 
growth in the presence of 8 µg/mL nalidixic acid; and growth in the presence of 1 
µg/mL gentamicin. Plasmids were also extracted from cells grown to early-logarithmic 
and stationary phase.  
 
Topoisomers were initially separated from the overnight cultures, mid-logarithmic 
controls and heat-shocked cells. This is shown in Figure 3.2.9.1. The pattern of 
supercoiling in the wild type and GyrA Asp87Gly cells was observed to be similar no 
matter the condition. Additionally, GyrA Ser83Phe cells consistently had a slightly 
more supercoiled profile than those from the other two strains. 
 
Subsequently, further topoisomers were separated from a wider range of conditions 
so as to determine how low-level stresses impacted topoisomer behaviour. The 
conditions chosen were based on either previous biolog data indicating gyrase 
mutants have a growth benefit under these conditions, or known inducers of stress 
responses seen to be up-regulated in the gyrase mutants. These were heat shock at 
42 ºC and exposure to gentamicin, nalidixic acid, triclosan, ethanol, acriflavine, 
sulphamethoxazole, acetone and boric acid. The topoisomer profiles of each strain 
under these conditions are shown in Figure 3.2.9.2, and are grouped by strain. 
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Figure 3.2.9.1: Plasmids extracted from S. Typhimurium under a range of conditions and subsequently separated. 
Topoisomer profiles for the plasmid pBR322, extracted from all three S. Typhimurium strains investigated in this study. ‘A’ and 
‘B’ reflect separate, independent plasmid extractions, patterns were essentially identical between replicates. Samples from 
overnight cultures are too smeared to allow for the determination of topoisomer distribution. SL1344 and GyrA Asp87Gly cells 
appear to have responded similarly to the 42 ºC shock and being grown to mid-logarithmic phase as they possess a similar 
pattern of separated topoisomers. GyrA Ser83Phe cells have a more supercoiled phenotype (i.e. the topoisomers have 
migrated further down the gel) in response to these conditions, but also appear more supercoiled in control conditions as well. 
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Figure 3.2.9.2: Plasmids extracted from S. Typhimurium under additional conditions and 
separated. One-dimensional gels of pBR322 samples extracted from SL1344 and the gyrA mutants 
after their having been exposed to a range of conditions. Patterns of topoisomer distribution roughly 
appear similar within strains, but differ in intensity. It appears as though plasmids do not migrate as far 
after treatment with chemicals in the gel of plasmids isolated from SL1344 cells, suggesting they are 
less supercoiled than those from control conditions but this could be artefactual. The migration of 
plasmids from gyrA mutants, and thus the levels of supercoiling, appears unchanged after treatment 
with chemicals or antibiotics. 
121 
In the SL1344 samples, shown in part A), samples from overnight cultures, those 
from samples grown at 37 ºC and those from samples grown at 42 ºC all appear to 
show a very similar banding pattern, with two distinct bands. This suggests that 
exposure to a raised temperature for 45 minutes does not appear to have much of an 
impact on supercoiling.  After treatment with antibiotics and chemicals, the 
topoisomer patterns appeared to have not migrated as far down the gel as those 
isolated from cells grown in control conditions, regardless of the antibiotic or chemical 
used, and are thus less supercoiled after treatment with drugs than in the untreated 
37 ºC samples,. Admittedly the gel is at a slight angle, but even once this is corrected 
for, samples from cells treated with drugs still have not migrated as far down the gel 
as those from cells that were not.  
 
The intensity of the bands appears to vary. Some samples, such as those isolated 
from cells treated with gentamicin or ethanol, have a much stronger band towards the 
bottom of the gel. Although this has not migrated as far as the bands isolated from 
cells grown at 37 ºC, it does appear more intense. This would suggest that there are 
a greater proportion of supercoiled topoisomers within samples from cells treated 
with ethanol or gentamicin, even if these topoisomers are not as highly supercoiled 
as those from cells grown in control conditions. 
 
The acriflavine sample cannot be seen; this could be because of acriflavine being a 
DNA-binding agent (Tubbs et al., 1964; Chan and Van Winkle, 1969) and possibly 
competing with the Midori Green, which functions similarly to ethidium bromide 
(Nippon Genetics Europe, n.d.), but this does not explain why it is visible in the GyrA 
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Asp87Gly samples. A more likely explanation is that, despite having calculated the 
volume of sample needed to load 300 ng of DNA onto the gel, the calculations were 
incorrect. 
 
Part B) shows samples from the GyrA Ser83Phe strain. In contrast to the wild type 
strain, there is little difference between the drug-treated samples and the non-treated 
samples. With the exception of those from overnight cultures, samples exhibit two 
very strong, clear bands close together. There are again differences in the intensity 
of the bands. Topoisomers from cells treated with nalidixic acid appear as a thick 
smear; the gel might benefit from being run for longer so as to make these appear 
more distinct. Topoisomers from cells treated with acriflavine still cannot be seen.  
 
In part C), samples which have been isolated from GyrA Asp87Gly cells exhibit 
subtile differences in the topoisomer distribution pattern when treated and untreated 
samples are compared. While there is some variation in the acriflavine and 
sulphamethoxazole-treated samples, this appears inconsistent between replicates. 
As the majority of topoisomers from each seem to be collected in one band fairly low 
down the gel, the pattern displayed is more similar to that topoisomers from SL1344 
cells, as opposed those from the GyrA Ser83Phe cells. 
 
Samples obtained from GyrA Asp87Gly cells that have been exposed to gentamicin, 
acriflavine and acetone are subtly different to the other samples. The topoisomer 
distributions in the samples from the remaining conditions appear to be broadly 
similar to one another, but this is likely a consequence of the concentration of DNA 
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being too high to distinguish different bands from one another. Topoisomers from 
GyrA Asp87Gly cells generally appear as thick black smears. Ideally a current could 
have been applied to the gel for longer, separating out the topoisomers further, or a 
lower concentration of DNA could have been used. 
 
In all samples taken from all strains when grown at 42 ºC, the patterns appeared 
identical to the samples taken from the same strain at 37 ºC. Densitometry plots were 
made from each sample and these were then directly compared across mutants in 
each condition (Figure 3.2.9.3).  
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Figure 3.2.9.3: Examples of topoisomer densitometry plots. In each triplet, the 
plots are from samples taken from SL1344, GyrA Ser83Phe and GyrA Asp87Gly 
cells, going left to right. A) Distribution of topoisomers in samples taken from mid-
logarithmic phase cultures grown at 37 ºC. b) Distribution of topoisomers in samples 
from mid-logarithmic phase cultures perturbed with nalidixic acid. C) Topoisomer 
distribution from samples treated with boric acid. D) Topoisomer distribution from 
samples treated with ethanol. E) Topoisomer distribution from samples treated with 
triclosan. F) Topoisomer distribution from samples treated with gentamicin. 
The pattern of supercoiling appears to change for SL1344 cells in response to drug 
treatment; the trace appears to smooth out after treatment with nalidixic acid, or 
bunch up into one peak after ethanol treatment. The pattern of supercoiling appears 
to be fixed for the GyrA Ser83Phe cells, with two peaks at roughly the same position 
about three quarters of the way down the gel, only varying in their intensity. The 
pattern of supercoiling appears to be fixed for the GyrA Asp87Gly cells, as there is 
one noticeably large peak visible in each trace, that appears at approximately the 
same distance down the gel no matter the condition in which the cells were grown. 
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 Figure 3.2.9.3 shows the topoisomer distribution patterns from all three strains under 
a series of representative conditions from those examined. Using the 37 ºC samples 
in part A) as a baseline, in the majority of cases treatments only resulted in changes 
in supercoiling in SL1344, whereas patterns of supercoiling the two GyrA strains 
were unchanged - this suggests that the mutations in gyrA override any condition-
induced change in supercoiling. Samples taken from SL1344 appear to be more 
supercoiled in other conditions. The GyrA Ser83Phe cells consistently show a pattern 
with two peaks of varying intensity, and the GyrA Asp87Gly cells show a pattern with 
one strong peak, at a distance intermediate to the peaks of the wild type and GyrA 
Ser83Phe cells. In the majority of conditions, the supercoiling states of topoisomers 
from the two mutants are unchanged compared with those taken from cells grown at 
37 ºC in the absence of any stressor.  
 
3.2.10 Two-Dimensional Separation of Topoisomers 
Supercoiling can be positive or negative, to determine if the changes in overall 
supercoiling levels were a result of changes in positive and/or negative supercoiling, 
topoisomers were separated in the second dimension in the presence of a greater 
chloroquine concentration. Figure 3.2.10.1 shows the gel photo from this assay, and 
the densitometry plots obtained from the gel. When separated in the second 
dimension, the migration of samples appeared to be uniform, suggesting that a 
difference in proportions of negatively and positively supercoiled topoisomers is not 
present. The patterns observed for wild type cells are in agreement with those seen 
previously (Webber et al., 2013) and in Sections 3.2.7 and 3.2.9; topoisomers 
isolated from GyrA Ser83Phe cells under control conditions appear to migrate further 
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than those isolated from wild type cells.  Incubation of samples in the presence of 
gentamicin appears to have no impact on the directionality of supercoiling, though 
topoisomers from GyrA Ser83Phe cells treated with gentamicin do not appear to 
migrate as far as those from their untreated counterparts. 
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Figure 3.2.10.1: Two-dimensional separation of topoisomers from S. Typhimurium. Part A) 
shows a two-dimensional gel of pBR322 samples isolated from S. Typhimurium, both with and without 
GyrA substitutions, grown in the presence and absence of gentamicin. The slanted pattern of the 
bands is a consequence of the gel being run in one direction for 2 hours, then being rotated 90º and 
run for a further 15 minutes. The large accumulation of sample in the GyrA Ser83Phe –gent lane is 
analogous to those seen in Figure 3.2.9.2, and does not appear to be anything special. A ladder was 
included but ran off the gel. Part B) shows densitometry plots of the traces from part A). The 
densitometry plots for wild type cells and untrated GyrA Ser83Phe cells appear identical.  The GyrA 
Asp87Gly plots have been distorted by the massive buildup of dye at that side of the gel. The red lines 
are again not relevant.  
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3.2.11 Relationship Between E. coli Topoisomerase Protein Sequences and 
Pathotype 
As E. coli comprises a broad range of strains adapted into separate pathotypes, 
differences in DNA gyrase sequence between strains of each pathotype were 
investigated. To determine if there was any relationship between topoisomerases 
and E. coli pathotypes, a number of E. coli strains from a range of pathotypes were 
identified through a literature survey. The protein sequences of GyrA, GyrB, ParE, 
ParC and TopA were then obtained from the NCBI database for these strains and 
used to construct cladograms. 
 
The cladogram for GyrA is shown in Figure 3.2.11.1. There is no apparent clustering 
based on pathotype. This was also observed for the other proteins (data not shown). 
Sequences from a selection of Salmonella strains were included as a positive control 
and these do cluster together. 
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Figure 3.2.11.1: Cladogram of GyrA protein sequences. Cladogram showing the relationship between the protein 
sequences of GyrA from Staphylococcus aureus, a range of Salmonella strains and a variety of Escherichia coli strains of 
different pathotypes. As this is a cladogram, branch lengths are arbitrary. The Salmonella sequences cluster together and the 
Staphylococcus sequence forms an outgroup, but, contrary to expectations, the E. coli sequences do not cluster based on 
pathotype. 
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3.3 Discussion 
3.3.1 Effects of GyrA Substitution on Topoisomerase Distribution, and 
Changes in Topoisomerase Distribution in Response to Stress 
In accordance with what was previously shown in the literature, it was confirmed that 
amino acid substitutions in GyrA resulted in alterations to baseline supercoiling levels 
and minimum inhibitory concentrations for these strains were, for the most part, in 
agreement with those previously published (Webber et al., 2013). Topoisomers from 
S. Typhimurium cells with GyrA substitutions were observed to migrate further than 
those from cells with the wild type form of the enzyme, suggestive of a the 
topoisomers from the gyrA mutants being more supercoiled than those from the wild 
type cells. It was not always consistent between experiments, but the largest change 
in supercoiling was usually seen in the GyrA Ser83Phe strain, though in vitro 
experiments have shown that the GyrA Asp87Gly substitution results in a larger 
reduction in supercoiling activity, as shown in Table 3.3.1 (Webber et al., 2017). 
Although GyrA Asp87Gly is less active than either the wild type or GyrA Ser83Phe, 
the similarity of its behaviour as compared with that of the wild type enzyme in the 
data presented in this chapter suggests that it is possibly more efficient than GyrA 
Ser83Phe. If the reduction in activity were coupled with a reduction in efficiency, one 
might perhaps expect to see DNA extracted from GyrA Asp87Gly cells under control 
condtions be less supercoiled than DNA extracted from other cells, given gyrase 
introduces supercoils into DNA. 
 
The plasmid pBR322 was isolated from E. coli and Salmonella and topoisomers 
separated out on a gel. This was used as a proxy measurement for levels of genomic 
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supercoiling. It has been shown in the literature that there should be differences in 
supercoiling between the two species in the absence of any stress or mutation 
(Cameron et al., 2011), but the data presented here suggest that the supercoiling in 
MG1655 and SL1344 was similar under such conditions. Differences in the migration 
of topoisomers were observed in strains with GyrA substitutions both between and 
within species, suggesting that these GyrA substitutions alter genomic supercoiling in 
both species, and do so differently.  
 
Work done as part of a collaboration with Tony Maxwell’s group at the University of 
East Anglia (Webber et al., 2017) has shown that gyrase with an Asp87Gly 
substitution is much less active than either the wild type version of the enzyme or the 
Ser83Leu version of the enzyme, as shown in Table 3.3.1. The data suggest that the 
GyrA Ser83Phe substitution has a more detrimental effect on the activity of GyrA in 
Salmonella than it does in E. coli, with the activity of the enzyme being reduced to 
30% that of the wild type level in the former species, and to 90% of the wild type level 
in the latter. The GyrA Ser83Phe substitution is associated with a greater fold-change 
in MIC in E. coli as well. In both E. coli and Salmonella, the GyrA Asp87Gly 
substitution reduces supercoiling activity by 85% relative to the wild type version of 
the enzyme and results in a 10-fold change of ciprofloxacin IC50. However, the GyrA 
Ser83Phe substitution reduces activity by 70% in Salmonella, conferring a 5-fold 
increase in ciprofloxacin IC50, and reduces activity by 10% in E. coli, conferring a 14-
fold increase in ciprofloxacin IC50. 
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These differences in supercoiling activity in the two species suggest a greater 
potential for differences in the transcriptome of the E. coli GyrA Asp87Gly cells 
compared with MG1655, and this could be investigated thoroughly with RNA 
sequencing. It would be useful to investigate how the supercoiling profile changes in 
E. coli and its related strains carrying GyrA substitutions in response to stresses, as 
was done with Salmonella. The impact on changes to supercoiling levels on 
pathogenicity and metabolic capacity in each species could also be compared with 
help understand how supercoiling is influencing the biology of each species and how 
changes to their evolved optimum influence each. 
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Species GyrA substitution Supercoiling activity  
relative to WT (%) 
Fold change  
in cipro IC50 
S. Typhimurium Wild type 100 n/a 
Ser83Phe 30 5 
Asp87Gly 15 10 
Ser83Phe+Asp87Gly 30 >14 
E. coli Wild type 100 n/a 
Ser83Phe 90 14 
Asp87Gly 15 10 
Ser83Phe+Asp87Gly 20 >200 
Table 3.3.1:  Comparison of changes in in vitro supercoiling activity and IC50 
values for ciprofloxacin as a result of GyrA substitution in S. Typhimurium and 
E. coli.  Table, adapted from (Webber et al., 2017), showing how different GyrA 
substitutions alter gyrase activity changes in Salmonella Typhimurium, as shown 
through in vitro experiments. Data are shown as percentages relative to the activity of 
the wild type version of the enzyme. All substitutions listed result in reduced activity 
relative to the wild type enzyme. The GyrA Asp87Gly substitution is less active than 
the GyrA Ser83Phe substitution. However, the GyrA Ser83Phe Asp87Gly double 
substitution is equally as active as the GyrA Ser83Phe substitution. 
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The Salmonella Typhimurium gyrA mutants had their genomes sequenced by 
MicrobesNG, with the intention of using the sequence data to identify single 
nucleotide polymorphisms. The genome sequence data was unfortunately of too poor 
quality for such an analysis to be meaningful. 
 
Despite previous results, and those presented here, showing that gyrA mutation 
confers reduced susceptibility to triclosan, this did not appear to provide a 
competitive advantage against the parental strain when each of the two gyrA mutant 
strains were grown in co-culture with SL1344. Only one concentration of triclosan 
(0.03 µg/ml) was used in these experiments, representing a sub-lethal exposure to 
mimic low levels of accumulation seen in the environment. When competition assays 
were performed in the absence of any drug, both gyrase mutants appeared to be less 
fit than SL1344. The most likely explanation for a lack of benefit in the triclosan 
experiments is that the concentration of triclosan used in these assays is too low to 
select against the parental strain sufficiently to advantage the gyrase mutants. 
Triclosan has been found at a concentration of 2.7 µg/mL in human urine from 
healthy volunteers (Pirard et al., 2012). This value is two orders of magnitude higher 
than the concentration used in the competition assays. This could be investigated 
further by repeating the competition assays using a range of concentrations of 
triclosan. 
 
Various permutations on the “quick” supercoiling gel protocol were investigated, 
leading to the conclusion that the optimal conditions were to run the gel for 4 hours at 
80 volts. It was observed that the presence or absence of chloroquine, a topoisomer 
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relaxation agent, made no appreciable difference to the supercoiling profile. It 
appeared as though the topoisomers in some samples were more concentrated than 
others, as evidenced by differences in band intensity. For example, in the gel 
comparing samples from GyrA Ser83Phe cells, the nalidixic acid samples were much 
darker than the samples from control conditions, suggesting that the topoisomers 
were more concentrated, and the samples from cells that were grown in the presence 
of acriflavine were completely invisible. Although samples were supposed to have 
been normalised to 300 ng of DNA per lane, this might not necessarily have worked 
in practice. 
 
3.3.2 Impacts of GyrA Substitution on Tolerance to Triclosan 
It has previously been shown that GyrA substitution confers reduced susceptibility to 
triclosan in Salmonella, and this is also the case in E. coli. To investigate the impact 
of this reduction in susceptibility on cell survival, competition assays were performed 
over the course of a week between wild type and gyrA mutant cells in the presence 
and absence of 0.03 µg/mL triclosan. In Salmonella, the wild type strain was able to 
outcompete both the GyrA Ser83Phe and GyrA Asp87Gly strains in both the 
presence and absence of triclosan. However, for Escherichia coli, the wild type and 
mutant strains were found to be in equal proportion after a week in the absence of 
triclosan. In the presence of triclosan, wild type cells out-competed the GyrA 
Ser83Leu cells, but were out-competed by GyrA Asp87Gly cells.  This suggests that 
the GyrA Asp87Gly substitution confers a much greater protective effect against low 
levels of triclosan in E. coli than it does in Salmonella. This could perhaps be a 
consequence of the same gyrA mutation having different impacts on gyrase 
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efficiency and consequently gene expression, but further investigation would be 
needed to determine the actual reason. 
 
This has implications for the potential evolution of gyrA mutants in each species – it 
may be that in E. coli there are benefits to carrying gyrA mutations in the presence of 
low levels of antimicrobial stress which will promote persistence of these strains. 
Fluoroquinolone resistance is relatively more common in E. coli than it is in 
Salmonella – data from isolates taken from broiler chickens in the European Union 
showed that 65.7% of E. coli isolates were being clinically resistant to ciprofloxacin, 
whereas only 53.5% of Salmonella isolates from broiler chickens were clinically 
resistant to ciprofloxacin (European Food Safety Authority and European Centre for 
Disease Prevention and Control, 2016). 
 
3.3.3 Analysis of E. coli Topoisomerase Protein Sequences and Their 
Relationship to Pathotype 
To determine if the protein sequence of topoisomerases was in any way linked to 
pathotype, the GyrA, GyrB, ParC, ParE and TopA protein sequences from 
Staphylococcus aureus, Salmonella Typhimurium and a range of Escherichia coli 
strains were analysed using bioinformatics. Phylogenetic trees were then constructed 
for each protein. It was expected that the protein sequences from E. coli would 
cluster together based on the strains’ pathotypes, but this was not observed. As 
expected, the Salmonella sequences clustered together, and the Staphylococcus 
sequence was noticeably an out-group. However, the sequences from 
enterohaemmorhagic E. coli did not cluster together, those from uropathogenic E. 
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coli sequences did not cluster together, et cetera. Therefore there is no evidence that 
alterations in supercoiling arising from topoisomerase genotypes have contributed to 
the divergent evolution of E. coli pathotypes. 
 
The impacts of exposure to different classes of antibiotics and a range of stresses 
had upon supercoiling were investigated, leading to the observations that the 
supercoiling profile of cells carrying the GyrA Asp87Gly substitution was ‘fixed’ under 
all conditions investigated and not sensitive to any of the conditions examined. This 
suggests that any change in gene expression that relates to supercoiling will be 
relatively constant and not a transient effect, which supports the phenotypes seen in 
this mutant.  
 
Transcriptomic data has previously shown the expression levels of a number of 
stress response regulators to be elevated in the GyrA Asp87Gly strain relative to 
SL1344, and it is hypothesised that this is a result of altered supercoiling (Webber et 
al., 2013). The evidence presented suggests that any benefit to the cell conferred by 
altered supercoiling, such as heightened stress responses, will be seen all the time in 
GyrA Asp87Gly cells as supercoiling appears to be fixed no matter what condition 
these cells are subjected to. To investigate this further, fluorescent reporter 
constructs were created. These constructs were designed to fluoresce when the cells 
were exposed to conditions that trigger specific stress responses, and they will be 
discussed in Chapter Four. 
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Chapter Four 
The Relationship Between GyrA 
Substitutions and Stress Responses 
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4.1 Introduction 
Changes in supercoiling as a consequence of gyrA mutation have previously been 
correlated with an altered transcriptome (Webber et al., 2013). It is also well 
established that supercoiling can change in response to exposure to various 
environmental factors and stresses and that changes in supercoiling can have global 
impacts on gene expression (Cameron et al., 2011).  
Transcription relies on RNA polymerase and the sigma factors are subunits of the 
RNA polymerase holoenzyme that guide it to specific promoter sequences. Cells 
have a catalogue of sigma factors available to them and the sigma factor 
incorporated into the holoenzyme can vary. This switching can be in response to 
changes in environment, growth phase, etc. currently being experienced by the cell.  
The common “housekeeping” sigma factor is sigma 70; other sigma factors control 
expression of genes that respond to envelope stress, nitrogen deficiency and 
adverse temperatures, to name a few. The incorporation of different sigma factors 
into RNA polymerase alters the transcriptome of the cell by changing which 
promoters are recognised, and, consequently, which genes are expressed (Feklístov 
et al., 2014; Österberg et al., 2011; Paget, 2015). Promoter availability can influence 
the rate at which a RNAP holoenzyme can bind a promoter and initiate transcription, 
the supercoiling state of DNA can influence this availability and hence influence 
transcription. 
 
As shown in the previous chapter, gyrA mutations confer a generic protective benefit 
against stresses. To test the hypothesis that this phenotype is a result of changes in 
stress response expression the purpose of this chapter was to investigate whether 
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expression of stress response operons was altered in the gyrase mutants using 
fluorescent reporter constructs controlled by different sigma factors. 
 
The specific hypotheses tested in this chapter are: 
• Changes in supercoiling conferred by gyrA mutations will alter the expression 
of stress response loci; 
• Alterations in stress response loci expression will provide a protective effect 
against quinolone and non-quinolone stresses; 
• Mutations in gyrA will “override” inducible changes in supercoiling. 
The aims for this chapter are:  
• To determine the impacts that separate GyrA Ser83Phe and GyrA Asp87Gly 
substitutions have on the expression of the SOS response loci recA and lexA;  
• To construct fluorescent reporter plasmids controlled by a range of sigma 
factors; 
• To determine the effects of gyrA mutations on the relationship between 
stresses and supercoiling in multiple conditions. 
 
4.2 Results 
4.2.1 Expression of SOS Response Regulators 
To determine the expression levels of genes involved in the SOS response and how 
this varied between cells with different gyrA mutations, cells were incubated with 
nalidixic acid. RNA was then extracted and used as a template for reverse 
transcription PCR of the lexA and recA mRNAs, and the 16S rRNA. 
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The expression levels of recA increased in all strains after the addition of nalidixic 
acid. There was a large but non-significant increase (Student’s t-test, p = 0.1) of recA 
mRNA levels in the GyrA Ser83Phe strain after the addition of nalidixic acid, relative 
to recA mRNA levels in untreated SL1344 cells, as shown in Figure 4.3.1.1. No 
significant change was observed in the levels of 16S rRNA or lexA mRNA in either 
the wild type strain or the two gyrA mutants after the addition of nalidixic acid (data 
not shown). 
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 SL1344   GyrA Ser83Phe   GyrA Asp87Gly 
 
Figure 4.2.1.1: RT-PCR of recA after the exposure, or lack thereof, of 
Salmonella Typhimurium to nalidixic acid. Relative expression of the SOS inducer 
recA in treated (+Nal) and untreated (-Nal) cells, as compared with untreated SL1344 
cells.  Key: white = SL1344, blue = GyrA Ser83Phe, red = GyrA Asp87Gly. Error bars 
= 95% confidence intervals. Data shown are the averages of six replicates. 
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4.2.2 Fluorescent Reporter Construction 
To determine the impacts of gyrA mutation on stress responses, fluorescent reporter 
constructs were made using pMW82, a plasmid containing an unstable gfp locus that 
lacked a promoter, and then transformed into SL1344 and the two gyrA mutant 
strains. The constructs had the promoters for either recA, gabD, glnA, bamA or opdA 
inserted upstream of the gfpmut2 locus. Promoters that had completely identical -10 
and -35 sequences in Salmonella and E. coli were chosen. The fluorescence of these 
constructs was used as a proxy for gene expression, which in turn was used as a 
proxy for the activity of the sigma factors responsible for their transcription.  
 
Positive control conditions to induce expression from each promoter were identified 
from literature searches and also the expression levels of the corresponding genes 
from which the promoters were amplified were queried using the SalCom dataset 
(Kröger et al., 2013). This dataset shows both the relative and absolute expression 
levels of over 85% of all known loci in Salmonella Typhimurium in an array of twenty-
two infection-relevant conditions. Of these conditions, the expression level of recA 
was found to be increased 6.18-fold when cells were exposed to peroxide shock. 
This is unsurprising, as peroxide is known to trigger oxidative stress, which in turn 
activates RecA as part of the SOS response. Its expression is also upregulated 2.1-
fold when cells were exposed to an oxygen shock. The dataset showed the 
expression of glnA was increased in mid-exponential phase and during oxygen shock 
(3.42 and 4.33-fold, respectively). It was downregulated in the all other conditions. 
The locus yaeT (bamA) was only upregulated during oxygen shock in the conditions 
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in the SalCom dataset (Kröger et al., 2013). Its expression was unchanged in mid-
exponential phase and it was downregulated under all other conditions. 
 
The SalCom dataset (Kröger et al., 2013)  showed the expression of the opdA gene 
(prlC, in Escherichia coli (Conlin et al., 1992)) was up-regulated 3.02-fold in peroxide 
shock, 2.12-fold during sodium chloride shock, 2-fold during low iron shock and 2.26-
fold during mid-exponential phase. It was increasingly downregulated from late 
exponential phase onwards. Although it has previously been shown to be part of an 
operon which is activated in response to heat shock (Conlin and Miller, 2000), this 
condition was not part of the bank of conditions tested. During a typhoid fever 
infection, the afflicted will run a temperature of around 39 to 40 ºC (Parry et al., 
2002), which is lower than the standard laboratory heat shock condition of 42 ºC. 
 
The expression of gabD was unchanged in the set of conditions in the SalCom 
database (Kröger et al., 2013). This is not consistent with what has otherwise been 
suggested by the literature, as it should be active during stationary phase (Bang et 
al., 2005), which was included in the range of conditions tested.  
 
The expression levels of the above genes under the conditions tested in the SalCom 
dataset are shown in Table 4.2.2.1, below. 
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1 
2.1 
1 
1.08 6.18 1.51 
1 
0.9 
gabD 
1 
1 2.4 1.29 
1 
1 1 1 1 1 1 1 
1 
1 
1 
1 1 1 
1 
1 
glnA 
1 
3.42 0.53 0.24 
1 
0.86 0.28 0.1 0.15 0.84 0.67 0.14 
1 
4.33 
1 
0.07 0.92 0.3 
1 
0.99 
yaeT 
1 
1 0.76 0.35 
1 
0.76 0.35 0.75 0.53 0.96 0.98 0.39 
1 
2.12 
1 
0.82 0.33 0.43 
1 
0.71 
opdA 
1 
2.26 0.63 0.61 
1 
1.33 0.16 0.39 2.12 1.05 2 0.64 
1 
1.38 
1 
0.91 3.02 1.62 
1 
1.05 
 
Relative to expression in early 
exponential phase 
  
Relative to expression during 
anaerobic growth 
  
Relative to expression in the 
absence of SPI2 
        
 
Relative to expression in mid-
exponential phase 
  
Relative to expression during 
SPI2 induction 
   
Table 4.2.2.1: Summary of changes in gene expression during various conditions experienced by Salmonella spp. 
during the infection cycle. This table summarises the data from the SalCom dataset (Kröger et al, 2013) as discussed in 
Section 4.2.2. It shows the relative changes in expression for the genes of which the promoters were used to create the 
pMW82 reporter constructs used in this study. Blue = expression relative to early exponential phase; green = expression 
relative to mid-exponential phase; orange = expression relative to during anaerobic growth; red = expression relative to during 
SPI2 induction; purple = expression relative to during the absence of SPI2. Not all the conditions tested as part of the 
fluorescence induction assays are found within the SalCom dataset. The gene gabD is only upregulated during late 
exponential and early stationary phase, whereas the expression of the other genes is affected by a wider range of conditions.
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4.2.3 Green Fluorescent Protein Assays 
The fluorescence levels of each of the constructs were read in a fluorescent plate 
reader under a range of conditions giving a total of approximately 270,000 
datapoints. Readings were normalised with respect to the cultures’ optical density, so 
as to determine the activity of the promoters, and thus the activity of various sigma 
factors, in real time. Figure 4.3.4.1 shows that the control strains fluoresced as 
expected: SL1344 with no plasmid showed a very low level of autofluorescence, 
SL1344/pMW82 pramA:gfpmut2 fluoresced strongly when induced by 
chlorpromazine but not without induction and SL1344 ΔramRA/pMW82 
pramA:gfpmut2 constitutively fluoresced at a high level. 
 
Data from a small selection of experiments are shown graphically in Figure 4.3.4.2. 
The rest can be found in the appendices. For the Salmonella mutants, there was no 
consistent up-regulation of any of the stress response pathways in any background. 
There was variation between fluorescence from different constructs and mutants but 
no consistent correlation with genotype was obvious. Examples of some conditions 
with different expression patterns are shown in Figure 4.3.4.2. The fluorescence 
levels increased over time for the pgabD construct in the SL1344 background in the 
presence of nalidixic acid, but remained low in the other backgrounds, as shown in 
part B). Additionally, the fluorescence levels of the pglnA construct in the GyrA 
Ser83Phe background remained elevated in the presence of chlorpromazine over the 
16-hour measurement period, as shown in part E).  
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Figure 4.2.3.1: Fluorescence levels of control strains in reporter assay experiments. Representative example of fluorescence/absorbance data 
from control strains in a time course assay. Similar readings were observed for all experiments. As expected, the fluorescence of cells with the 
constitutive reporter plasmid increases over time, and the fluorescence of cells with the inducible reporter plasmid in the presence of the inducer is at a 
consistently high level. No fluorescence is observed in cells lacking the reporter, cells with a promoterless version of the reporter plasmid, or cells with 
the inducible reporter plasmid in the absence of the inducer. 
Key: SL1344 = red; SL1344/pMW82 = blue; SL1344/pMW82 pramA:gfpmut2 (without chlorpromazine) = purple; SL1344/pMW82 pramA:gfpmut2 (with 
chlorpromazine) = orange; SL1344 ΔramRA/pMW82 pramA:gfpmut2 = green. Data shown are the averages of two independent replicates.
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 SL1344   GyrA Ser83Phe   GyrA Asp87Gly 
Figure 4.2.3.2: Optical density-adjusted fluorescence levels of a number of reporter 
constructs under a selection of conditions. Data shown are the averages of four independent 
replicates. Parts A), E) and F) show the fluorescence of various reporters (precA, pglnA and 
popdA, respectively) in response to chlorpromazine exposure. The expression of these reporters 
in the GyrA Ser83Phe background appears to persist at a higher level than in the other 
backgrounds.  Part B) shows the pgabD construct in the presence of nalidixic acid; its expression 
increases over time in SL1344 but does not increase in the other backgrounds.. Part C) shows 
pglnA in the presence of LB broth and is included for control purposes. The pglnA construct is 
also shown in part D), in the presence of nalidixic acid.   
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 SL1344   GyrA Ser83Phe   GyrA Asp87Gly 
Figure 4.2.3.3: Optical density-adjusted fluorescence levels recalculated 
relative to the reading for SL1344 carrying the reporter of interest exposed to 
the condition of interest at time zero. These are the same data as shown in Figure 
4.2.3.2, but corrected to account for any differences in initial inoculum. 
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The relative fluorescence readings were also normalised to the level observed in the 
wild type background at time zero, for each of the six inducers. An example of this is 
shown in Figure 4.2.3.3. Patterns of the data were similar after normalisation. In the 
GyrA Ser83Phe background, fluorescence appeared to relatively constant for the 
precA, popdA and pglnA constructs in the presence of chlorpromazine, remaining at 
a consistently high level throughout. The fluorescence of the pgabD construct in the 
SL1344 background increased over time in the presence of nalidixic acid. However, 
the fluorescence of most reporter constructs fell over time, no matter the strain they 
were in or condition to which they were exposed, reaching a plateau at around one 
and a half hours after measurements started. Therefore, although the fluorescence of 
some reporters increased in some backgrounds, there was no consistent 
upregulation of stress responses based on strains or conditions. 
 
4.2.4 Transformation of E. coli with pMW82 Constructs, and Subsequent 
Fluorescence Induction Assays 
To determine how sigma factor activity changes in E. coli with respect to gyrA 
mutation and in response to stresses, the pMW82 reporters described earlier were 
transformed into E. coli MG1655 and the two gyrA mutant strains. A literature survey 
showed that the promoters used to make the pMW82 constructs were strongly 
conserved within Gammaproteobacteria (data from Conlin and Miller, 2000; Merrick, 
1993; Nonaka, 2006; Rhodius et al., 2005; Skovierova et al., 2006; Weisemann and 
Weinstock, 1991) so the reporters were expected to work in E. coli without needing 
modification. Figure 4.2.4.1 shows, for example, the similarity of the promoter 
sequences recognised by σH in both species, and a comparison of these with the 
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sequence inserted into pMW82 to make the popdA construct. However, it should be 
noted that even small variations in promoter sequence, such as a single nucleotide 
change, or slight changes in the number of repeat sequences, can have dramatic 
impacts upon gene expression (Browning and Busby, 2016). This could potentially 
explain the observed differenes in reporter expression between E. coli and S. 
Typhimurium. 
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                    -35         -10 
 
Figure 4.2.4.1: Promoter sequences recognised by !H in Salmonella and E. coli. This figure shows the conserved -35 and 
-10 promoter sequences recognised by H in Salmonella and E. coli, highlighted in colour. Both species have a shared -35 
sequence of TTGAAA and both have species a conserved CCCAT sequence at -10. These sequences are shown alongside 
the 5’ UTR of opdA, which was inserted into pMW82 to make the popdA reporter construct, with the -35 and -10 sequences 
again highlighted in colour. The !H recognition sequences in the insert and the canonical !H recognition sequences are largely 
identical. 
153 
The fluorescence levels of the reporter constructs were read in a fluorescent plate 
reader under a range of conditions, in the same manner as in Salmonella. Readings 
were again normalised with respect to the cultures’ optical density, so as to 
determine the activity of the promoters, and thus the activity of various sigma factors, 
in real time.  
 
Figure 4.2.4.3 shows the relative fluorescence readings for the precA, pgabD, pglnA 
and pbamA constructs in the absence of stress, normalised to the level observed in 
the wild type strain at time zero. Data from a selection of other experiments are 
shown in Figure 4.2.4.4, and are normalised to the wild type at time zero in Figure 
4.2.4.5. Whilst as with Salmonella there was variation of expression across the 
various conditions it was evident that, in the absence of stress, the GyrA Asp87Gly 
strain demonstrated increased fluorescence from four of the reporters, suggesting 
constitutive de-repression of these pathways in this strain. 
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 MG1655 
(no plasmid) 
 MG1655/ 
pMW82 
  GyrA Ser83Leu/ 
pMW82 
  GyrA Asp87Gly/ 
pMW82 
 
Figure 4.2.4.2: Growth curves for E. coli strains carrying the pMW82 reporter 
constructs under control conditions. Cells were grown in unsupplemented LB 
broth at 37 ºC overnight. In most cases, plasmid carriage does not appear to 
adversely affect growth rates, nor does gyrA mutation. However, cells with a GyrA 
Asp87Gly substitution and carrying the glnA reporter construct appeared to remain in 
logarithmic phase for longer than other cells carrying this reporter construct. Data 
shown are the averages of four independent replicates. 
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 MG1655   GyrA Ser83Leu   GyrA Asp87Gly 
 
Figure 4.2.4.3: Fluorescence of reporter constructs in E. coli under control 
conditions. Data shown are the averages of four independent replicates, and have 
been recalculated relative to the fluorescence of the reporter assayed in MG1655 at 
time zero. Expression of gfpmut2 from the recA promoter is constant in the GyrA 
Asp87Gly background, and its expression from the other promoters is elevated in 
that background compared with the others. When in the MG1655 and the GyrA 
Ser83Leu cells, the reporters appear to follow a similar pattern of expression 
irrespective of the background. 
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 MG1655   GyrA Ser83Leu   GyrA Asp87Gly 
Figure 4.2.4.4: Optical density-adjusted fluorescence levels of a number of reporter constructs 
under a selection of conditions in E. coli. Data shown are the averages of 4 independent replicates. 
Parts A), E) & F) show the fluorescence of various reporters (precA, pglnA and popdA, respectively) in 
response to chlorpromazine exposure. Part B) shows the pgabD construct in the presence of nalidixic acid. 
Part C) shows pglnA in the presence of LB broth and is included for control purposes. The pglnA construct 
is also shown in part D), in the presence of nalidixic acid. With the exception of Part B), where the 
expression of the reporter in the MG1655 background is highest, and part D), where the expression of the 
reporter in the MG1655 background increases over time, the expression of the reporters is highest in the 
GyrA Asp87Gly background, which was not expected. 
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 MG1655   GyrA Ser83Leu   GyrA Asp87Gly 
Figure 4.2.4.5: Optical density-adjusted fluorescence levels recalculated 
relative to the reading for MG1655 carrying the reporter of interest exposed to 
the condition of interest at time zero. These are the same data as shown in Figure 
5.2.5.3, but corrected to account for any differences in initial inoculum.  
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4.2.5 Flow Cytometry 
To determine fluorescence levels in Salmonella on a per cell basis, flow cytometry 
was used. The same reporter constructs were used as in the FluoStar assays 
described above and in the wild type and gyrase mutant backgrounds. Initial 
experiments carried out by Robyn Iddles in my absence as part of her BMedSci 
intercalation project (data not shown) showed that the proportion of fluorescent cells 
in each background was around 20-25% in the absence of any stressor. This was 
irrespective of the reporter construct being used, though the fluorescence intensity of 
gfp-positive cells carrying the pgabD and pglnA constructs appeared to be higher 
(data not shown). Subsequently, the fluorescence levels of the pgabD and pglnA 
constructs in the absence of any stress were determined in more detail using flow 
cytometry. Samples containing 50,000 cells were analysed on four separate 
occasions, with each repeat containing one sample from each of the three 
backgrounds. The data are represented graphically in Figure 4.2.5.1. These data 
supported the initial screen showing a greater proportion of GyrA Ser83Phe cells 
(and to a lesser extent Asp87Gly cells) expressed the pgabD construct than SL1344 
cells. However, whilst a larger number of the gyrase mutants were expressing gabD, 
the level of fluorescence of those cells that were producing GFP was lower than for 
those that were expressing gabD in SL1344. To summarise, gyrA mutants were more 
likely to be expressing gabD than SL1344, but when a wild type cell was expressing 
gabD the level of fluorescence was higher than in a mutant cell. 
 
A preliminary experiment to investigate how nalidixic acid affected the fluorescence 
of the pgabD and pglnA constructs in all three backgrounds was carried out and the 
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results are shown in Figure 4.2.5.2.  Fluorescence appeared to increase in all strains 
after incubation with nalidixic acid, except for the pgabD construct in SL1344. 
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Figure 4.2.5.1: Flow cytometry data for Salmonella pgabD and pglnA constructs. Key (all parts): White = SL1344; Blue = GyrA 
Ser83Phe; Red = GyrA Asp87Gly. Part A) shows the percentage of cells in a population of 50,000 expressing gfpmut2 from the 
gabD construct. Part B) shows the percentage of cells in a population of 50,000 expressing gfpmut2 from the pglnA construct. Part 
C) shows the mean fluorescence level of cells that were expressing gfpmut2 from the pgabD construct. Part D) shows the mean 
fluorescence level of cells that were expressing gfpmut2 from the pglnA construct. A greater proportion of cells within the mutant 
populations are expressing GFP from the reporter plasmids compared with the wild type populations, although the overall 
fluorescence level of the wild type population is higher. Data are taken from four independent replicates. 
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Figure 4.2.5.2: Preliminary flow cytometry data from Salmonella nalidixic acid 
exposure experiments. Figure showing the mean fluorescence level of pgabD and 
pglnA reporters in SL1344 (WT) and the two gyrA mutant backgrounds that had been 
grown to mid-logarithmic phase and incubated in the presence of absence of nalidixic 
acid for 45 minutes. Aside from the pgabD reporter in the SL1344 background, 
fluorescence appeared to increase after nalidixic acid exposure in all cases, though 
this experiment was only repeated once. Data are from samples of 50,000 cells. 
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4.3 Discussion 
4.3.1 Expression of SOS Response Regulators in Salmonella 
One possible mechanism by which mutation in gyrA may provide antimicrobial 
protection is by initiating the SOS response which helps the cell repair DNA damage. 
To examine this recA expression was measured in the presence and absence of the 
inducer, nalidixic acid. The data show that the gyrA mutants do not show a 
constitutive up-regulation of recA and so this is unlikely to be the mechanism 
underpinning their broad antimicrobial tolerance. The data show a non-significant 
increase in the expression of the SOS response regulator recA after exposure of all 
three of S. Typhimurium SL1344, GyrA Ser83Phe and GyrA Asp87Gly cells to 
nalidixic acid. It has previously been shown multiple times by multiple different 
authors that nalidixic acid would be expected to induce recA in the wild type (Piddock 
and Wise, 1987; Power and Phillips, 1993; Ysern et al., 1990).  
 
The large but non-significant increase in recA expression in the Salmonella GyrA 
Ser83Phe strain, compared with the lower increases in SL1344 and the GyrA 
Asp87Gly strain, suggests that nalidixic acid exposure is sensed more easily by GyrA 
Ser83Phe cells, despite the increase in minimum inhibitory concentration the 
substitution confers. The concentration of nalidixic acid used here is ten-fold higher 
than that used as an inducer in published work; this higher concentration was used 
as it was expected that there would be a dose-dependent shift in RNA levels – a 
dose-dependent change in the levels of SOS proteins in response to nalidixic acid 
has previously been observed (Piddock and Wise, 1987). A lack of a change in recA 
expression would be understandable in SL1344, given the MIC for nalidixic acid 
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against this strain is 4 µg/mL, as shown in previously (Webber et al., 2013), but the 
MIC against GyrA Ser83Phe and GyrA Asp87Gly is at least 256 µg/mL. It would be 
pertinent to see how the SOS response changes for the gyrA mutant strains at 
nalidixic acid concentrations approaching the MIC although recA expression does not 
appear to be key to the phenotype of the gyrase mutants. 
 
4.3.2 Fluorescent Reporter Construction and Salmonella Typhimurium 
Induction Assays 
A very large set of data was assembled of fluorescence from various stress 
responsive promoter-gfp reporters measured in the three strain backgrounds in the 
presence of various stresses. In the Salmonella strains, there was no consistent up-
regulation of any of the stresses associated with a particular genotype, and the 
reporters were not necessarily always induced by the agents that the literature 
survey suggested would induce them. For example, it was expected that the RpoN 
reporter, with the glnA promoter, should have been induced by serine hydroxamate, 
but it was difficult to tell if this had actually occurred. It might perhaps have been 
more appropriate to use a fluorescent plate reader with an injector function; this 
would have allowed for the fluorescence of the cell populations to be measured 
before the addition of any supposed inducer. As it stands, readings were only taken 
after the addition of inducing agents, owing to how the plate reader that was used 
works; measuring fluorescence from a point prior to the addition of an inducer would 
mean that one would more easily be able to determine if any changes in 
fluorescence were a genuine response to the inducer. The current setup leaves 
some ambiguity as to whether or not the reporters are functioning correctly.  
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There were some interesting alterations in expression of some reporters. For 
example, the apparent constant fluorescence of the precA and pglnA constructs in 
the GyrA Ser83Phe background in the presence of chlorpromazine suggests that, 
given the gfpmut2 found in pMW82 is unstable (Bumann and Valdivia, 2007), more 
GFP is being produced on account of continual transcription of the mRNA from those 
promoters in that condition. This suggests that the SOS response and nitrogen stress 
response are both elevated in GyrA Ser83Phe cells under this condition. It is unlikely 
that this increased expression is purely the consequence of induction by 
chlorpromazine, as one would expect the reporter constructs to be equally as active 
in the other backgrounds if that were the case. It has been shown in Pseudomonas 
aeruginosa that heightened stress responses are correlated with antibiotic 
resistance, and could contribute to resistance phenotypes (Poole, 2014); it might be 
possible that something similar is occurring here, though if this were the case, one 
would also expect to see increased expression of the reporter constructs in the GyrA 
Asp87Gly cells in a wide range of conditions, which does not appear to be the case 
either. The RpoS reporter also appeared to have elevated expression levels in 
SL1344 in the presence of nalidixic acid. This is perhaps unsurprising as RpoS has 
been shown to become activated in response to DNA damage, as well as a range of 
other conditions (Bougdour et al., 2008). Additionally, the nucleoid-associated 
proteins H-NS and Fis have been shown to prevent transcription by RNA 
polymerases containing the housekeeping sigma factor and encourage transcription 
by RNA polymerases containing the stationary phase sigma factor (Grainger et al., 
2008). 
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4.3.3 Fluorescent Reporter Induction in E. coli 
Fluorescent reporter induction assays in E. coli showed consistently higher 
fluorescence when constructs were transformed into the GyrA Asp87Gly background, 
suggesting elevated stress responses in this strain. This is in contrast to the data 
from Salmonella, where there was no consistent upregulation of stress responses 
based on either strain or condition. The constant level of expression of the precA 
construct in the E. coli GyrA Asp87Gly background suggests that the SOS response 
loci are expressed at a semi-constant elevated level compared to in other 
backgrounds. The constant level of expression is important given the GFP used is 
unstable; it is thus being replenished. The increased expression of GFP from this 
promoter is likely a consequence of global changes in gene expression caused by 
the altered supercoiling state of this strain, given the equivalent substitution in 
Salmonella has been shown to result in heightened gene expression (Webber, et al. 
2013). Another way of verifying this would be to use RNA seq or an RT-PCR based 
approach to determine transcript levels as was used in Salmonella. The increased 
expression levels of stress response loci in this strain could explain why it is better 
able to tolerate exposure to triclosan and other stresses than either the GyrA 
Ser83Leu strain or MG1655.  
 
One further avenue of interest would be to compare the effects of gyrA mutation in E. 
coli and Salmonella with the effects of equivalent parC mutations in a Gram-positive 
species. The equivalent mutations in parC in a Gram-positive species would be of 
greater interest than the identical mutations in gyrA on account of how quinolones 
are usually more active against topoisomerase IV than gyrase in Gram-positive 
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organisms (Drlica et al., 2008). Additionally, time did not allow for the exposure of 
cells to various stresses and then assaying how the topoisomer profile changes as a 
result, as was done in Salmonella, which would be included if this line of questioning 
was pursued further in future. 
 
4.3.4 Flow Cytometry 
Whilst the data from assays measuring expression from whole populations allowed a 
large number of conditions to be assayed the resolution of the data is not able to 
inform responses within a population which may differ. Therefore, for selected 
conditions flow cytometry was also used. The flow cytometry data suggest that the 
proportion of cells in the population that are fluorescent is higher in the GyrA 
Ser83Phe and GyrA Asp87Gly backgrounds, for both the pgabD and pglnA 
constructs, than in SL1344.  However, the mean fluorescence levels appear to be 
higher in the SL1344 background. Therefore, more of the gyrA mutant populations 
are producing these stress responses constitutively although the range of expression 
appears to be curtailed. This pattern of expression was not obvious from the whole 
population fluorescence assays and shows that the gyrase mutants are more likely to 
be producing a potentially protective stress response at any given time.  
 
Previously published data based on a transcriptomic experiment has shown that a 
range of stress response genes had significantly increased expression in GyrA 
Asp87Gly cells compared with SL1344, including but not limited to rpoE, rpoS, rpoD, 
rpoN and recA (Webber et al., 2013). The flow cytometry data here support this data 
and provide a more detailed view of the expression dynamics. 
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The exposure of the pgabD and pglnA constructs to nalidixic acid and their 
subsequent analysis with flow cytometry lacks sufficient replicates to be able to draw 
an adequate conclusion. If this experiment were to be repeated again, it could be 
expanded to include the other promoter constructs and a wide range of stressors. 
 
The data presented in this chapter show that the gyrase mutants appear to be pre-
disposed to expression of glnA and gabD suggesting these stress response 
pathways are constitutively expressed in a significant fraction of cells. This may help 
explain the antimicrobial tolerance in these strains. The data was however not 
conclusive and the up-regulation of stress responses was not universally conserved 
in different conditions. The specific impact of these stress responses on the 
antimicrobial tolerance of gyrase mutants could be investigated by inactivating these 
pathways and measuring the impact on phenotype.  
 
One interesting question relates to the mechanism by which gyrA mutation could 
impact on expression of stress responses. To test the impact of supercoiling another 
avenue for investigation would be to see if there is any interplay between positional 
effects on gene expression, as described by Bryant et al. (2014), and gyrA mutation-
mediated changes in gene expression. This could be achieved by recombining the 
promoter:gfpmut2 fusions into differently supercoiled locations in the chromosomes 
of SL1344 and the two gyrA mutant strains.  
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5. Overall Discussion, Future Work and Conclusions 
5.1 Discussion 
The experiments presented in this thesis set out to investigate the impacts of two 
separate clinically relevant GyrA substitutions, GyrA Ser83Phe and GyrA Asp87Gly, 
on supercoiling in Salmonella Typhimurium and to determine what effects any 
changes in supercoiling had on antibiotic resistance and gene expression. The 
impacts of equivalent substitutions in Escherichia coli, GyrA Ser83Leu and GyrA 
Asp87Gly, were also investigated. 
 
The data presented herein agree with the previously published observation that gyrA 
mutation reduces susceptibility to the quinolones and fluoroquinolones, antibiotics 
that inhibit topoisomerase function. These data also agree with the observation that 
gyrA mutation decreases susceptibility to the biocide triclosan (Webber et al., 2013). 
However, GyrA substitution did not confer any advantages to Salmonella in 
competition assays using 0.03 µg/mL triclosan. This is below the wild type MIC of 
triclosan and was chosen to see if low concentrations of triclosan would promote 
emergence of gyrA mutants which would represent a “real-world” threat given these 
concentrations are now common in the environment. Further experiments at higher 
concentrations may perhaps show otherwise; the concentration used is likely 
insufficient to fall within what Drlica (2003) has described as the “mutant selection 
window”. Conversely, in E. coli, GyrA Asp87Gly cells were able to outcompete 
MG1655 cells when this concentration of triclosan was used showing a much greater 
impact of the GyrA Asp87Gly substitution in E. coli. Previous selection experiments 
have shown that exposure of Salmonella to triclosan does not increase the frequency 
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with which mutations occur, but does enrich the mutants that are already present in 
the population (Birošová and Mikulášová, 2009).  
 
Both the gyrA mutations examined changed the MIC of triclosan against both 
Salmonella and E. coli from 0.06 µg/mL to 0.25 µg/mL (Webber et al., 2017), so it 
might be of interest to perform competition assays between different gyrA mutants in 
the same species, or the same gyrA mutants in different species. Despite S. 
Typhimurium SL1344 having a lower triclosan MIC than either of the two gyrA 
mutants in that species, it still managed to outcompete them when the concentration 
of triclosan was sub-inhibitory demonstrating that, in Salmonella the growth deficit 
incurred by gyrA mutation is greater than the relative increase in triclosan tolerance 
at low concentrations. 
 
It has been shown in the literature that GyrA substitutions have an associated fitness 
cost (S. Baker et al., 2013), but this was not seen in the growth kinetics data 
presented here, as growth kinetics are not the most sensitive measure of fitness and 
small changes are not necessarily reported using this method. The competition 
assays used did show a reduction in fitness for the gyrA mutants in Salmonella 
although this was smaller in the GyrA Asp87Gly strain than it was in the GyrA 
Ser83Leu strain, smaller costs were seen in E. coli. The impacts of mutations on 
fitness are highly condition specific. It has been suggested through a combination of 
mathematical modelling and selection experiments that, in E. coli, in the presence of 
ciprofloxacin the most favourable route for acquiring substitutions that reduce 
quinolone susceptibility is an initial change to GyrA Ser83Leu, followed by additional 
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substitutions of GyrA Ser83Leu ParC Ser80Ile, then finally GyrA Ser83Leu Asp87Asn 
ParC Ser80Ile. This is considered to be the case because other substitutions are less 
energetically favourable and are outcompeted by the ones mentioned (Huseby et al., 
2017). However, in Salmonella Typhi, the equivalent triple substitution (GyrA 
Ser83Phe Asp87Gly ParC Ser80Ile), despite conferring the largest observed change 
in norfloxacin MIC, is energetically unfavourable in control conditions. However, 
another two-step substitution, GyrA Ser83Phe Asp87Asn confers sufficient change in 
norfloxacin MIC to make the cells clinically resistant to the antibiotic, and has a 
comparatively high selection coefficient (S. Baker et al., 2013). In my experiments, 
we did not focus on the impact of quinolones as selective agents – the GyrA 
Asp87Gly substitution is seen in non-laboratory settings but was of interest here as it 
has previously been repeatedly selected by exposure to non-quinolone biocides. It 
has been shown here that this substitution confers a greater protective effect to 
triclosan (particularly in E. coli) than the GyrA Ser83Leu substitution that is favoured 
under quinolone selection alone. Therefore, the local selective conditions will greatly 
impact the fitness of different mutations making predictions from laboratory data 
alone about selection in the field difficult. 
 
Using the plasmid pBR322 as a proxy for genomic supercoiling, experiments 
presented herein have reconfirmed the previously published observation that gyrA 
mutation alters supercoiling in Salmonella (Webber et al., 2013) – the GyrA 
Ser83Phe substitution increases supercoiling levels in comparison to SL1344, 
whereas the GyrA Asp87Gly substitution results in a similar topoisomer distribution to 
that seen in the wild type. It has also previously been shown that there are 
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differences in basal levels of supercoiling between Salmonella and E. coli (Cameron 
et al., 2011), with which these data are in agreement. The experiments here have 
shown for the first time that the impacts of equivalent substitutions in E. coli upon 
supercoiling differ significantly to those seen in Salmonella, with the GyrA Asp87Gly 
substitution resulting in a much more supercoiled profile in E. coli than either the 
MG1655 strain, the E. coli GyrA Ser83Leu strain, or any of the Salmonella strains. 
This large difference in impact is interesting given the close relationship of E. coli and 
Salmonella and, in concert with the previous observations that the two species 
maintain a different basal level of supercoiling suggests changes to supercoiling 
affect global regulatory networks and phenotypic outputs which result differently. 
 
Other methods of investigating supercoiling which directly analyse the chromosome 
tend to be in vitro and strip DNA from the cellular context, e.g. using “magnetic 
tweezers” and fusing DNA to a glass slide (Lebel et al., 2014). A recent study used 
fluorescence resonance energy transfer to measure supercoiling, by inserting 
sequences tagged with a fluorophore and a quencher into a plasmid, such that they 
were located far apart (and thus fluorescent) when the plasmid was relaxed, and 
adjacent (and thus not fluorescent) when the plasmid was supercoiled (Gu et al., 
2016). This approach could perhaps be applied in future experiments and used to 
monitor changes in supercoiling in real time, without having to extract the plasmid 
from the cell. 
 
When mid-logarithmic phase Salmonella were incubated with antibiotics, how they 
responded appeared to be linked to whether or not the cells carried a gyrA mutation. 
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Plasmids from cells lacking gyrA mutations generally appeared to become less 
supercoiled after antibiotic treatment, which appears consistent with the observed 
relaxation of topoisomers observed when S. enterica was incubated with varying 
concentrations of sodium chloride (Cameron et al., 2011). Conversely, the 
supercoiling state did not appear to change for plasmids isolated from cells with 
either a GyrA Ser83Phe or a GyrA Asp87Gly substitution after incubation with an 
antibiotic or other chemical. It therefore appears that gyrA mutation confers a generic 
protective effect against antibiotics, in terms of preserving the supercoiling state.  
 
The use of fluorescent reporter constructs showed that there was a general elevation 
of stress responses in the GyrA Asp87Gly background in E. coli under all conditions. 
There was a much less obvious pattern in Salmonella where more cells were found 
to be expressing the gabD and glnA reporters in the GyrA Asp87Gly background 
although the level of expression from these cells appeared to be capped compared 
with those wild type cells that were expressing these stress responses. These data 
are consistent with our hypothesis that the phenotypic tolerance to non-quinolone 
antibiotics seen in the GyrA Asp87Gly mutant relates to altered expression of stress 
responses. The addition of various stresses did not change the picture and there was 
no consistent difference in response of these stress response pathways in different 
conditions in the gyrA mutants compared with the parent in both species. Therefore 
the mutants do not appear to respond to stress better than their parents, but to be in 
a generic state of enhanced protection. 
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The wider impact on the transcriptome has been suggested in Salmonella (Webber 
et al., 2013). This could be followed up under multiple conditions in both species to 
get a more comprehensive picture of expression changes by RNA sequencing. 
 
5.2 Future Work 
It has previously been shown that supercoiling varies between regions of the 
chromosome (Higgins et al., 1996; Postow et al., 2004). It follows that, if a gene is 
moved from its native region to a different part of the chromosome, the supercoiling 
state of this gene will be dictated by the supercoiling state of the surrounding region 
into which it is inserted, and that this will alter the its expression. Therefore, 
supercoiling has been suggested to be a “master regulator” of gene expression. This 
has been shown in E. coli through the insertion of a GFP locus into differentially 
supercoiled chromosomal macrodomains and measuring fluorescence as a proxy for 
gene expression. It has also been shown that gene expression can be altered by 
disturbing the supercoiling profile with novobiocin, a gyrase inhibitor (Bryant et al., 
2014). One might therefore expect that inserting a gfp reporter into different regions 
of the S. Typhimurium genome should result in different expression levels depending 
on where the reporter is inserted. It would also be expected that the expression of the 
gfp reporter in S. Typhimurium should differ from its expression in E. coli, because of 
the inherent differences in the supercoiling state of the genomes of the two species, 
and that the expression of the gfp reporter should be altered by differences in the 
supercoiling state that are a consequence of GyrA substitutions. One way to address 
these hypotheses would be to create aph fusions with the existing pMW82 reporter 
constructs, and then transduce these into different sites on the chromosome using 
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the Datsenko-Wanner λ-Red phage recombination method (Datsenko and Wanner, 
2000). It is primarily used to create gene knockouts, but could be used for the 
insertion of sequences. This would work by flanking the aph locus and promoter:gfp 
fusion with FLP recognition target sites and sequences homologous to sections of 
the chromosome, and introducing them into various positions in the chromosome 
using the recombinase λ-Red. Kanamycin ould then be used to select for successful 
recombinants. The fluorescence of the resulting cells could then be measured under 
a variety of conditions. It might be possible to achieve this aim in another way, such 
as by using a more targeted method, such as the CRISPR/Cas9 system (Choi and 
Lee, 2016; Doudna and Charpentier, 2014) or no-SCAR system (Reisch and Prather, 
2015). These methods eliminate the need for the introduction of an antibiotic 
resistance marker, cutting down on the number of steps needed to edit the genome. 
However, the λ-Red method has been used in this laboratory previously (Eaves et 
al., 2004) and thus the materials and expertise needed to use this method are more 
readily available and affordable than CRISPR/Cas9. 
 
Previous work by Webber et al (2013) used microarrays to examine changes in the 
transcriptome of Salmonella as a result of gyrA mutation. This experiment could be 
repeated in E. coli in a similar manner. Other sets of experiments that would allow a 
more thorough comparison of the effects of gyrA mutation in E. coli compared to 
Salmonella would be to repeat the flow cytometry assays in E. coli, as well as the 
topoisomer separation assays performed after exposing mid-logarithmic phase cells 
to a stress. These experiments would use similar methods to those described in this 
thesis. 
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The experiments presented herein investigated the impacts of gyrA mutation in 
Escherichia coli and Salmonella Typhimurium, which are Gram negative bacteria. It 
might be interesting to investigate the effects of equivalent substitutions in gyrA upon 
a Gram positive species, such as Staphylococcus aureus or Streptococcus 
pneumoniae. One possible approach would be to create isogenic mutants by taking a 
transformable laboratory strain of S. aureus or S. pneumoniae and introducing 
separate substitutions equivalent to GyrA Ser83Phe and GyrA Asp87Gly using an 
appropriate homologous recombination method. These could then be used to 
introduce the plasmid pBR322 into cells, and then the experiments presented herein 
could be repeated in those species. 
 
The experiments presented do not show the impacts of gyrA mutation in an 
immunological context. Examples of questions one might pose include “Does gyrA 
mutation alter virulence?”, “How is invasion affected?”, and “Does gyrA mutation 
improve survival after uptake by macrophages?”. Traditionally, mouse models might 
be used to do this (Masopust et al., 2017), but this approach is costly and an ethical 
quagmire (Ramarao et al., 2012). An experiment that could be performed to assess 
impacts on virulence would be to feed Gallerica mellonnella larvae, which have a 
similar innate immune response to vertebrates (Tsai et al., 2016), nutrient agar 
enriched with either wild type Salmonella or Salmonella with a gyrA mutation, and 
monitor the survival of the larvae over a 96 hour period, as used by Wang-Kan et al., 
(2017). Impacts on invasion and survival in macrophages could be assessed using a 
tissue culture model. The model used by Wang-Kan et al (2017) to investigate the 
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effects of the loss of efflux pump function in Salmonella on invasion and macrophage 
survival uses Caco2 intestinal epithelial cells and J774 murine macrophages, so 
these cells would be appropriate for a similar study about gyrA mutation. 
 
5.3 Conclusions 
In conclusion, gyrA mutation alters supercoiling in both Salmonella and E. coli, 
decreasing susceptibility to quinolones and triclosan. This impact was much greater 
for the GyrA Asp87Gly substitution in E. coli, which outcompetes its parent in low 
triclosan concentrations. This was not seen in Salmonella. The data also show that 
the GyrA Asp87Gly substitution confers a generic protective effect against a range of 
chemicals and antibiotics, as the supercoiling does not appear to change in this 
strain. There is also a general upregulation of stress responses, which in response to 
non-specific stresses in Salmonella, but occurs under control conditions for the GyrA 
Asp87Gly strain in E. coli. The upregulation of stress responses is likely a result of 
changes in supercoiling causing widespread alterations in gene expression by 
changing the accessibility of promoters, and these elevated stress responses are 
responsible for the generic protective effect gyrA mutation confers against quinolone 
and non-quinolone antibiotics.  
 
Taken together these data show that mutations in gyrA can influence susceptibility to 
non-quinolone antibiotics but that this impact is species and condition dependent – 
the potential impacts on fitness of such mutations are hard to predict in a non-
laboratory setting. More work is needed to assess the potential of non-quinolone 
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antimicrobials, including those that are now common in the environment, to act as 
drivers of clinically important quinolone resistance. 
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Figure A.1.1: Gel photo from which Figure 3.2.5.1 was formed. 
Gel photo showing topoisomers distribution of the plasmid pBR322, extracted from 
cell cultures that were grown to stationary phase and then incubated for a further 45 
minutes in either the presence or absence of nalidixic acid. The more supercoiled 
DNA is, the further it migrates down the gel. There are two samples of treated (+Nal) 
and untreated (-Nal) cells from each background. All samples are from Salmonella 
Typhimurium. Lanes B, G, and K were used to create Figure 3.2.5.1, and the contrast 
was adjusted to aid in visibility. 
Lane A: HyperLadder 1kb. Lane B: SL1344, -Nal (1) Lane C: SL1344, +Nal (1) 
Lane D: SL1344 -Nal (2) Lane E: Empty Lane F: SL1344 +Nal (2) Lane G: GyrA 
Ser83Phe -Nal (1) Lane H: GyrA Ser83Phe +Nal (2) Lane I: GyrA Ser83Phe -Nal (2) 
Lane J: GyrA Ser83Phe +Nal (2) Lane K: GyrA Asp87Gly, -Nal (1) Lane L: GyrA 
Asp87Gly +Nal (1) Lane M: empty Lane N: GyrA Asp87Gly, -Nal (2) Lane O: GyrA 
Asp87Gly +Nal (2). 
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SL1344 GyrA Ser83Phe GyrA Asp87Gly
Figure A.1.2: Optical density-adjusted fluorescence levels of precA reporter 
constructs under a selection of conditions in Salmonella. Data shown are the 
averages of four independent replicates. Fluorescence appears to be higher in the 
GyrA Ser83Phe background than other backgrounds in all conditions tested, with 
fluorescence after chlorpromazine exposure appearing to be roughly constant. In the 
SL1344 and GyrA Asp87Gly backgrounds, the fluorescence level falls over time. 
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SL1344 GyrA Ser83Phe GyrA Asp87Gly
Figure A.1.3: Optical density-adjusted fluorescence levels of pgabD reporter 
constructs under a selection of conditions in Salmonella. Data shown are the 
averages of four independent replicates. Fluorescence from this reporter is highest in 
the SL1344 background, but reduces over time in all backgrounds in all conditions 
except for when the SL1344 cells were exposed to nalidixic acid, where it increases. 
Fluorescence in the GyrA Asp87Gly background is lowest. The fluorescence in the 
SL1344 and GyrA Ser83Phe backgrounds appears to be identical after exposure to 
serine hydroxamate. 
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SL1344 GyrA Ser83Phe GyrA Asp87Gly
Figure A.1.4: Optical density-adjusted fluorescence levels of pglnA reporter 
constructs under a selection of conditions in Salmonella. Data shown are the 
averages of four independent replicates. Fluorescence appears to be highest in the 
GyrA Ser83Phe background in most conditions, though still declines and reaches a 
plateau after about an hour and a half in most cases. It appears to remain elevated in 
the GyrA Ser83Phe background after exposure to chlorpromazine. After around 10 
hours of sucrose exposure, fluorescence increases in the SL1344 background. 
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SL1344 GyrA Ser83Phe GyrA Asp87Gly
Figure A.1.5: Optical density-adjusted fluorescence levels of pyaeT reporter 
constructs under a selection of conditions in Salmonella. Data shown are the 
averages of four independent replicates. Fluorescence appears to decline much less 
sharply in the GyrA Asp87Gly background than others, except when cells were 
exposed to sucrose or sterile distilled water. Fluorescence is generally highest in this 
background, though it is similar in SL1344 cells after sucrose exposure, and is higher 
in SL1344 cells after exposure to nalidixic acid. Fluorescence is lowest in GyrA 
Ser83Phe cells. 
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SL1344 GyrA Ser83Phe GyrA Asp87Gly
Figure A.1.6: Optical density-adjusted fluorescence levels of popdA reporter 
constructs under a selection of conditions in Salmonella. Data shown are the 
averages of four independent replicates. Fluorescence declines over time in all 
backgrounds in all conditions, though declines more slowly in GyrA Ser83Phe cells 
after exposure to chlorpromazine. There is also an increase in fluorescence levels in 
the SL1344 background after nalidixic acid exposure, at around 8 hours. 
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MG1655 GyrA Ser83Leu GyrA Asp87Gly
Figure A.1.7: Optical density-adjusted fluorescence levels of precA reporter 
constructs under a selection of conditions in E. coli. Data shown are the 
averages of four independent replicates. Fluorescence remains roughly constant 
over the experimental period in the GyrA Asp87Gly background, except after 
exposure to chlorpromazine, where it increases over time. Fluorescence also 
remains at a high level and declines slowly in the MG1655 cells after exposure to 
nalidixic acid. In all other cases, fluorescence in MG1655 and GyrA Ser83Phe cells 
declines over time. 
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MG1655 GyrA Ser83Leu GyrA Asp87Gly
Figure A.1.8: Optical density-adjusted fluorescence levels of pgabD reporter 
constructs under a selection of conditions in E. coli. Data shown are the 
averages of four independent replicates. Fluorescence reaches a plateau in all 
backgrounds after chlorpromazine exposure, but is highest in GyrA Asp87Gly cells. 
Fluorescence decreases over time in most other conditions in all backgrounds, and 
fluorescence in the GyrA Asp87Gly background is usually highest. The exception is 
nalidixic acid exposure, where fluorescence in the MG1655 background is highest 
and reaches a plateau higher than other backgrounds after 6 hours. 
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MG1655 GyrA Ser83Leu GyrA Asp87Gly
Figure A.1.9: Optical density-adjusted fluorescence levels of pglnA reporter 
constructs under a selection of conditions in E. coli. Data shown are the 
averages of four independent replicates. Fluorescence in GyrA Asp87Gly cells is 
highest and lowest in GyrA Ser83Leu cells in most conditions. However, 
fluorescence increase over time in MG1655 cells after exposure to nalidixic acid, 
after reaching a nadir at around 2 hours.  
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MG1655 GyrA Ser83Leu GyrA Asp87Gly
Figure A.1.10: Optical density-adjusted fluorescence levels of pbamA reporter 
constructs under a selection of conditions in E. coli. Data shown are the 
averages of four independent replicates. Fluorescence appears to be highest in GyrA 
Asp87Gly cells in all conditions, with the exception of after nalidixic acid exposure, 
where it is suprassed by MG1655 cells at around 5 hours. In most conditions, 
fluorescence levels in MG1655 cells and GyrA Ser83Phe cells appears identical. 
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MG1655 GyrA Ser83Leu GyrA Asp87Gly
Figure A.1.11: Optical density-adjusted fluorescence levels of popdA reporter 
constructs under a selection of conditions in E. coli. Data shown are the 
averages of four independent replicates. Fluorescence is generally highest in GyrA 
Asp87Gly cells. It increases over time in MG1655 cells exposed to sucrose and 
nalidixic acid, after reaching a nadir at around 2 hours, ultimately reaching similar 
levels of fluorescence to GyrA Asp87Gly cells exposed to the same inducers. 
Fluorescence in GyrA Ser83Leu cells generally follows the same downward trend as 
MG1655 cells, with the exception of the two aforementioned conditions. 
